

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
001	ALAN AMINO ALT/SGPT			CLIA TEST ID #: 255		EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}							
2025-391	5	ENZ. 37 C		194	BIOLIS-24S	154	(IDG)	10	222.200	12.197	5.49	189.000	256.000
2025-391	5	ENZ. 37 C		197	ARCHITECT	1	ABBOTT	19	204.789	6.396	3.12	174.000	236.000
2025-391	8	OX.OF NADH		220	Medica E.	130	MEDICA	12	192.500	7.388	3.84	164.000	221.000
2025-391	11	MOD. IFCC		38	SIEMENS DI	143	SIEMENS	77	227.289	5.541	2.44	193.000	261.000
2025-391	11	MOD. IFCC		184	INTEGRA	93	ROCHE	18	207.389	5.417	2.61	176.000	238.000
2025-391	11	MOD. IFCC		186	BECK. COUL	76	AU-BECKMAN	33	189.406	5.279	2.79	161.000	218.000
2025-391	11	MOD. IFCC		191	RX-SERIES	126	RANDOX	26	242.480	15.562	6.42	206.000	279.000
2025-391	11	MOD. IFCC		203	ROCHE	93	ROCHE	44	210.295	5.731	2.73	179.000	242.000
2025-391	11	MOD. IFCC		219	ATELLICA	143	SIEMENS	22	243.682	6.167	2.53	207.000	280.000
2025-391	12	IFCC witho		203	ROCHE	93	ROCHE	17	210.765	5.846	2.77	179.000	242.000
2025-391	13	ALA &aKETO		165	VITROS	155	ALTV	126	199.524	5.086	2.55	170.000	229.000
2025-392	5	ENZ. 37 C		194	BIOLIS-24S	154	(IDG)	10	29.800	5.474	18.37	24.000	36.000
2025-392	5	ENZ. 37 C		197	ARCHITECT	1	ABBOTT	19	10.421	1.184	11.36	4.000	16.000
2025-392	8	OX.OF NADH		220	Medica E.	130	MEDICA	12	16.417	1.935	11.78	10.000	22.000
2025-392	11	MOD. IFCC		38	SIEMENS DI	143	SIEMENS	77	16.487	1.697	10.30	10.000	22.000
2025-392	11	MOD. IFCC		184	INTEGRA	93	ROCHE	18	10.000	1.054	10.54	4.000	16.000
2025-392	11	MOD. IFCC		186	BECK. COUL	76	AU-BECKMAN	33	10.152	0.557	5.49	4.000	16.000
2025-392	11	MOD. IFCC		191	RX-SERIES	126	RANDOX	26	12.800	1.265	9.88	7.000	19.000
2025-392	11	MOD. IFCC		203	ROCHE	93	ROCHE	44	10.651	1.412	13.26	5.000	17.000
2025-392	11	MOD. IFCC		219	ATELLICA	143	SIEMENS	22	13.864	2.095	15.11	8.000	20.000
2025-392	12	IFCC witho		203	ROCHE	93	ROCHE	17	9.941	2.313	23.27	4.000	16.000
2025-392	13	ALA &aKETO		165	VITROS	155	ALTV	126	9.315	0.745	7.99	3.000	15.000
2025-393	5	ENZ. 37 C		194	BIOLIS-24S	154	(IDG)	10	81.700	3.132	3.83	69.000	94.000
2025-393	5	ENZ. 37 C		197	ARCHITECT	1	ABBOTT	19	67.842	2.700	3.98	58.000	78.000
2025-393	8	OX.OF NADH		220	Medica E.	130	MEDICA	12	67.583	1.706	2.52	57.000	78.000
2025-393	11	MOD. IFCC		38	SIEMENS DI	143	SIEMENS	77	79.882	2.465	3.09	68.000	92.000
2025-393	11	MOD. IFCC		184	INTEGRA	93	ROCHE	18	68.833	2.409	3.50	59.000	79.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-393		11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	33	63.545	1.876	2.95	54.000	73.000
2025-393		11	MOD. IFCC	191	RX-SERIES	126	RANDOX	26	80.808	4.930	6.10	69.000	93.000
2025-393		11	MOD. IFCC	203	ROCHE	93	ROCHE	44	70.045	2.412	3.44	60.000	81.000
2025-393		11	MOD. IFCC	219	ATELLICA	143	SIEMENS	22	82.810	2.481	3.00	70.000	95.000
2025-393		12	IFCC witho	203	ROCHE	93	ROCHE	17	69.941	2.667	3.81	59.000	80.000
2025-393		13	ALA &aKETO	165	VITROS	155	ALTV	126	69.927	2.304	3.30	59.000	80.000
001 ALAN	AMINO ALT/SGPT			CLIA	TEST ID #: 255	EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}							
2025-394		5	ENZ. 37 C	194	BIOLIS-24S	154	(IDG)	10	399.600	35.828	8.97	340.000	460.000
2025-394		5	ENZ. 37 C	197	ARCHITECT	1	ABBOTT	19	392.789	18.444	4.70	334.000	452.000
2025-394		8	OX.OF NADH	220	Medica E.	130	MEDICA	12	352.333	12.392	3.52	299.000	405.000
2025-394		11	MOD. IFCC	38	SIEMENS DI	143	SIEMENS	77	420.566	11.293	2.69	357.000	484.000
2025-394		11	MOD. IFCC	184	INTEGRA	93	ROCHE	18	387.722	11.718	3.02	330.000	446.000
2025-394		11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	33	356.515	14.943	4.19	303.000	410.000
2025-394		11	MOD. IFCC	191	RX-SERIES	126	RANDOX	26	439.880	25.417	5.78	374.000	506.000
2025-394		11	MOD. IFCC	203	ROCHE	93	ROCHE	44	394.114	11.046	2.80	335.000	453.000
2025-394		11	MOD. IFCC	219	ATELLICA	143	SIEMENS	22	453.273	14.394	3.18	385.000	521.000
2025-394		12	IFCC witho	203	ROCHE	93	ROCHE	17	392.882	14.684	3.74	334.000	452.000
2025-394		13	ALA &aKETO	165	VITROS	155	ALTV	126	360.419	12.280	3.41	306.000	414.000
2025-395		5	ENZ. 37 C	194	BIOLIS-24S	154	(IDG)	10	315.900	16.164	5.12	269.000	363.000
2025-395		5	ENZ. 37 C	197	ARCHITECT	1	ABBOTT	19	299.632	10.737	3.58	255.000	345.000
2025-395		8	OX.OF NADH	220	Medica E.	130	MEDICA	12	275.167	10.221	3.71	234.000	316.000
2025-395		11	MOD. IFCC	38	SIEMENS DI	143	SIEMENS	77	325.667	9.244	2.84	277.000	375.000
2025-395		11	MOD. IFCC	184	INTEGRA	93	ROCHE	18	300.278	8.157	2.72	255.000	345.000
2025-395		11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	33	272.242	10.652	3.91	231.000	313.000
2025-395		11	MOD. IFCC	191	RX-SERIES	126	RANDOX	26	347.577	22.285	6.41	295.000	400.000
2025-395		11	MOD. IFCC	203	ROCHE	93	ROCHE	44	304.136	9.491	3.12	259.000	350.000
2025-395		11	MOD. IFCC	219	ATELLICA	143	SIEMENS	22	351.182	6.913	1.97	299.000	404.000
2025-395		12	IFCC witho	203	ROCHE	93	ROCHE	17	302.059	10.304	3.41	257.000	347.000
2025-395		13	ALA &aKETO	165	VITROS	155	ALTV	126	280.161	7.101	2.53	238.000	322.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
002 ALBUMIN				CLIA TEST ID #: 265				EVALUATION CRITERIA: TARGET VALUE 8 %					
2025-391	3	DYE BI-B.G	165	VITROS	63	KODAK	135	3.942	0.102	2.59	3.600	4.300	
2025-391	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	27	3.948	0.100	2.52	3.600	4.300	
2025-391	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	33	3.812	0.081	2.12	3.500	4.100	
2025-391	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	28	3.814	0.127	3.34	3.500	4.100	
2025-391	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	3.900	0.077	1.99	3.600	4.200	
2025-391	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	16	3.706	0.075	2.02	3.400	4.000	
2025-391	3	DYE BI-B.G	203	ROCHE	93	ROCHE	60	3.932	0.085	2.17	3.600	4.200	
2025-391	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	22	3.886	0.106	2.72	3.600	4.200	
2025-391	3	DYE BI-B.G	220	Medica E.	130	MEDICA	13	3.962	0.169	4.26	3.600	4.300	
2025-391	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	82	3.499	0.114	3.25	3.200	3.800	
2025-392	3	DYE BI-B.G	165	VITROS	63	KODAK	135	1.954	0.068	3.46	1.800	2.100	
2025-392	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	27	2.173	0.059	2.72	2.000	2.300	
2025-392	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	33	2.033	0.068	3.35	1.900	2.200	
2025-392	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	28	2.093	0.080	3.82	1.900	2.300	
2025-392	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	2.050	0.092	4.50	1.900	2.200	
2025-392	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	16	1.919	0.053	2.74	1.800	2.100	
2025-392	3	DYE BI-B.G	203	ROCHE	93	ROCHE	60	2.178	0.085	3.88	2.000	2.400	
2025-392	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	22	2.050	0.058	2.85	1.900	2.200	
2025-392	3	DYE BI-B.G	220	Medica E.	130	MEDICA	13	2.054	0.115	5.61	1.900	2.200	
2025-392	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	82	1.744	0.065	3.72	1.600	1.900	
2025-393	3	DYE BI-B.G	165	VITROS	63	KODAK	135	2.529	0.080	3.16	2.300	2.700	
2025-393	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	27	2.722	0.087	3.21	2.500	2.900	
2025-393	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	33	2.558	0.060	2.36	2.400	2.800	
2025-393	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	28	2.604	0.087	3.32	2.400	2.800	
2025-393	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	2.590	0.054	2.08	2.400	2.800	
2025-393	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	16	2.450	0.061	2.50	2.300	2.600	
2025-393	3	DYE BI-B.G	203	ROCHE	93	ROCHE	60	2.710	0.086	3.16	2.500	2.900	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
	2025-393	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	22	2.564	0.057	2.21	2.400	2.800
	2025-393	3	DYE BI-B.G	220	Medica E.	130	MEDICA	13	2.585	0.117	4.51	2.400	2.800
	2025-393	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	82	2.257	0.087	3.85	2.100	2.400
002	ALBUMIN			CLIA TEST ID #: 265				EVALUATION CRITERIA: TARGET VALUE 8 %					
	2025-394	3	DYE BI-B.G	165	VITROS	63	KODAK	135	5.726	0.175	3.05	5.300	6.200
	2025-394	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	27	5.356	0.191	3.57	4.900	5.800
	2025-394	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	33	5.388	0.155	2.88	5.000	5.800
	2025-394	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	28	5.278	0.177	3.36	4.900	5.700
	2025-394	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	5.580	0.209	3.74	5.100	6.000
	2025-394	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	16	5.225	0.192	3.68	4.800	5.600
	2025-394	3	DYE BI-B.G	203	ROCHE	93	ROCHE	60	5.390	0.123	2.28	5.000	5.800
	2025-394	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	22	5.550	0.131	2.35	5.100	6.000
	2025-394	3	DYE BI-B.G	220	Medica E.	130	MEDICA	13	5.569	0.281	5.05	5.100	6.000
	2025-394	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	82	5.088	0.188	3.69	4.700	5.500
	2025-395	3	DYE BI-B.G	165	VITROS	63	KODAK	135	4.859	0.132	2.71	4.500	5.200
	2025-395	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	27	4.693	0.109	2.31	4.300	5.100
	2025-395	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	33	4.588	0.165	3.59	4.200	5.000
	2025-395	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	28	4.571	0.139	3.03	4.200	4.900
	2025-395	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	4.720	0.125	2.65	4.300	5.100
	2025-395	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	16	4.481	0.113	2.52	4.100	4.800
	2025-395	3	DYE BI-B.G	203	ROCHE	93	ROCHE	60	4.688	0.105	2.24	4.300	5.100
	2025-395	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	22	4.718	0.123	2.61	4.300	5.100
	2025-395	3	DYE BI-B.G	220	Medica E.	130	MEDICA	13	4.808	0.173	3.60	4.400	5.200
	2025-395	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	82	4.286	0.160	3.73	3.900	4.600
003	ALKALINE PHOSPHATE			CLIA TEST ID #: 275				EVALUATION CRITERIA: TARGET VALUE 20 %					
	2025-391	3	COLORIMET.	184	INTEGRA	93	ROCHE	22	172.227	3.729	2.16	138.000	207.000
	2025-391	3	COLORIMET.	203	ROCHE	93	ROCHE	41	172.390	6.589	3.82	138.000	207.000
	2025-391	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	155.818	11.930	7.66	125.000	187.000
	2025-391	6	KINETIC 37	165	VITROS	63	KODAK	135	155.104	8.147	5.25	124.000	186.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-391	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	33	134.515	12.811	9.52	108.000	161.000	
2025-391	10	IFCC	203	ROCHE	93	ROCHE	11	172.000	4.221	2.45	138.000	206.000	
2025-391	10	IFCC	219	ATELLICA	143	SIEMENS	22	164.909	8.140	4.94	132.000	198.000	
2025-391	11	Modified I	38	SIEMENS DI	143	SIEMENS	75	181.527	6.437	3.55	145.000	218.000	
2025-391	11	Modified I	191	RX-SERIES	126	RANDOX	24	151.208	10.689	7.07	121.000	181.000	
2025-391	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	11	146.182	12.561	8.59	117.000	175.000	
2025-391	12	P NITRO PH	220	Medica E.	130	MEDICA	12	147.333	7.814	5.30	118.000	177.000	
003 ALKALINE PHOSPHATE				CLIA TEST ID #: 275		EVALUATION CRITERIA: TARGET VALUE 20 %							
2025-392	3	COLORIMET.	184	INTEGRA	93	ROCHE	22	30.455	1.233	4.05	24.000	37.000	
2025-392	3	COLORIMET.	203	ROCHE	93	ROCHE	41	30.325	1.506	4.97	24.000	36.000	
2025-392	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	27.727	2.700	9.74	22.000	33.000	
2025-392	6	KINETIC 37	165	VITROS	63	KODAK	135	49.216	3.116	6.33	39.000	59.000	
2025-392	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	33	23.061	2.616	11.35	18.000	28.000	
2025-392	10	IFCC	203	ROCHE	93	ROCHE	11	30.545	1.076	3.52	24.000	37.000	
2025-392	10	IFCC	219	ATELLICA	143	SIEMENS	22	28.591	1.557	5.45	23.000	34.000	
2025-392	11	Modified I	38	SIEMENS DI	143	SIEMENS	75	30.838	2.809	9.11	25.000	37.000	
2025-392	11	Modified I	191	RX-SERIES	126	RANDOX	24	27.125	2.333	8.60	22.000	33.000	
2025-392	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	11	25.364	2.346	9.25	20.000	30.000	
2025-392	12	P NITRO PH	220	Medica E.	130	MEDICA	12	28.000	2.380	8.50	22.000	34.000	
2025-393	3	COLORIMET.	184	INTEGRA	93	ROCHE	22	71.318	2.530	3.55	57.000	86.000	
2025-393	3	COLORIMET.	203	ROCHE	93	ROCHE	41	70.850	2.475	3.49	57.000	85.000	
2025-393	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	65.455	6.528	9.97	52.000	79.000	
2025-393	6	KINETIC 37	165	VITROS	63	KODAK	135	88.091	4.094	4.65	70.000	106.000	
2025-393	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	33	54.939	5.268	9.59	44.000	66.000	
2025-393	10	IFCC	203	ROCHE	93	ROCHE	11	70.364	2.012	2.86	56.000	84.000	
2025-393	10	IFCC	219	ATELLICA	143	SIEMENS	22	67.591	3.486	5.16	54.000	81.000	
2025-393	11	Modified I	38	SIEMENS DI	143	SIEMENS	75	74.081	3.770	5.09	59.000	89.000	
2025-393	11	Modified I	191	RX-SERIES	126	RANDOX	24	63.208	5.252	8.31	51.000	76.000	
2025-393	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	11	60.000	4.632	7.72	48.000	72.000	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-393		12	P NITRO PH	220	Medica E.	130	MEDICA	12	62.250	4.746	7.62	50.000	75.000
003 ALKALINE PHOSPHATE				CLIA TEST ID #: 275				EVALUATION CRITERIA: TARGET VALUE 20 %					
2025-394		3	COLORIMET.	184	INTEGRA	93	ROCHE	22	320.048	6.321	1.97	256.000	384.000
2025-394		3	COLORIMET.	203	ROCHE	93	ROCHE	41	316.463	10.827	3.42	253.000	380.000
2025-394		5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	286.455	19.778	6.90	229.000	344.000
2025-394		6	KINETIC 37	165	VITROS	63	KODAK	135	192.955	11.932	6.18	154.000	232.000
2025-394		8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	33	249.394	23.094	9.26	200.000	299.000
2025-394		10	IFCC	203	ROCHE	93	ROCHE	11	316.727	10.154	3.21	253.000	380.000
2025-394		10	IFCC	219	ATELLICA	143	SIEMENS	22	302.955	15.953	5.27	242.000	364.000
2025-394		11	Modified I	38	SIEMENS DI	143	SIEMENS	75	336.176	11.147	3.32	269.000	403.000
2025-394		11	Modified I	191	RX-SERIES	126	RANDOX	24	264.458	19.662	7.43	212.000	317.000
2025-394		12	P NITRO PH	197	ARCHITECT	1	ABBOTT	11	264.364	19.256	7.28	211.000	317.000
2025-394		12	P NITRO PH	220	Medica E.	130	MEDICA	12	267.417	13.531	5.06	214.000	321.000
2025-395		3	COLORIMET.	184	INTEGRA	93	ROCHE	22	245.591	6.213	2.53	196.000	295.000
2025-395		3	COLORIMET.	203	ROCHE	93	ROCHE	41	243.659	8.916	3.66	195.000	292.000
2025-395		5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	220.182	14.484	6.58	176.000	264.000
2025-395		6	KINETIC 37	165	VITROS	63	KODAK	135	181.647	10.143	5.58	145.000	218.000
2025-395		8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	33	190.909	18.390	9.63	153.000	229.000
2025-395		10	IFCC	203	ROCHE	93	ROCHE	11	242.727	5.785	2.38	194.000	291.000
2025-395		10	IFCC	219	ATELLICA	143	SIEMENS	22	234.000	10.238	4.38	187.000	281.000
2025-395		11	Modified I	38	SIEMENS DI	143	SIEMENS	75	259.392	9.726	3.75	208.000	311.000
2025-395		11	Modified I	191	RX-SERIES	126	RANDOX	24	208.667	16.859	8.08	167.000	250.000
2025-395		12	P NITRO PH	197	ARCHITECT	1	ABBOTT	11	206.545	18.067	8.75	165.000	248.000
2025-395		12	P NITRO PH	220	Medica E.	130	MEDICA	12	207.917	10.226	4.92	166.000	250.000
004 AMYLASE				CLIA TEST ID #: 285									
2025-391		3	ENZYM. 37C	165	VITROS	63	KODAK	84	122.679	6.192	5.05	98.000	147.000
2025-391		4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	20	157.400	2.311	1.47	126.000	189.000
2025-391		9	ENZ/COL.37	203	ROCHE	93	ROCHE	30	162.600	3.200	1.97	130.000	195.000
2025-391		10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	121.438	8.314	6.85	97.000	146.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-391		11	KINETIC	219	ATELLICA	143	SIEMENS	16	180.875	5.302	2.93	145.000	217.000
004 AMYLASE				CLIA TEST ID #: 285 EVALUATION CRITERIA: TARGET VALUE 20 %									
2025-392		3	ENZYM. 37C	165	VITROS	63	KODAK	84	30.543	1.078	3.53	24.000	37.000
2025-392		4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	20	26.850	0.572	2.13	21.000	32.000
2025-392		9	ENZ/COL.37	203	ROCHE	93	ROCHE	30	28.067	0.727	2.59	22.000	34.000
2025-392		10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	20.063	1.676	8.35	16.000	24.000
2025-392		11	KINETIC	219	ATELLICA	143	SIEMENS	16	31.375	0.857	2.73	25.000	38.000
2025-393		3	ENZYM. 37C	165	VITROS	63	KODAK	84	52.798	5.614	10.63	42.000	63.000
2025-393		4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	20	64.400	1.200	1.86	52.000	77.000
2025-393		9	ENZ/COL.37	203	ROCHE	93	ROCHE	30	66.600	1.562	2.35	53.000	80.000
2025-393		10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	49.750	3.992	8.02	40.000	60.000
2025-393		11	KINETIC	219	ATELLICA	143	SIEMENS	16	74.500	2.179	2.93	60.000	89.000
2025-394		3	ENZYM. 37C	165	VITROS	63	KODAK	84	208.000	7.616	3.66	166.000	250.000
2025-394		4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	20	283.850	5.489	1.93	227.000	341.000
2025-394		9	ENZ/COL.37	203	ROCHE	93	ROCHE	30	293.367	7.842	2.67	235.000	352.000
2025-394		10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	217.875	15.451	7.09	174.000	261.000
2025-394		11	KINETIC	219	ATELLICA	143	SIEMENS	16	325.313	14.399	4.43	260.000	390.000
2025-395		3	ENZYM. 37C	165	VITROS	63	KODAK	84	166.892	5.082	3.05	134.000	200.000
2025-395		4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	20	220.200	4.045	1.84	176.000	264.000
2025-395		9	ENZ/COL.37	203	ROCHE	93	ROCHE	30	227.700	5.361	2.35	182.000	273.000
2025-395		10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	168.375	12.956	7.69	135.000	202.000
2025-395		11	KINETIC	219	ATELLICA	143	SIEMENS	16	254.563	7.062	2.77	204.000	305.000
005 ASP. AMINO AST/SGOT				CLIA TEST ID #: 295 EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}									
2025-391		1	ASPAR&KETO	165	VITROS	63	KODAK	132	284.455	9.592	3.37	242.000	327.000
2025-391		1	ASPAR&KETO	220	Medica E.	130	MEDICA	13	213.692	5.928	2.77	182.000	246.000
2025-391		5	ENZYM.37C	38	SIEMENS DI	143	SIEMENS	83	228.000	6.196	2.72	194.000	262.000
2025-391		11	MOD. IFCC	184	INTEGRA	93	ROCHE	20	239.950	6.866	2.86	204.000	276.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2025-391	11	MOD. IFCC	186	BECK. COUL	76 AU-BECKMAN	34	202.382	9.327	4.61	172.000	233.000		
2025-391	11	MOD. IFCC	191	RX-SERIES	126 RANDOX	26	264.115	19.486	7.38	224.000	304.000		
2025-391	11	MOD. IFCC	203	ROCHE	93 ROCHE	41	236.927	6.497	2.74	201.000	272.000		
2025-391	11	MOD. IFCC	219	ATELLICA	143 SIEMENS	22	260.227	7.311	2.81	221.000	299.000		
2025-391	12	IFCC witho	203	ROCHE	93 ROCHE	17	239.706	7.575	3.16	204.000	276.000		
2025-391	13	NADH wo P5	197	ARCHITECT	1 ABBOTT	13	268.538	23.283	8.67	228.000	309.000		
005 ASP. AMINO AST/SGOT			CLIA TEST ID #: 295			EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}							
2025-392	1	ASPAR&KETO	165	VITROS	63 KODAK	132	17.262	0.837	4.85	11.000	23.000		
2025-392	1	ASPAR&KETO	220	Medica E.	130 MEDICA	13	17.000	1.617	9.51	11.000	23.000		
2025-392	5	ENZYM. 37C	38	SIEMENS DI	143 SIEMENS	83	16.341	1.399	8.56	10.000	22.000		
2025-392	11	MOD. IFCC	184	INTEGRA	93 ROCHE	20	15.000	1.095	7.30	9.000	21.000		
2025-392	11	MOD. IFCC	186	BECK. COUL	76 AU-BECKMAN	34	13.485	0.925	6.86	7.000	19.000		
2025-392	11	MOD. IFCC	191	RX-SERIES	126 RANDOX	26	17.400	2.135	12.27	11.000	23.000		
2025-392	11	MOD. IFCC	203	ROCHE	93 ROCHE	41	15.250	0.733	4.81	9.000	21.000		
2025-392	11	MOD. IFCC	219	ATELLICA	143 SIEMENS	22	19.773	1.952	9.87	14.000	26.000		
2025-392	12	IFCC witho	203	ROCHE	93 ROCHE	17	14.824	1.097	7.40	9.000	21.000		
2025-392	13	NADH wo P5	197	ARCHITECT	1 ABBOTT	13	17.154	1.350	7.87	11.000	23.000		
2025-393	1	ASPAR&KETO	165	VITROS	63 KODAK	132	87.992	3.505	3.98	75.000	101.000		
2025-393	1	ASPAR&KETO	220	Medica E.	130 MEDICA	13	74.615	3.476	4.66	63.000	86.000		
2025-393	5	ENZYM. 37C	38	SIEMENS DI	143 SIEMENS	83	78.916	3.257	4.13	67.000	91.000		
2025-393	11	MOD. IFCC	184	INTEGRA	93 ROCHE	20	81.800	2.977	3.64	70.000	94.000		
2025-393	11	MOD. IFCC	186	BECK. COUL	76 AU-BECKMAN	34	70.294	3.634	5.17	60.000	81.000		
2025-393	11	MOD. IFCC	191	RX-SERIES	126 RANDOX	26	92.500	6.494	7.02	79.000	106.000		
2025-393	11	MOD. IFCC	203	ROCHE	93 ROCHE	41	81.195	2.559	3.15	69.000	93.000		
2025-393	11	MOD. IFCC	219	ATELLICA	143 SIEMENS	22	91.182	3.214	3.52	78.000	105.000		
2025-393	12	IFCC witho	203	ROCHE	93 ROCHE	17	81.529	2.329	2.86	69.000	94.000		
2025-393	13	NADH wo P5	197	ARCHITECT	1 ABBOTT	13	91.231	8.011	8.78	78.000	105.000		
2025-394	1	ASPAR&KETO	165	VITROS	63 KODAK	132	601.076	33.428	5.56	511.000	691.000		

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE								
ANALYTE														
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2025-394	1	ASPAR&KETO	220	Medica E.	130	MEDICA	13	385.615	14.167	3.67	328.000	443.000		
2025-394	5	ENZYM.37C	38	SIEMENS DI	143	SIEMENS	83	435.284	18.135	4.17	370.000	501.000		
2025-394	11	MOD. IFCC	184	INTEGRA	93	ROCHE	20	446.350	14.578	3.27	379.000	513.000		
2025-394	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	34	379.588	22.514	5.93	323.000	437.000		
2025-394	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	26	486.200	35.631	7.33	413.000	559.000		
2025-394	11	MOD. IFCC	203	ROCHE	93	ROCHE	41	440.902	12.193	2.77	375.000	507.000		
2025-394	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	22	482.273	18.121	3.76	410.000	555.000		
2025-394	12	IFCC witho	203	ROCHE	93	ROCHE	17	445.529	13.823	3.10	379.000	512.000		
2025-394	13	NADH wo P5	197	ARCHITECT	1	ABBOTT	13	497.385	43.763	8.80	423.000	572.000		
005 ASP. AMINO AST/SGOT			CLIA TEST ID #: 295		EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}									
2025-395	1	ASPAR&KETO	165	VITROS	63	KODAK	132	440.409	18.864	4.28	374.000	506.000		
2025-395	1	ASPAR&KETO	220	Medica E.	130	MEDICA	13	305.231	11.095	3.63	259.000	351.000		
2025-395	5	ENZYM.37C	38	SIEMENS DI	143	SIEMENS	83	332.073	11.245	3.39	282.000	382.000		
2025-395	11	MOD. IFCC	184	INTEGRA	93	ROCHE	20	346.100	10.931	3.16	294.000	398.000		
2025-395	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	34	290.235	14.829	5.11	247.000	334.000		
2025-395	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	26	383.115	32.184	8.40	326.000	441.000		
2025-395	11	MOD. IFCC	203	ROCHE	93	ROCHE	41	341.220	11.304	3.31	290.000	392.000		
2025-395	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	22	372.909	7.323	1.96	317.000	429.000		
2025-395	12	IFCC witho	203	ROCHE	93	ROCHE	17	343.647	12.266	3.57	292.000	395.000		
2025-395	13	NADH wo P5	197	ARCHITECT	1	ABBOTT	13	386.000	33.252	8.61	328.000	444.000		
006 BILIRUBIN, TOTAL			CLIA TEST ID #: 305		EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.40 {GREATER}									
2025-391	1	BICHR.NO B	194	BIOLIS-24S	154	(IDG)	10	2.959	0.206	6.98	2.370	3.550		
2025-391	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	80	3.564	0.214	5.99	2.850	4.280		
2025-391	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	32	3.435	0.137	3.99	2.750	4.120		
2025-391	4	J-G WITH B	191	RX-SERIES	126	RANDOX	20	3.467	0.175	5.04	2.770	4.160		
2025-391	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	3.077	0.188	6.10	2.460	3.690		
2025-391	7	DIAZO-DYPH	165	VITROS	63	KODAK	133	3.474	0.147	4.24	2.780	4.170		
2025-391	13	AZOBIL.	184	INTEGRA	93	ROCHE	12	3.153	0.105	3.34	2.520	3.780		
2025-391	13	AZOBIL.	203	ROCHE	93	ROCHE	39	3.084	0.107	3.46	2.470	3.700		
2025-391	14	VANADATE	219	ATELLICA	143	SIEMENS	22	3.556	0.184	5.18	2.840	4.270		

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-391		14	VANADATE	219	ATELLICA	143	SIEMENS	22	4.218	0.267	6.32	3.370	5.060
2025-391		18	COLORIMETR	184	INTEGRA	93	ROCHE	10	3.086	0.089	2.89	2.470	3.700
2025-391		18	COLORIMETR	203	ROCHE	93	ROCHE	18	3.043	0.121	3.99	2.430	3.650
006 BILIRUBIN, TOTAL			CLIA TEST ID #: 305			EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.40 {GREATER}							
2025-392		1	BICHR.NO B	194	BIOLIS-24S	154	(IDG)	10	0.192	0.035	18.31	0	0.590
2025-392		4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	80	0.117	0.034	28.91	0	0.520
2025-392		4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	32	0.181	0.015	8.22	0	0.580
2025-392		4	J-G WITH B	191	RX-SERIES	126	RANDOX	20	0.133	0.057	42.56	0	0.530
2025-392		5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	0.110	0.015	14.08	0	0.510
2025-392		7	DIAZO-DYPH	165	VITROS	63	KODAK	133	0.110	0.024	21.81	0	0.510
2025-392		13	AZOBIL.	184	INTEGRA	93	ROCHE	12	0.127	0.031	24.19	0	0.530
2025-392		13	AZOBIL.	203	ROCHE	93	ROCHE	39	0.147	0.031	21.09	0	0.550
2025-392		14	VANADATE	219	ATELLICA	143	SIEMENS	22	0.203	0.044	21.56	0	0.600
2025-392		14	VANADATE	219	ATELLICA	143	SIEMENS	22	0.174	0.023	13.15	0	0.570
2025-392		18	COLORIMETR	184	INTEGRA	93	ROCHE	10	0.134	0.023	17.08	0	0.530
2025-392		18	COLORIMETR	203	ROCHE	93	ROCHE	18	0.147	0.026	17.80	0	0.550
2025-393		1	BICHR.NO B	194	BIOLIS-24S	154	(IDG)	10	1.049	0.081	7.74	0.650	1.450
2025-393		4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	80	1.122	0.063	5.66	0.720	1.520
2025-393		4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	32	1.165	0.051	4.38	0.770	1.570
2025-393		4	J-G WITH B	191	RX-SERIES	126	RANDOX	20	1.083	0.088	8.14	0.680	1.480
2025-393		5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	1.051	0.112	10.62	0.650	1.450
2025-393		7	DIAZO-DYPH	165	VITROS	63	KODAK	133	1.096	0.073	6.69	0.700	1.500
2025-393		13	AZOBIL.	184	INTEGRA	93	ROCHE	12	1.003	0.049	4.84	0.600	1.400
2025-393		13	AZOBIL.	203	ROCHE	93	ROCHE	39	0.969	0.036	3.75	0.570	1.370
2025-393		14	VANADATE	219	ATELLICA	143	SIEMENS	22	1.169	0.068	5.83	0.770	1.570
2025-393		14	VANADATE	219	ATELLICA	143	SIEMENS	22	1.400	0.101	7.24	1.000	1.800
2025-393		18	COLORIMETR	184	INTEGRA	93	ROCHE	10	0.976	0.028	2.83	0.580	1.380
2025-393		18	COLORIMETR	203	ROCHE	93	ROCHE	18	0.947	0.042	4.44	0.550	1.350

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE		METHOD	SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
006 BILIRUBIN, TOTAL			CLIA TEST ID #: 305			EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.40 {GREATER}							
2025-394	1	BICHR.NO B	194	BIOLIS-24S	154	(IDG)	10	5.465	0.393	7.19	4.370	6.560	
2025-394	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	80	6.873	0.388	5.64	5.500	8.250	
2025-394	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	32	6.305	0.234	3.71	5.040	7.570	
2025-394	4	J-G WITH B	191	RX-SERIES	126	RANDOX	20	6.557	0.315	4.81	5.250	7.870	
2025-394	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	5.733	0.272	4.74	4.590	6.880	
2025-394	7	DIAZO-DYPH	165	VITROS	63	KODAK	133	6.606	0.268	4.06	5.280	7.930	
2025-394	13	AZOBIL.	184	INTEGRA	93	ROCHE	12	5.950	0.260	4.38	4.760	7.140	
2025-394	13	AZOBIL.	203	ROCHE	93	ROCHE	39	5.899	0.232	3.93	4.720	7.080	
2025-394	14	VANADATE	219	ATELLICA	143	SIEMENS	22	7.903	0.465	5.88	6.320	9.480	
2025-394	14	VANADATE	219	ATELLICA	143	SIEMENS	22	6.786	0.374	5.51	5.430	8.140	
2025-394	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	5.779	0.135	2.33	4.620	6.930	
2025-394	18	COLORIMETR	203	ROCHE	93	ROCHE	18	5.846	0.240	4.11	4.680	7.020	
2025-395	1	BICHR.NO B	194	BIOLIS-24S	154	(IDG)	10	4.263	0.315	7.40	3.410	5.120	
2025-395	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	80	5.226	0.301	5.75	4.180	6.270	
2025-395	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	32	4.847	0.169	3.49	3.880	5.820	
2025-395	4	J-G WITH B	191	RX-SERIES	126	RANDOX	20	4.984	0.299	6.00	3.990	5.980	
2025-395	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	4.432	0.227	5.12	3.550	5.320	
2025-395	7	DIAZO-DYPH	165	VITROS	63	KODAK	133	5.009	0.217	4.32	4.010	6.010	
2025-395	13	AZOBIL.	184	INTEGRA	93	ROCHE	12	4.588	0.156	3.41	3.670	5.510	
2025-395	13	AZOBIL.	203	ROCHE	93	ROCHE	39	4.526	0.179	3.95	3.620	5.430	
2025-395	14	VANADATE	219	ATELLICA	143	SIEMENS	22	5.214	0.261	5.01	4.170	6.260	
2025-395	14	VANADATE	219	ATELLICA	143	SIEMENS	22	6.087	0.349	5.74	4.870	7.300	
2025-395	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	4.434	0.112	2.53	3.550	5.320	
2025-395	18	COLORIMETR	203	ROCHE	93	ROCHE	18	4.479	0.173	3.86	3.580	5.380	
010 CALCIUM, TOTAL			CLIA TEST ID #: 345			EVALUATION CRITERIA: TARGET VALUE 1.00							
2025-391	3	ARSEN. -III	165	VITROS	63	KODAK	151	9.247	0.224	2.42	8.200	10.200	
2025-391	3	ARSEN. -III	186	BECK. COUL	76	AU-BECKMAN	36	9.258	0.196	2.12	8.300	10.300	
2025-391	3	ARSEN. -III	191	RX-SERIES	126	RANDOX	28	9.485	0.259	2.73	8.500	10.500	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-391	3	ARSEN. - III	194	BIOLIS-24S	154	(IDG)	10	9.510	0.197	2.07	8.500	10.500	
2025-391	3	ARSEN. - III	197	ARCHITECT	1	ABBOTT	11	8.909	0.100	1.12	7.900	9.900	
2025-391	3	ARSEN. - III	220	Medica E.	130	MEDICA	12	9.025	0.213	2.36	8.000	10.000	
2025-391	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	83	9.013	0.295	3.27	8.000	10.000	
2025-391	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	14	9.236	0.167	1.81	8.200	10.200	
2025-391	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	9.240	0.120	1.30	8.200	10.200	
2025-391	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	17	9.106	0.351	3.85	8.100	10.100	
2025-391	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	15	9.227	0.302	3.27	8.200	10.200	
2025-391	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	49	9.231	0.184	2.00	8.200	10.200	
010 CALCIUM, TOTAL			CLIA TEST ID #: 345		EVALUATION CRITERIA: TARGET VALUE 1.00								
2025-392	3	ARSEN. - III	165	VITROS	63	KODAK	151	5.806	0.157	2.71	4.800	6.800	
2025-392	3	ARSEN. - III	186	BECK. COUL	76	AU-BECKMAN	36	5.774	0.202	3.50	4.800	6.800	
2025-392	3	ARSEN. - III	191	RX-SERIES	126	RANDOX	28	6.161	0.286	4.64	5.200	7.200	
2025-392	3	ARSEN. - III	194	BIOLIS-24S	154	(IDG)	10	6.270	0.265	4.22	5.300	7.300	
2025-392	3	ARSEN. - III	197	ARCHITECT	1	ABBOTT	11	5.727	0.114	1.98	4.700	6.700	
2025-392	3	ARSEN. - III	220	Medica E.	130	MEDICA	12	5.100	0.271	5.31	4.100	6.100	
2025-392	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	83	5.910	0.239	4.04	4.900	6.900	
2025-392	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	14	5.800	0.125	2.16	4.800	6.800	
2025-392	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	5.870	0.078	1.33	4.900	6.900	
2025-392	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	17	5.594	0.251	4.48	4.600	6.600	
2025-392	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	15	5.893	0.241	4.08	4.900	6.900	
2025-392	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	49	5.890	0.122	2.07	4.900	6.900	
2025-393	3	ARSEN. - III	165	VITROS	63	KODAK	151	6.786	0.177	2.61	5.800	7.800	
2025-393	3	ARSEN. - III	186	BECK. COUL	76	AU-BECKMAN	36	6.760	0.199	2.94	5.800	7.800	
2025-393	3	ARSEN. - III	191	RX-SERIES	126	RANDOX	28	7.039	0.375	5.33	6.000	8.000	
2025-393	3	ARSEN. - III	194	BIOLIS-24S	154	(IDG)	10	7.220	0.279	3.86	6.200	8.200	
2025-393	3	ARSEN. - III	197	ARCHITECT	1	ABBOTT	11	6.609	0.108	1.64	5.600	7.600	
2025-393	3	ARSEN. - III	220	Medica E.	130	MEDICA	12	6.325	0.224	3.54	5.300	7.300	
2025-393	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	83	6.762	0.235	3.47	5.800	7.800	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-393	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	14	6.786	0.125	1.84	5.800	7.800	
2025-393	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	6.830	0.162	2.37	5.800	7.800	
2025-393	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	17	6.647	0.315	4.73	5.600	7.600	
2025-393	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	15	6.820	0.259	3.79	5.800	7.800	
2025-393	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	49	6.822	0.125	1.83	5.800	7.800	
010 CALCIUM, TOTAL			CLIA	TEST ID #: 345		EVALUATION CRITERIA: TARGET VALUE 1.00							
2025-394	3	ARSEN.-III	165	VITROS	63	KODAK	151	12.122	0.316	2.61	11.100	13.100	
2025-394	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	36	12.522	0.343	2.74	11.500	13.500	
2025-394	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	28	12.281	0.482	3.93	11.300	13.300	
2025-394	3	ARSEN.-III	194	BIOLIS-24S	154	(IDG)	10	12.150	0.446	3.67	11.200	13.200	
2025-394	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	11	12.073	0.331	2.74	11.100	13.100	
2025-394	3	ARSEN.-III	220	Medica E.	130	MEDICA	12	12.567	0.327	2.61	11.600	13.600	
2025-394	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	83	12.037	0.342	2.84	11.000	13.000	
2025-394	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	14	12.457	0.247	1.98	11.500	13.500	
2025-394	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	12.170	0.224	1.84	11.200	13.200	
2025-394	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	17	12.300	0.389	3.16	11.300	13.300	
2025-394	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	15	12.300	0.502	4.08	11.300	13.300	
2025-394	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	49	12.361	0.267	2.16	11.400	13.400	
2025-395	3	ARSEN.-III	165	VITROS	63	KODAK	151	10.711	0.260	2.43	9.700	11.700	
2025-395	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	36	10.780	0.232	2.15	9.800	11.800	
2025-395	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	28	10.789	0.337	3.13	9.800	11.800	
2025-395	3	ARSEN.-III	194	BIOLIS-24S	154	(IDG)	10	10.900	0.228	2.09	9.900	11.900	
2025-395	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	11	10.473	0.176	1.68	9.500	11.500	
2025-395	3	ARSEN.-III	220	Medica E.	130	MEDICA	12	10.800	0.300	2.78	9.800	11.800	
2025-395	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	83	10.459	0.325	3.11	9.500	11.500	
2025-395	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	14	10.807	0.167	1.54	9.800	11.800	
2025-395	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	10.800	0.313	2.90	9.800	11.800	
2025-395	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	17	10.824	0.383	3.54	9.800	11.800	
2025-395	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	15	10.747	0.332	3.09	9.700	11.700	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-395		15	CA-NM-BAPT	203	ROCHE	93	ROCHE	49	10.759	0.234	2.17	9.800	11.800
011 CHLORIDE				CLIA TEST ID #: 355		EVALUATION CRITERIA: TARGET VALUE 5 %							
2025-391		3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	102.433	2.290	2.24	97.000	108.000
2025-391		3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	34	99.647	1.348	1.35	95.000	105.000
2025-391		3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	103.786	1.970	1.90	99.000	109.000
2025-391		3	ISE DILUTE	203	ROCHE	93	ROCHE	61	98.754	1.762	1.78	94.000	104.000
2025-391		4	ISE UND-DI	165	VITROS	63	KODAK	57	100.786	1.497	1.48	96.000	106.000
2025-391		4	ISE UND-DI	165	VITROS	156	Kit 32	92	101.185	1.359	1.34	96.000	106.000
2025-391		4	ISE UND-DI	191	RX-SERIES	126	RANDOX	29	100.759	2.028	2.01	96.000	106.000
2025-391		4	ISE UND-DI	220	Medica E.	130	MEDICA	16	100.438	1.731	1.72	95.000	105.000
2025-391		8	IMT	219	ATELLICA	143	SIEMENS	22	103.500	1.901	1.84	98.000	109.000
2025-391		9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	101.469	1.458	1.44	96.000	107.000
2025-392		3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	86.767	2.459	2.83	82.000	91.000
2025-392		3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	34	86.382	1.085	1.26	82.000	91.000
2025-392		3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	89.000	1.414	1.59	85.000	93.000
2025-392		3	ISE DILUTE	203	ROCHE	93	ROCHE	61	83.639	1.820	2.18	79.000	88.000
2025-392		4	ISE UND-DI	165	VITROS	63	KODAK	57	87.339	1.366	1.56	83.000	92.000
2025-392		4	ISE UND-DI	165	VITROS	156	Kit 32	92	87.467	1.246	1.42	83.000	92.000
2025-392		4	ISE UND-DI	191	RX-SERIES	126	RANDOX	29	85.172	1.763	2.07	81.000	89.000
2025-392		4	ISE UND-DI	220	Medica E.	130	MEDICA	16	83.000	1.969	2.37	79.000	87.000
2025-392		8	IMT	219	ATELLICA	143	SIEMENS	22	88.864	1.391	1.57	84.000	93.000
2025-392		9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	84.049	1.369	1.63	80.000	88.000
2025-393		3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	91.103	1.626	1.78	87.000	96.000
2025-393		3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	34	89.353	1.412	1.58	85.000	94.000
2025-393		3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	92.500	1.296	1.40	88.000	97.000
2025-393		3	ISE DILUTE	203	ROCHE	93	ROCHE	61	87.230	1.859	2.13	83.000	92.000
2025-393		4	ISE UND-DI	165	VITROS	63	KODAK	57	90.930	1.776	1.95	86.000	95.000
2025-393		4	ISE UND-DI	165	VITROS	156	Kit 32	92	90.714	1.432	1.58	86.000	95.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE		METHOD		SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-393	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	29	88.690	2.119	2.39		84.000	93.000
2025-393	4	ISE UND-DI	220	Medica E.	130	MEDICA	16	86.875	1.996	2.30		83.000	91.000
2025-393	8	IMT	219	ATELLICA	143	SIEMENS	22	92.227	1.565	1.70		88.000	97.000
2025-393	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	88.222	1.507	1.71		84.000	93.000
011 CHLORIDE				CLIA TEST ID #: 355		EVALUATION CRITERIA: TARGET VALUE 5 %							
2025-394	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	117.700	3.743	3.18		112.000	124.000
2025-394	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	34	112.441	2.003	1.78		107.000	118.000
2025-394	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	115.000	1.773	1.54		109.000	121.000
2025-394	3	ISE DILUTE	203	ROCHE	93	ROCHE	61	113.328	2.380	2.10		108.000	119.000
2025-394	4	ISE UND-DI	165	VITROS	63	KODAK	57	115.268	1.941	1.68		110.000	121.000
2025-394	4	ISE UND-DI	165	VITROS	156	Kit 32	92	114.989	2.051	1.78		109.000	121.000
2025-394	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	29	115.069	2.852	2.48		109.000	121.000
2025-394	4	ISE UND-DI	220	Medica E.	130	MEDICA	16	117.938	4.130	3.50		112.000	124.000
2025-394	8	IMT	219	ATELLICA	143	SIEMENS	22	115.545	3.538	3.06		110.000	121.000
2025-394	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	117.025	2.404	2.05		111.000	123.000
2025-395	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	109.867	3.471	3.16		104.000	115.000
2025-395	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	34	104.727	1.562	1.49		99.000	110.000
2025-395	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	108.500	1.547	1.43		103.000	114.000
2025-395	3	ISE DILUTE	203	ROCHE	93	ROCHE	61	105.328	2.223	2.11		100.000	111.000
2025-395	4	ISE UND-DI	165	VITROS	63	KODAK	57	107.281	1.971	1.84		102.000	113.000
2025-395	4	ISE UND-DI	165	VITROS	156	Kit 32	92	107.099	1.631	1.52		102.000	112.000
2025-395	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	29	106.414	1.752	1.65		101.000	112.000
2025-395	4	ISE UND-DI	220	Medica E.	130	MEDICA	16	109.313	3.868	3.54		104.000	115.000
2025-395	8	IMT	219	ATELLICA	143	SIEMENS	22	108.818	2.229	2.05		103.000	114.000
2025-395	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	108.134	1.974	1.83		103.000	114.000
012 CHOLESTEROL, TOTAL				CLIA TEST ID #: 365		EVALUATION CRITERIA: TARGET VALUE 10 %							
2025-391	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	80	160.848	6.069	3.77		145.000	177.000
2025-391	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	80	169.000	5.099	3.02		152.000	186.000
2025-391	1	ENZYMATIC	165	VITROS	63	KODAK	135	184.067	5.073	2.76		166.000	202.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2025-391	1	ENZYMATIC	184	INTEGRA	93	ROCHE	13	175.923	3.385	1.92	158.000	194.000	
2025-391	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	32	190.355	7.412	3.89	171.000	209.000	
2025-391	1	ENZYMATIC	194	BIOLIS-24S	154	(IDG)	10	183.700	4.540	2.47	165.000	202.000	
2025-391	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	11	174.273	6.662	3.82	157.000	192.000	
2025-391	1	ENZYMATIC	203	ROCHE	93	ROCHE	20	179.050	4.759	2.66	161.000	197.000	
2025-391	1	ENZYMATIC	220	Medica E.	130	MEDICA	13	180.923	3.710	2.05	163.000	199.000	
2025-391	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	11	174.364	5.104	2.93	157.000	192.000	
2025-391	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	32	173.839	3.437	1.98	156.000	191.000	
2025-391	8	ENZYMATIC	203	ROCHE	93	ROCHE	17	178.353	5.052	2.83	161.000	196.000	
2025-391	9	ENZYMATIC	203	ROCHE	93	ROCHE	18	180.000	4.619	2.57	162.000	198.000	
2025-391	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	22	181.409	8.100	4.46	163.000	200.000	
012 CHOLESTEROL, TOTAL			CLIA TEST ID #: 365		EVALUATION CRITERIA: TARGET VALUE 10 %								
2025-392	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	80	114.000	2.160	1.89	103.000	125.000	
2025-392	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	80	109.785	3.977	3.62	99.000	121.000	
2025-392	1	ENZYMATIC	165	VITROS	63	KODAK	135	112.141	3.629	3.24	101.000	123.000	
2025-392	1	ENZYMATIC	184	INTEGRA	93	ROCHE	13	117.000	4.385	3.75	105.000	129.000	
2025-392	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	32	124.323	5.584	4.49	112.000	137.000	
2025-392	1	ENZYMATIC	194	BIOLIS-24S	154	(IDG)	10	123.200	2.315	1.88	111.000	136.000	
2025-392	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	11	116.455	3.846	3.30	105.000	128.000	
2025-392	1	ENZYMATIC	203	ROCHE	93	ROCHE	20	117.850	3.229	2.74	106.000	130.000	
2025-392	1	ENZYMATIC	220	Medica E.	130	MEDICA	13	121.154	2.413	1.99	109.000	133.000	
2025-392	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	11	117.091	1.379	1.18	105.000	129.000	
2025-392	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	32	115.065	2.805	2.44	104.000	127.000	
2025-392	8	ENZYMATIC	203	ROCHE	93	ROCHE	17	118.000	3.049	2.58	106.000	130.000	
2025-392	9	ENZYMATIC	203	ROCHE	93	ROCHE	18	119.000	2.196	1.85	107.000	131.000	
2025-392	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	22	116.136	5.146	4.43	105.000	128.000	
2025-393	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	80	123.165	4.259	3.46	111.000	135.000	
2025-393	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	80	129.667	3.300	2.54	117.000	143.000	
2025-393	1	ENZYMATIC	165	VITROS	63	KODAK	135	132.246	3.908	2.96	119.000	145.000	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2025-393	1	ENZYMATIC	184	INTEGRA	93	ROCHE	13	133.538	3.543	2.65	120.000	147.000	
2025-393	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	32	143.516	5.918	4.12	129.000	158.000	
2025-393	1	ENZYMATIC	194	BIOLIS-24S	154	(IDG)	10	140.200	5.325	3.80	126.000	154.000	
2025-393	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	11	131.818	5.750	4.36	119.000	145.000	
2025-393	1	ENZYMATIC	203	ROCHE	93	ROCHE	20	135.000	3.592	2.66	122.000	149.000	
2025-393	1	ENZYMATIC	220	Medica E.	130	MEDICA	13	138.462	4.181	3.02	125.000	152.000	
2025-393	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	11	133.091	2.391	1.80	120.000	146.000	
2025-393	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	32	130.968	2.192	1.67	118.000	144.000	
2025-393	8	ENZYMATIC	203	ROCHE	93	ROCHE	17	134.647	3.772	2.80	121.000	148.000	
2025-393	9	ENZYMATIC	203	ROCHE	93	ROCHE	18	135.412	1.972	1.46	122.000	149.000	
2025-393	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	22	134.591	6.103	4.53	121.000	148.000	
012 CHOLESTEROL, TOTAL			CLIA TEST ID #: 365		EVALUATION CRITERIA: TARGET VALUE 10 %								
2025-394	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	80	218.000	7.483	3.43	196.000	240.000	
2025-394	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	80	210.295	8.037	3.82	189.000	231.000	
2025-394	1	ENZYMATIC	165	VITROS	63	KODAK	135	254.733	8.754	3.44	229.000	280.000	
2025-394	1	ENZYMATIC	184	INTEGRA	93	ROCHE	13	231.000	4.804	2.08	208.000	254.000	
2025-394	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	32	254.031	11.865	4.67	229.000	279.000	
2025-394	1	ENZYMATIC	194	BIOLIS-24S	154	(IDG)	10	246.600	5.517	2.24	222.000	271.000	
2025-394	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	11	227.636	13.660	6.00	205.000	250.000	
2025-394	1	ENZYMATIC	203	ROCHE	93	ROCHE	20	235.400	8.188	3.48	212.000	259.000	
2025-394	1	ENZYMATIC	220	Medica E.	130	MEDICA	13	239.385	9.369	3.91	215.000	263.000	
2025-394	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	11	227.273	6.929	3.05	205.000	250.000	
2025-394	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	32	230.097	5.438	2.36	207.000	253.000	
2025-394	8	ENZYMATIC	203	ROCHE	93	ROCHE	17	235.118	6.597	2.81	212.000	259.000	
2025-394	9	ENZYMATIC	203	ROCHE	93	ROCHE	18	237.556	5.560	2.34	214.000	261.000	
2025-394	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	22	239.818	12.265	5.11	216.000	264.000	
2025-395	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	80	185.128	7.865	4.25	167.000	204.000	
2025-395	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	80	194.000	7.789	4.01	175.000	213.000	
2025-395	1	ENZYMATIC	165	VITROS	63	KODAK	135	218.830	6.858	3.13	197.000	241.000	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-395		1	ENZYMATIC	184	INTEGRA	93	ROCHE	13	201.846	5.736	2.84	182.000	222.000
2025-395		1	ENZYMATIC	191	RX-SERIES	126	RANDOX	32	222.219	12.056	5.43	200.000	244.000
2025-395		1	ENZYMATIC	194	BIOLIS-24S	154	(IDG)	10	214.400	8.040	3.75	193.000	236.000
2025-395		1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	11	201.000	8.883	4.42	181.000	221.000
2025-395		1	ENZYMATIC	203	ROCHE	93	ROCHE	20	206.400	6.621	3.21	186.000	227.000
2025-395		1	ENZYMATIC	220	Medica E.	130	MEDICA	13	207.538	3.342	1.61	187.000	228.000
2025-395		5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	11	200.273	3.956	1.98	180.000	220.000
2025-395		8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	32	200.774	5.458	2.72	181.000	221.000
2025-395		8	ENZYMATIC	203	ROCHE	93	ROCHE	17	206.765	6.950	3.36	186.000	227.000
2025-395		9	ENZYMATIC	203	ROCHE	93	ROCHE	18	209.059	4.304	2.06	188.000	230.000
2025-395		9	ENZYMATIC	219	ATELLICA	143	SIEMENS	22	210.136	8.874	4.22	189.000	231.000
013 CHOLESTEROL, (HDL)				CLIA TEST ID #: 375		EVALUATION CRITERIA: TARGET VALUE 20 % OR 6.00 {GREATER}							
2025-391		5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	56.050	1.767	3.15	44.800	67.300
2025-391		11	ENC.-COLO.	165	VITROS	63	KODAK	132	51.825	2.410	4.65	41.500	62.200
2025-391		11	ENC.-COLO.	184	INTEGRA	93	ROCHE	29	62.543	3.232	5.17	50.000	75.100
2025-391		11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	33	58.948	2.871	4.87	47.200	70.700
2025-391		11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	34	55.124	4.970	9.02	44.100	66.100
2025-391		11	ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	44.400	2.245	5.06	35.500	53.300
2025-391		11	ENC.-COLO.	203	ROCHE	93	ROCHE	50	61.800	2.429	3.93	49.400	74.200
2025-391		11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	21	58.619	3.741	6.38	46.900	70.300
2025-391		11	ENC.-COLO.	220	Medica E.	130	MEDICA	13	52.538	2.845	5.42	42.000	63.000
2025-391		12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	57.083	3.095	5.42	45.700	68.500
2025-391		13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	78	58.125	2.208	3.80	46.500	69.800
2025-391		13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	78	46.530	2.945	6.33	37.200	55.800
2025-392		5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	40.270	2.387	5.93	32.200	48.300
2025-392		11	ENC.-COLO.	165	VITROS	63	KODAK	132	36.554	1.664	4.55	29.200	43.900
2025-392		11	ENC.-COLO.	184	INTEGRA	93	ROCHE	29	49.521	2.607	5.26	39.600	59.400
2025-392		11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	33	39.688	1.525	3.84	31.800	47.600
2025-392		11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	34	38.088	3.486	9.15	30.500	45.700

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
	2025-392	11	ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	29.400	1.960	6.67	23.400	35.400
	2025-392	11	ENC.-COLO.	203	ROCHE	93	ROCHE	50	48.656	2.455	5.05	38.900	58.400
	2025-392	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	21	39.300	2.511	6.39	31.400	47.200
	2025-392	11	ENC.-COLO.	220	Medica E.	130	MEDICA	13	34.385	1.643	4.78	27.500	41.300
	2025-392	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	39.583	2.290	5.78	31.700	47.500
	2025-392	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	78	42.888	2.520	5.88	34.300	51.500
	2025-392	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	78	41.150	2.137	5.19	32.900	49.400
013 CHOLESTEROL, (HDL)				CLIA TEST ID #: 375		EVALUATION CRITERIA: TARGET VALUE 20 % OR 6.00 {GREATER}							
	2025-393	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	43.820	1.609	3.67	35.100	52.600
	2025-393	11	ENC.-COLO.	165	VITROS	63	KODAK	132	39.644	1.949	4.92	31.700	47.600
	2025-393	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	29	53.182	2.701	5.08	42.500	63.800
	2025-393	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	33	45.184	1.729	3.83	36.100	54.200
	2025-393	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	34	42.244	4.254	10.07	33.800	50.700
	2025-393	11	ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	33.900	1.921	5.67	27.100	40.700
	2025-393	11	ENC.-COLO.	203	ROCHE	93	ROCHE	50	51.992	1.990	3.83	41.600	62.400
	2025-393	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	21	44.990	2.208	4.91	36.000	54.000
	2025-393	11	ENC.-COLO.	220	Medica E.	130	MEDICA	13	39.385	1.982	5.03	31.500	47.300
	2025-393	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	43.833	2.303	5.25	35.100	52.600
	2025-393	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	78	45.525	2.727	5.99	36.400	54.600
	2025-393	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	78	43.869	2.630	5.99	35.100	52.600
	2025-394	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	73.250	3.750	5.12	58.600	87.900
	2025-394	11	ENC.-COLO.	165	VITROS	63	KODAK	132	74.462	4.781	6.42	59.600	89.400
	2025-394	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	29	72.643	3.657	5.03	58.100	87.200
	2025-394	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	33	77.839	3.577	4.60	62.300	93.400
	2025-394	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	34	70.564	5.448	7.72	56.500	84.700
	2025-394	11	ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	60.200	3.219	5.35	48.200	72.200
	2025-394	11	ENC.-COLO.	203	ROCHE	93	ROCHE	50	71.734	3.203	4.47	57.400	86.100
	2025-394	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	21	76.343	5.062	6.63	61.100	91.600
	2025-394	11	ENC.-COLO.	220	Medica E.	130	MEDICA	13	69.308	4.286	6.18	55.400	83.200

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
	2025-394	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	72.083	3.989	5.53	57.700	86.500
	2025-394	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	78	48.384	2.912	6.02	38.700	58.100
	2025-394	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	78	73.300	3.378	4.61	58.600	88.000
013 CHOLESTEROL, (HDL)				CLIA TEST ID #: 375			EVALUATION CRITERIA: TARGET VALUE 20 % OR 6.00 {GREATER}						
	2025-395	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	64.280	2.574	4.00	51.400	77.100
	2025-395	11	ENC.-COLO.	165	VITROS	63	KODAK	132	61.048	3.097	5.07	48.800	73.300
	2025-395	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	29	67.618	3.452	5.10	54.100	81.100
	2025-395	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	33	67.867	3.262	4.81	54.300	81.400
	2025-395	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	34	63.088	4.615	7.32	50.500	75.700
	2025-395	11	ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	51.700	2.865	5.54	41.400	62.000
	2025-395	11	ENC.-COLO.	203	ROCHE	93	ROCHE	50	66.568	2.833	4.26	53.300	79.900
	2025-395	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	21	67.262	4.184	6.22	53.800	80.700
	2025-395	11	ENC.-COLO.	220	Medica E.	130	MEDICA	13	60.538	2.763	4.56	48.400	72.600
	2025-395	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	64.500	3.476	5.39	51.600	77.400
	2025-395	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	78	65.450	1.584	2.42	52.400	78.500
	2025-395	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	78	47.079	3.252	6.91	37.700	56.500
014 CREATINE KINASE (CK)				CLIA TEST ID #: 385			EVALUATION CRITERIA: TARGET VALUE 20 %						
	2025-391	3	KINETIC 37	165	VITROS	63	KODAK	68	291.358	17.291	5.93	233.000	350.000
	2025-391	3	KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	314.588	16.435	5.22	252.000	378.000
	2025-391	5	SZASZ-MOD.	219	ATELLICA	143	SIEMENS	17	344.188	19.217	5.58	275.000	413.000
	2025-391	8	Hexokinase	203	ROCHE	93	ROCHE	11	343.727	5.011	1.46	275.000	412.000
	2025-391	9	SIEMENS	38	SIEMENS DI	143	SIEMENS	22	342.591	10.798	3.15	274.000	411.000
	2025-391	10	ENZYMATIC-	203	ROCHE	93	ROCHE	16	351.438	11.291	3.21	281.000	422.000
	2025-392	3	KINETIC 37	165	VITROS	63	KODAK	68	40.194	3.261	8.11	32.000	48.000
	2025-392	3	KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	37.176	2.093	5.63	30.000	45.000
	2025-392	5	SZASZ-MOD.	219	ATELLICA	143	SIEMENS	17	43.471	2.476	5.70	35.000	52.000
	2025-392	8	Hexokinase	203	ROCHE	93	ROCHE	11	45.727	2.004	4.38	37.000	55.000
	2025-392	9	SIEMENS	38	SIEMENS DI	143	SIEMENS	22	43.045	2.286	5.31	34.000	52.000
	2025-392	10	ENZYMATIC-	203	ROCHE	93	ROCHE	16	48.063	1.749	3.64	38.000	58.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
014 CREATINE KINASE (CK)			CLIA TEST ID #: 385		EVALUATION CRITERIA: TARGET VALUE 20 %							
2025-393	3	KINETIC 37	165 VITROS	63	KODAK	68	122.985	8.875	7.22	98.000	148.000	
2025-393	3	KINETIC 37	186 BECK. COUL	76	AU-BECKMAN	17	121.059	5.620	4.64	97.000	145.000	
2025-393	5	SZASZ-MOD.	219 ATELLICA	143	SIEMENS	17	133.438	7.738	5.80	107.000	160.000	
2025-393	8	Hexokinase	203 ROCHE	93	ROCHE	11	135.545	2.500	1.84	108.000	163.000	
2025-393	9	SIEMENS	38 SIEMENS DI	143	SIEMENS	22	134.364	3.926	2.92	107.000	161.000	
2025-393	10	ENZYMATIC-	203 ROCHE	93	ROCHE	16	136.750	3.700	2.71	109.000	164.000	
2025-394	3	KINETIC 37	165 VITROS	63	KODAK	68	453.821	25.399	5.60	363.000	545.000	
2025-394	3	KINETIC 37	186 BECK. COUL	76	AU-BECKMAN	17	574.765	32.984	5.74	460.000	690.000	
2025-394	5	SZASZ-MOD.	219 ATELLICA	143	SIEMENS	17	614.882	49.210	8.00	492.000	738.000	
2025-394	8	Hexokinase	203 ROCHE	93	ROCHE	11	618.727	14.194	2.29	495.000	742.000	
2025-394	9	SIEMENS	38 SIEMENS DI	143	SIEMENS	22	619.773	17.957	2.90	496.000	744.000	
2025-394	10	ENZYMATIC-	203 ROCHE	93	ROCHE	16	624.250	23.053	3.69	499.000	749.000	
2025-395	3	KINETIC 37	165 VITROS	63	KODAK	68	384.955	23.104	6.00	308.000	462.000	
2025-395	3	KINETIC 37	186 BECK. COUL	76	AU-BECKMAN	17	444.824	20.420	4.59	356.000	534.000	
2025-395	5	SZASZ-MOD.	219 ATELLICA	143	SIEMENS	17	487.500	25.556	5.24	390.000	585.000	
2025-395	8	Hexokinase	203 ROCHE	93	ROCHE	11	483.727	13.335	2.76	387.000	580.000	
2025-395	9	SIEMENS	38 SIEMENS DI	143	SIEMENS	22	489.909	13.771	2.81	392.000	588.000	
2025-395	10	ENZYMATIC-	203 ROCHE	93	ROCHE	16	491.188	13.593	2.77	393.000	589.000	
016 CREATININE			CLIA TEST ID #: 405		EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.20 {GREATER}							
2025-391	2	AK. PIC. N	191 RX-SERIES	126	RANDOX	22	3.419	0.258	7.54	3.080	3.760	
2025-391	2	AK. PIC. N	194 BIOLIS-24S	154	(IDG)	10	3.802	0.092	2.43	3.420	4.180	
2025-391	4	ENZYMATIC	203 ROCHE	93	ROCHE	12	3.924	0.121	3.09	3.530	4.320	
2025-391	4	ENZYMATIC	220 Medica E.	130	MEDICA	16	4.005	0.084	2.10	3.600	4.410	
2025-391	6	KIN. ALK P	184 INTEGRA	93	ROCHE	15	3.874	0.147	3.80	3.490	4.260	
2025-391	6	KIN. ALK P	186 BECK. COUL	76	AU-BECKMAN	36	3.906	0.116	2.97	3.520	4.300	
2025-391	6	KIN. ALK P	197 ARCHITECT	1	ABBOTT	18	4.182	0.158	3.77	3.760	4.600	
2025-391	6	KIN. ALK P	203 ROCHE	93	ROCHE	29	3.882	0.142	3.67	3.490	4.270	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2025-391	8	IDMS-CREA	165	VITROS	63	KODAK	150	3.853	0.086	2.22	3.470	4.240	
2025-391	9	MODIFIED	219	ATELLICA	143	SIEMENS	21	3.901	0.131	3.36	3.510	4.290	
2025-391	10	JAFFE COMP	203	ROCHE	93	ROCHE	14	3.896	0.129	3.31	3.510	4.290	
2025-391	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	77	4.055	0.110	2.70	3.650	4.460	
2025-391	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	77	3.990	0.114	2.85	3.590	4.390	
016 CREATININE			CLIA	TEST ID #: 405		EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.20 {GREATER}							
2025-392	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	22	0.715	0.075	10.51	0.520	0.920	
2025-392	2	AK. PIC. N	194	BIOLIS-24S	154	(IDG)	10	0.757	0.044	5.76	0.560	0.960	
2025-392	4	ENZYMATIC	203	ROCHE	93	ROCHE	12	0.607	0.062	10.24	0.410	0.810	
2025-392	4	ENZYMATIC	220	Medica E.	130	MEDICA	16	0.682	0.031	4.50	0.480	0.880	
2025-392	6	KIN. ALK P	184	INTEGRA	93	ROCHE	15	0.614	0.027	4.44	0.410	0.810	
2025-392	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	36	0.556	0.039	6.94	0.360	0.760	
2025-392	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	0.611	0.029	4.74	0.410	0.810	
2025-392	6	KIN. ALK P	203	ROCHE	93	ROCHE	29	0.573	0.036	6.35	0.370	0.770	
2025-392	8	IDMS-CREA	165	VITROS	63	KODAK	150	0.621	0.030	4.79	0.420	0.820	
2025-392	9	MODIFIED	219	ATELLICA	143	SIEMENS	21	0.566	0.050	8.83	0.370	0.770	
2025-392	10	JAFFE COMP	203	ROCHE	93	ROCHE	14	0.572	0.018	3.23	0.370	0.770	
2025-392	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	77	0.593	0.019	3.24	0.390	0.790	
2025-392	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	77	0.563	0.059	10.45	0.360	0.760	
2025-393	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	22	1.518	0.110	7.25	1.320	1.720	
2025-393	2	AK. PIC. N	194	BIOLIS-24S	154	(IDG)	10	1.658	0.073	4.40	1.460	1.860	
2025-393	4	ENZYMATIC	203	ROCHE	93	ROCHE	12	1.604	0.067	4.15	1.400	1.800	
2025-393	4	ENZYMATIC	220	Medica E.	130	MEDICA	16	1.641	0.043	2.61	1.440	1.840	
2025-393	6	KIN. ALK P	184	INTEGRA	93	ROCHE	15	1.627	0.074	4.53	1.430	1.830	
2025-393	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	36	1.550	0.063	4.07	1.350	1.750	
2025-393	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	1.538	0.092	5.99	1.340	1.740	
2025-393	6	KIN. ALK P	203	ROCHE	93	ROCHE	29	1.589	0.073	4.60	1.390	1.790	
2025-393	8	IDMS-CREA	165	VITROS	63	KODAK	150	1.571	0.048	3.06	1.370	1.770	
2025-393	9	MODIFIED	219	ATELLICA	143	SIEMENS	21	1.563	0.062	3.97	1.360	1.760	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2025-393	10	JAFFE COMP	203	ROCHE	93	ROCHE	14	1.586	0.062	3.89	1.390	1.790	
2025-393	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	77	1.646	0.079	4.78	1.450	1.850	
2025-393	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	77	1.458	0.043	2.93	1.260	1.660	
016 CREATININE			CLIA	TEST ID #: 405	EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.20 {GREATER}								
2025-394	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	22	5.821	0.435	7.48	5.240	6.400	
2025-394	2	AK. PIC. N	194	BIOLIS-24S	154	(IDG)	10	6.683	0.248	3.72	6.010	7.350	
2025-394	4	ENZYMATIC	203	ROCHE	93	ROCHE	12	6.765	0.358	5.28	6.090	7.440	
2025-394	4	ENZYMATIC	220	Medica E.	130	MEDICA	16	7.246	0.158	2.18	6.520	7.970	
2025-394	6	KIN. ALK P	184	INTEGRA	93	ROCHE	15	6.515	0.261	4.01	5.860	7.170	
2025-394	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	36	6.950	0.266	3.82	6.260	7.650	
2025-394	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	7.641	0.415	5.43	6.880	8.400	
2025-394	6	KIN. ALK P	203	ROCHE	93	ROCHE	29	6.643	0.290	4.36	5.980	7.310	
2025-394	8	IDMS-CREA	165	VITROS	63	KODAK	150	6.991	0.193	2.76	6.290	7.690	
2025-394	9	MODIFIED	219	ATELLICA	143	SIEMENS	21	6.961	0.209	3.00	6.260	7.660	
2025-394	10	JAFFE COMP	203	ROCHE	93	ROCHE	14	6.698	0.199	2.98	6.030	7.370	
2025-394	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	77	7.483	0.205	2.74	6.730	8.230	
2025-394	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	77	7.372	0.240	3.26	6.630	8.110	
2025-395	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	22	4.721	0.394	8.35	4.250	5.190	
2025-395	2	AK. PIC. N	194	BIOLIS-24S	154	(IDG)	10	5.375	0.171	3.19	4.840	5.910	
2025-395	4	ENZYMATIC	203	ROCHE	93	ROCHE	12	5.429	0.175	3.23	4.890	5.970	
2025-395	4	ENZYMATIC	220	Medica E.	130	MEDICA	16	5.637	0.120	2.13	5.070	6.200	
2025-395	6	KIN. ALK P	184	INTEGRA	93	ROCHE	15	5.207	0.162	3.11	4.690	5.730	
2025-395	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	36	5.419	0.208	3.83	4.880	5.960	
2025-395	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	5.948	0.256	4.30	5.350	6.540	
2025-395	6	KIN. ALK P	203	ROCHE	93	ROCHE	29	5.276	0.208	3.95	4.750	5.800	
2025-395	8	IDMS-CREA	165	VITROS	63	KODAK	150	5.413	0.142	2.62	4.870	5.950	
2025-395	9	MODIFIED	219	ATELLICA	143	SIEMENS	21	5.506	0.152	2.77	4.960	6.060	
2025-395	10	JAFFE COMP	203	ROCHE	93	ROCHE	14	5.309	0.163	3.06	4.780	5.840	
2025-395	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	77	5.708	0.184	3.22	5.140	6.280	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-395		11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	77	5.698	0.144	2.54	5.130	6.270
017 GLUCOSE				CLIA TEST ID #: 415				EVALUATION CRITERIA: TARGET VALUE 8 % OR 6.00 {GREATER}					
2025-391		3	GL. OXI. C	165	VITROS	63	KODAK	152	90.340	2.113	2.34	83.000	98.000
2025-391		5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	83	96.195	3.066	3.19	88.000	104.000
2025-391		5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	91.000	1.897	2.09	84.000	98.000
2025-391		5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	36	89.829	1.844	2.05	83.000	97.000
2025-391		5	HEXOKINASE	191	RX-SERIES	126	RANDOX	25	93.640	5.534	5.91	86.000	101.000
2025-391		5	HEXOKINASE	203	ROCHE	93	ROCHE	37	90.568	2.074	2.29	83.000	98.000
2025-391		6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	89.300	2.052	2.30	82.000	96.000
2025-391		6	HEXOKI. CO	220	Medica E.	130	MEDICA	16	93.313	2.053	2.20	86.000	101.000
2025-391		12	HEXOKINASE	184	INTEGRA	93	ROCHE	20	92.150	2.515	2.73	85.000	100.000
2025-391		12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	15	87.267	1.569	1.80	80.000	94.000
2025-391		12	HEXOKINASE	203	ROCHE	93	ROCHE	23	89.087	1.932	2.17	82.000	96.000
2025-391		12	HEXOKINASE	219	ATELLICA	143	SIEMENS	22	88.409	2.774	3.14	81.000	95.000
2025-392		3	GL. OXI. C	165	VITROS	63	KODAK	152	32.733	1.043	3.19	27.000	39.000
2025-392		5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	83	38.366	1.743	4.54	32.000	44.000
2025-392		5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	36.100	0.831	2.30	30.000	42.000
2025-392		5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	36	35.417	1.090	3.08	29.000	41.000
2025-392		5	HEXOKINASE	191	RX-SERIES	126	RANDOX	25	40.160	2.203	5.49	34.000	46.000
2025-392		5	HEXOKINASE	203	ROCHE	93	ROCHE	37	35.243	0.851	2.42	29.000	41.000
2025-392		6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	37.700	2.002	5.31	32.000	44.000
2025-392		6	HEXOKI. CO	220	Medica E.	130	MEDICA	16	36.688	1.310	3.57	31.000	43.000
2025-392		12	HEXOKINASE	184	INTEGRA	93	ROCHE	20	36.050	1.244	3.45	30.000	42.000
2025-392		12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	15	33.400	0.879	2.63	27.000	39.000
2025-392		12	HEXOKINASE	203	ROCHE	93	ROCHE	23	34.957	0.955	2.73	29.000	41.000
2025-392		12	HEXOKINASE	219	ATELLICA	143	SIEMENS	22	35.500	1.197	3.37	30.000	42.000
2025-393		3	GL. OXI. C	165	VITROS	63	KODAK	152	47.653	1.479	3.10	42.000	54.000
2025-393		5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	83	55.024	2.175	3.95	49.000	61.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-393		5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	52.300	1.005	1.92	46.000	58.000
2025-393		5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	36	51.543	1.592	3.09	46.000	58.000
2025-393		5	HEXOKINASE	191	RX-SERIES	126	RANDOX	25	55.520	3.048	5.49	50.000	62.000
2025-393		5	HEXOKINASE	203	ROCHE	93	ROCHE	37	51.324	1.092	2.13	45.000	57.000
2025-393		6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	52.300	1.676	3.21	46.000	58.000
2025-393		6	HEXOKI. CO	220	Medica E.	130	MEDICA	16	53.438	1.694	3.17	47.000	59.000
2025-393		12	HEXOKINASE	184	INTEGRA	93	ROCHE	20	52.650	1.236	2.35	47.000	59.000
2025-393		12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	15	48.933	0.998	2.04	43.000	55.000
2025-393		12	HEXOKINASE	203	ROCHE	93	ROCHE	23	50.826	1.578	3.11	45.000	57.000
2025-393		12	HEXOKINASE	219	ATELLICA	143	SIEMENS	22	50.682	1.963	3.87	45.000	57.000
017 GLUCOSE				CLIA TEST ID #: 415				EVALUATION CRITERIA: TARGET VALUE 8 % OR 6.00 {GREATER}					
2025-394		3	GL. OXI. C	165	VITROS	63	KODAK	152	146.000	3.533	2.42	134.000	158.000
2025-394		5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	83	150.675	4.485	2.98	139.000	163.000
2025-394		5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	141.400	4.386	3.10	130.000	153.000
2025-394		5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	36	142.111	4.221	2.97	131.000	153.000
2025-394		5	HEXOKINASE	191	RX-SERIES	126	RANDOX	25	144.640	9.068	6.27	133.000	156.000
2025-394		5	HEXOKINASE	203	ROCHE	93	ROCHE	37	143.083	3.336	2.33	132.000	155.000
2025-394		6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	142.500	3.202	2.25	131.000	154.000
2025-394		6	HEXOKI. CO	220	Medica E.	130	MEDICA	16	145.500	4.472	3.07	134.000	157.000
2025-394		12	HEXOKINASE	184	INTEGRA	93	ROCHE	20	145.850	4.339	2.98	134.000	158.000
2025-394		12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	15	136.867	5.123	3.74	126.000	148.000
2025-394		12	HEXOKINASE	203	ROCHE	93	ROCHE	23	140.773	2.131	1.51	130.000	152.000
2025-394		12	HEXOKINASE	219	ATELLICA	143	SIEMENS	22	137.591	5.263	3.82	127.000	149.000
2025-395		3	GL. OXI. C	165	VITROS	63	KODAK	152	117.553	2.712	2.31	108.000	127.000
2025-395		5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	83	122.927	4.322	3.52	113.000	133.000
2025-395		5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	117.900	2.385	2.02	108.000	127.000
2025-395		5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	36	115.361	3.824	3.31	106.000	125.000
2025-395		5	HEXOKINASE	191	RX-SERIES	126	RANDOX	25	118.640	5.761	4.86	109.000	128.000
2025-395		5	HEXOKINASE	203	ROCHE	93	ROCHE	37	116.694	3.072	2.63	107.000	126.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-395		6	HEXOKI. CO	194	BIOLIS-24S	154 (IDG)	10	114.800	2.135	1.86	106.000	124.000	
2025-395		6	HEXOKI. CO	220	Medica E.	130 MEDICA	16	119.063	2.839	2.38	110.000	129.000	
2025-395		12	HEXOKINASE	184	INTEGRA	93 ROCHE	20	119.150	2.670	2.24	110.000	129.000	
2025-395		12	HEXOKINASE	197	ARCHITECT	1 ABBOTT	15	112.267	2.489	2.22	103.000	121.000	
2025-395		12	HEXOKINASE	203	ROCHE	93 ROCHE	23	115.000	2.993	2.60	106.000	124.000	
2025-395		12	HEXOKINASE	219	ATELLICA	143 SIEMENS	22	113.182	3.701	3.27	104.000	122.000	
018 IRON, TOTAL			CLIA TEST ID #: 425				EVALUATION CRITERIA: TARGET VALUE 15 %						
2025-391		4	COULOMETR.	165	VITROS	63 KODAK	19	210.222	7.004	3.33	179.000	242.000	
2025-392		4	COULOMETR.	165	VITROS	63 KODAK	19	59.211	4.884	8.25	50.000	68.000	
2025-393		4	COULOMETR.	165	VITROS	63 KODAK	19	99.474	7.322	7.36	85.000	114.000	
2025-394		4	COULOMETR.	165	VITROS	63 KODAK	19	390.789	14.873	3.81	332.000	449.000	
2025-395		4	COULOMETR.	165	VITROS	63 KODAK	19	292.632	11.527	3.94	249.000	337.000	
019 LACTASE DEHY. (LDH)			CLIA TEST ID #: 435										
2025-391		3	KINETIC-37	186	BECK. COUL	76 AU-BECKMAN	19	313.000	21.636	6.91	266.000	360.000	
2025-391		6	NADH	203	ROCHE	93 ROCHE	27	403.630	10.914	2.70	343.000	464.000	
2025-391		6	NADH	219	ATELLICA	143 SIEMENS	17	391.529	9.525	2.43	333.000	450.000	
2025-391		7	SIEMENS 37	38	SIEMENS DI	143 SIEMENS	30	384.700	13.352	3.47	327.000	442.000	
2025-391		9	LDH1	165	VITROS	63 KODAK	65	493.754	16.029	3.25	420.000	568.000	
2025-392		3	KINETIC-37	186	BECK. COUL	76 AU-BECKMAN	19	43.105	2.900	6.73	37.000	50.000	
2025-392		6	NADH	203	ROCHE	93 ROCHE	27	57.444	1.912	3.33	49.000	66.000	
2025-392		6	NADH	219	ATELLICA	143 SIEMENS	17	53.882	2.564	4.76	46.000	62.000	
2025-392		7	SIEMENS 37	38	SIEMENS DI	143 SIEMENS	30	53.567	5.315	9.92	46.000	62.000	
2025-392		9	LDH1	165	VITROS	63 KODAK	65	68.609	4.550	6.63	58.000	79.000	
2025-393		3	KINETIC-37	186	BECK. COUL	76 AU-BECKMAN	19	123.316	8.688	7.05	105.000	142.000	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-393		6	NADH	203	ROCHE	93	ROCHE	27	160.481	4.954	3.09	136.000	185.000
2025-393		6	NADH	219	ATELLICA	143	SIEMENS	17	157.471	4.742	3.01	134.000	181.000
2025-393		7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	30	150.400	6.616	4.40	128.000	173.000
2025-393		9	LDH1	165	VITROS	63	KODAK	65	197.906	6.654	3.36	168.000	228.000
019 LACTASE DEHY. (LDH)				CLIA TEST ID #: 435				EVALUATION CRITERIA: TARGET VALUE 15 %					
2025-394		3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	566.789	39.303	6.93	482.000	652.000
2025-394		6	NADH	203	ROCHE	93	ROCHE	27	715.962	21.639	3.02	609.000	823.000
2025-394		6	NADH	219	ATELLICA	143	SIEMENS	17	687.118	33.664	4.90	584.000	790.000
2025-394		7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	30	696.069	27.684	3.98	592.000	800.000
2025-394		9	LDH1	165	VITROS	63	KODAK	65	876.462	47.775	5.45	745.000	1008.000
2025-395		3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	436.684	26.758	6.13	371.000	502.000
2025-395		6	NADH	203	ROCHE	93	ROCHE	27	562.037	16.585	2.95	478.000	646.000
2025-395		6	NADH	219	ATELLICA	143	SIEMENS	17	544.118	17.146	3.15	463.000	626.000
2025-395		7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	30	543.700	23.710	4.36	462.000	625.000
2025-395		9	LDH1	165	VITROS	63	KODAK	65	697.169	32.097	4.60	593.000	802.000
021 MAGNESIUM				CLIA TEST ID #: 455									
2025-391		5	COLOR./K E	165	VITROS	63	KODAK	28	3.921	0.115	2.92	3.300	4.500
2025-391		8	XYLIDYL B.	203	ROCHE	93	ROCHE	10	3.670	0.078	2.13	3.100	4.200
2025-391		8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	3.550	0.220	6.20	3.000	4.100
2025-392		5	COLOR./K E	165	VITROS	63	KODAK	28	1.421	0.086	6.05	1.200	1.600
2025-392		8	XYLIDYL B.	203	ROCHE	93	ROCHE	10	1.440	0.136	9.42	1.200	1.700
2025-392		8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	1.340	0.066	4.95	1.100	1.500
2025-393		5	COLOR./K E	165	VITROS	63	KODAK	28	2.157	0.105	4.87	1.800	2.500
2025-393		8	XYLIDYL B.	203	ROCHE	93	ROCHE	10	2.060	0.066	3.22	1.800	2.400
2025-393		8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	1.970	0.078	3.96	1.700	2.300
2025-394		5	COLOR./K E	165	VITROS	63	KODAK	28	6.279	0.182	2.90	5.300	7.200

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-394		8	XYLIDYL B.	203	ROCHE	93	ROCHE	10	5.880	0.293	4.98	5.000	6.800
2025-394		8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	5.800	0.683	11.77	4.900	6.700
021 MAGNESIUM			CLIA TEST ID #: 455			EVALUATION CRITERIA: TARGET VALUE 15 %							
2025-395		5	COLOR./K E	165	VITROS	63	KODAK	28	5.079	0.135	2.65	4.300	5.800
2025-395		8	XYLIDYL B.	203	ROCHE	93	ROCHE	10	4.760	0.136	2.85	4.000	5.500
2025-395		8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	4.650	0.369	7.95	4.000	5.300
022 POTASSIUM			CLIA TEST ID #: 465			EVALUATION CRITERIA: TARGET VALUE 0.30							
2025-391		3	ISE DILUT.	184	INTEGRA	93	ROCHE	28	4.100	0.100	2.44	3.800	4.400
2025-391		3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	35	4.029	0.074	1.84	3.700	4.300
2025-391		3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	4.053	0.050	1.23	3.800	4.400
2025-391		3	ISE DILUT.	203	ROCHE	93	ROCHE	62	4.126	0.084	2.04	3.800	4.400
2025-391		4	ISE UNDIL.	165	VITROS	63	KODAK	58	4.111	0.069	1.69	3.800	4.400
2025-391		4	ISE UNDIL.	165	VITROS	156	Kit 32	92	4.127	0.063	1.53	3.800	4.400
2025-391		4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	28	4.050	0.124	3.06	3.800	4.400
2025-391		4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	28	3.871	0.128	3.30	3.600	4.200
2025-391		4	ISE UNDIL.	220	Medica E.	130	MEDICA	16	3.994	0.056	1.39	3.700	4.300
2025-391		5	IMT	219	ATELLICA	143	SIEMENS	22	3.977	0.067	1.68	3.700	4.300
2025-391		6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	81	4.063	0.068	1.67	3.800	4.400
2025-392		3	ISE DILUT.	184	INTEGRA	93	ROCHE	28	2.011	0.050	2.47	1.700	2.300
2025-392		3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	35	2.076	0.049	2.35	1.800	2.400
2025-392		3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	1.993	0.057	2.88	1.700	2.300
2025-392		3	ISE DILUT.	203	ROCHE	93	ROCHE	62	2.055	0.073	3.57	1.800	2.400
2025-392		4	ISE UNDIL.	165	VITROS	63	KODAK	58	1.996	0.042	2.09	1.700	2.300
2025-392		4	ISE UNDIL.	165	VITROS	156	Kit 32	92	1.995	0.040	2.01	1.700	2.300
2025-392		4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	28	2.143	0.127	5.91	1.800	2.400
2025-392		4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	28	2.186	0.083	3.81	1.900	2.500
2025-392		4	ISE UNDIL.	220	Medica E.	130	MEDICA	16	1.938	0.048	2.50	1.600	2.200
2025-392		5	IMT	219	ATELLICA	143	SIEMENS	22	1.964	0.048	2.45	1.700	2.300
2025-392		6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	81	1.924	0.045	2.36	1.600	2.200

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
022 POTASSIUM				CLIA TEST ID #: 465				EVALUATION CRITERIA: TARGET VALUE 0.30					
2025-393	3	ISE DILUT.	184	INTEGRA	93	ROCHE	28	2.604	0.019	0.73	2.300	2.900	
2025-393	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	35	2.620	0.047	1.78	2.300	2.900	
2025-393	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	2.593	0.068	2.62	2.300	2.900	
2025-393	3	ISE DILUT.	203	ROCHE	93	ROCHE	62	2.648	0.067	2.52	2.300	2.900	
2025-393	4	ISE UNDIL.	165	VITROS	63	KODAK	58	2.603	0.052	2.01	2.300	2.900	
2025-393	4	ISE UNDIL.	165	VITROS	156	Kit 32	92	2.600	0.051	1.98	2.300	2.900	
2025-393	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	28	2.678	0.113	4.23	2.400	3.000	
2025-393	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	28	2.643	0.049	1.87	2.300	2.900	
2025-393	4	ISE UNDIL.	220	Medica E.	130	MEDICA	16	2.513	0.060	2.39	2.200	2.800	
2025-393	5	IMT	219	ATELLICA	143	SIEMENS	22	2.555	0.050	1.95	2.300	2.900	
2025-393	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	81	2.541	0.061	2.39	2.200	2.800	
2025-394	3	ISE DILUT.	184	INTEGRA	93	ROCHE	28	6.143	0.155	2.52	5.800	6.400	
2025-394	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	35	5.989	0.139	2.32	5.700	6.300	
2025-394	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	6.073	0.195	3.21	5.800	6.400	
2025-394	3	ISE DILUT.	203	ROCHE	93	ROCHE	62	6.150	0.112	1.82	5.900	6.500	
2025-394	4	ISE UNDIL.	165	VITROS	63	KODAK	58	6.260	0.140	2.24	6.000	6.600	
2025-394	4	ISE UNDIL.	165	VITROS	156	Kit 32	92	6.241	0.122	1.95	5.900	6.500	
2025-394	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	28	5.896	0.299	5.08	5.600	6.200	
2025-394	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	28	5.543	0.199	3.59	5.200	5.800	
2025-394	4	ISE UNDIL.	220	Medica E.	130	MEDICA	16	6.050	0.187	3.09	5.800	6.400	
2025-394	5	IMT	219	ATELLICA	143	SIEMENS	22	5.971	0.128	2.14	5.700	6.300	
2025-394	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	81	6.103	0.122	2.01	5.800	6.400	
2025-395	3	ISE DILUT.	184	INTEGRA	93	ROCHE	28	5.129	0.160	3.12	4.800	5.400	
2025-395	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	35	4.979	0.093	1.87	4.700	5.300	
2025-395	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	5.047	0.088	1.75	4.700	5.300	
2025-395	3	ISE DILUT.	203	ROCHE	93	ROCHE	62	5.148	0.095	1.85	4.800	5.400	
2025-395	4	ISE UNDIL.	165	VITROS	63	KODAK	58	5.150	0.109	2.11	4.900	5.500	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
	2025-395	4	ISE UNLIL.	165	VITROS	156	Kit 32	92	5.157	0.101	1.97	4.900	5.500
	2025-395	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	28	5.004	0.184	3.68	4.700	5.300
	2025-395	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	28	4.700	0.169	3.60	4.400	5.000
	2025-395	4	ISE UNLIL.	220	Medica E.	130	MEDICA	16	4.988	0.105	2.11	4.700	5.300
	2025-395	5	IMT	219	ATELLICA	143	SIEMENS	22	4.982	0.115	2.32	4.700	5.300
	2025-395	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	81	5.058	0.098	1.94	4.800	5.400
023	SODIUM			CLIA TEST ID #: 475				EVALUATION CRITERIA: TARGET VALUE 4.00					
	2025-391	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	144.357	2.715	1.88	140.000	148.000
	2025-391	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	35	144.057	2.164	1.50	140.000	148.000
	2025-391	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	144.917	2.019	1.39	141.000	149.000
	2025-391	3	ISE DILUTE	203	ROCHE	93	ROCHE	56	145.527	2.114	1.45	142.000	150.000
	2025-391	3	ISE DILUTE	203	ROCHE	93	ROCHE	56	140.857	2.167	1.54	137.000	145.000
	2025-391	4	ISE UNLIL.	165	VITROS	63	KODAK	55	143.333	1.700	1.19	139.000	147.000
	2025-391	4	ISE UNLIL.	165	VITROS	63	KODAK	55	146.327	2.312	1.58	142.000	150.000
	2025-391	4	ISE UNLIL.	165	VITROS	156	Kit 32	95	146.126	1.842	1.26	142.000	150.000
	2025-391	4	ISE UNLIL.	165	VITROS	156	Kit 32	95	146.667	2.427	1.65	143.000	151.000
	2025-391	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	29	144.393	2.024	1.40	140.000	148.000
	2025-391	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	29	140.857	2.167	1.54	137.000	145.000
	2025-391	4	ISE UNLIL.	220	Medica E.	130	MEDICA	16	144.500	2.031	1.41	141.000	149.000
	2025-391	5	IMT	197	ARCHITECT	1	ABBOTT	10	144.600	1.800	1.24	141.000	149.000
	2025-391	5	IMT	219	ATELLICA	143	SIEMENS	22	144.182	2.269	1.57	140.000	148.000
	2025-391	5	IMT	219	ATELLICA	143	SIEMENS	22	140.857	2.167	1.54	137.000	145.000
	2025-391	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	146.247	2.146	1.47	142.000	150.000
	2025-391	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	146.667	2.427	1.65	143.000	151.000
	2025-392	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	125.593	1.705	1.36	122.000	130.000
	2025-392	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	35	125.971	1.844	1.46	122.000	130.000
	2025-392	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	125.000	2.000	1.60	121.000	129.000
	2025-392	3	ISE DILUTE	203	ROCHE	93	ROCHE	56	125.429	1.841	1.47	121.000	129.000
	2025-392	3	ISE DILUTE	203	ROCHE	93	ROCHE	56	126.055	1.612	1.28	122.000	130.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
	2025-392	4	ISE UNDIL.	165	VITROS	63	KODAK	55	123.833	1.922	1.55	120.000	128.000
	2025-392	4	ISE UNDIL.	165	VITROS	63	KODAK	55	126.000	2.160	1.71	122.000	130.000
	2025-392	4	ISE UNDIL.	165	VITROS	156	Kit 32	95	126.667	1.106	0.87	123.000	131.000
	2025-392	4	ISE UNDIL.	165	VITROS	156	Kit 32	95	123.789	1.569	1.27	120.000	128.000
	2025-392	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	29	125.429	1.841	1.47	121.000	129.000
	2025-392	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	29	125.179	1.965	1.57	121.000	129.000
	2025-392	4	ISE UNDIL.	220	Medica E.	130	MEDICA	16	124.500	1.581	1.27	121.000	129.000
	2025-392	5	IMT	197	ARCHITECT	1	ABBOTT	10	125.400	1.855	1.48	121.000	129.000
	2025-392	5	IMT	219	ATELLICA	143	SIEMENS	22	125.429	1.841	1.47	121.000	129.000
	2025-392	5	IMT	219	ATELLICA	143	SIEMENS	22	126.182	1.641	1.30	122.000	130.000
	2025-392	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	126.667	1.106	0.87	123.000	131.000
	2025-392	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	128.293	1.656	1.29	124.000	132.000
023 SODIUM				CLIA TEST ID #: 475				EVALUATION CRITERIA: TARGET VALUE 4.00					
	2025-393	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	130.148	1.556	1.20	126.000	134.000
	2025-393	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	35	130.000	2.070	1.59	126.000	134.000
	2025-393	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	129.250	2.650	2.05	125.000	133.000
	2025-393	3	ISE DILUTE	203	ROCHE	93	ROCHE	56	130.818	1.810	1.38	127.000	135.000
	2025-393	3	ISE DILUTE	203	ROCHE	93	ROCHE	56	128.571	1.498	1.17	125.000	133.000
	2025-393	4	ISE UNDIL.	165	VITROS	63	KODAK	55	129.333	0.471	0.36	125.000	133.000
	2025-393	4	ISE UNDIL.	165	VITROS	63	KODAK	55	129.491	2.035	1.57	125.000	133.000
	2025-393	4	ISE UNDIL.	165	VITROS	156	Kit 32	95	129.000	1.714	1.33	125.000	133.000
	2025-393	4	ISE UNDIL.	165	VITROS	156	Kit 32	95	130.500	1.258	0.96	127.000	135.000
	2025-393	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	29	129.724	1.981	1.53	126.000	134.000
	2025-393	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	29	128.571	1.498	1.17	125.000	133.000
	2025-393	4	ISE UNDIL.	220	Medica E.	130	MEDICA	16	128.813	2.157	1.67	125.000	133.000
	2025-393	5	IMT	197	ARCHITECT	1	ABBOTT	10	130.300	1.952	1.50	126.000	134.000
	2025-393	5	IMT	219	ATELLICA	143	SIEMENS	22	130.682	2.009	1.54	127.000	135.000
	2025-393	5	IMT	219	ATELLICA	143	SIEMENS	22	128.571	1.498	1.17	125.000	133.000
	2025-393	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	132.593	1.817	1.37	129.000	137.000
	2025-393	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	130.500	1.258	0.96	127.000	135.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
023 SODIUM				CLIA TEST ID #: 475				EVALUATION CRITERIA: TARGET VALUE 4.00					
2025-394	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	161.179	3.818	2.37	157.000	165.000	
2025-394	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	35	161.743	3.857	2.38	158.000	166.000	
2025-394	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	161.917	5.008	3.09	158.000	166.000	
2025-394	3	ISE DILUTE	203	ROCHE	93	ROCHE	56	154.714	1.829	1.18	151.000	159.000	
2025-394	3	ISE DILUTE	203	ROCHE	93	ROCHE	56	163.161	2.865	1.76	159.000	167.000	
2025-394	4	ISE UNDIL.	165	VITROS	63	KODAK	55	168.778	2.961	1.75	165.000	173.000	
2025-394	4	ISE UNDIL.	165	VITROS	63	KODAK	55	161.667	3.091	1.91	158.000	166.000	
2025-394	4	ISE UNDIL.	165	VITROS	156	Kit 32	95	163.000	3.559	2.18	159.000	167.000	
2025-394	4	ISE UNDIL.	165	VITROS	156	Kit 32	95	167.809	2.639	1.57	164.000	172.000	
2025-394	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	29	154.714	1.829	1.18	151.000	159.000	
2025-394	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	29	163.379	3.671	2.25	159.000	167.000	
2025-394	4	ISE UNDIL.	220	Medica E.	130	MEDICA	16	163.375	4.226	2.59	159.000	167.000	
2025-394	5	IMT	197	ARCHITECT	1	ABBOTT	10	160.900	2.508	1.56	157.000	165.000	
2025-394	5	IMT	219	ATELLICA	143	SIEMENS	22	154.714	1.829	1.18	151.000	159.000	
2025-394	5	IMT	219	ATELLICA	143	SIEMENS	22	159.619	3.579	2.24	156.000	164.000	
2025-394	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	163.000	3.559	2.18	159.000	167.000	
2025-394	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	161.925	2.333	1.44	158.000	166.000	
2025-395	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	152.179	3.675	2.41	148.000	156.000	
2025-395	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	35	151.353	3.047	2.01	147.000	155.000	
2025-395	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	152.250	2.454	1.61	148.000	156.000	
2025-395	3	ISE DILUTE	203	ROCHE	93	ROCHE	56	153.418	2.661	1.73	149.000	157.000	
2025-395	3	ISE DILUTE	203	ROCHE	93	ROCHE	56	147.000	1.690	1.15	143.000	151.000	
2025-395	4	ISE UNDIL.	165	VITROS	63	KODAK	55	152.000	1.633	1.07	148.000	156.000	
2025-395	4	ISE UNDIL.	165	VITROS	63	KODAK	55	156.564	2.820	1.80	153.000	161.000	
2025-395	4	ISE UNDIL.	165	VITROS	156	Kit 32	95	155.642	2.379	1.53	152.000	160.000	
2025-395	4	ISE UNDIL.	165	VITROS	156	Kit 32	95	154.167	2.609	1.69	150.000	158.000	
2025-395	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	29	152.621	3.357	2.20	149.000	157.000	
2025-395	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	29	147.000	1.690	1.15	143.000	151.000	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
	2025-395	4	ISE UNDIL.	220	Medica E.	130	MEDICA	16	153.813	2.721	1.77	150.000	158.000
	2025-395	5	IMT	197	ARCHITECT	1	ABBOTT	10	152.300	2.571	1.69	148.000	156.000
	2025-395	5	IMT	219	ATELLICA	143	SIEMENS	22	151.318	3.308	2.19	147.000	155.000
	2025-395	5	IMT	219	ATELLICA	143	SIEMENS	22	147.000	1.690	1.15	143.000	151.000
	2025-395	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	152.805	2.611	1.71	149.000	157.000
	2025-395	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	82	154.167	2.609	1.69	150.000	158.000
024 TOTAL PROTEIN				CLIA TEST ID #: 485				EVALUATION CRITERIA: TARGET VALUE 8 %					
	2025-391	1	BIURET	38	SIEMENS DI	143	SIEMENS	81	5.988	0.133	2.22	5.500	6.500
	2025-391	1	BIURET	165	VITROS	63	KODAK	134	5.813	0.131	2.25	5.300	6.300
	2025-391	1	BIURET	165	VITROS	63	KODAK	134	5.800	0.000	0.00	5.300	6.300
	2025-391	1	BIURET	184	INTEGRA	93	ROCHE	17	5.612	0.141	2.51	5.200	6.100
	2025-391	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	32	5.791	0.153	2.64	5.300	6.300
	2025-391	1	BIURET	191	RX-SERIES	126	RANDOX	27	5.793	0.186	3.22	5.300	6.300
	2025-391	1	BIURET	194	BIOLIS-24S	154	(IDG)	10	6.260	0.150	2.39	5.800	6.800
	2025-391	1	BIURET	197	ARCHITECT	1	ABBOTT	19	5.989	0.155	2.59	5.500	6.500
	2025-391	1	BIURET	203	ROCHE	93	ROCHE	47	5.813	0.141	2.42	5.300	6.300
	2025-391	1	BIURET	219	ATELLICA	143	SIEMENS	22	5.827	0.145	2.49	5.400	6.300
	2025-391	1	BIURET	220	Medica E.	130	MEDICA	13	5.546	0.290	5.23	5.100	6.000
	2025-391	3	BIURET COL	203	ROCHE	93	ROCHE	17	5.829	0.089	1.53	5.400	6.300
	2025-392	1	BIURET	38	SIEMENS DI	143	SIEMENS	81	3.179	0.084	2.65	2.900	3.400
	2025-392	1	BIURET	165	VITROS	63	KODAK	134	3.033	0.047	1.55	2.800	3.300
	2025-392	1	BIURET	165	VITROS	63	KODAK	134	3.223	0.088	2.72	3.000	3.500
	2025-392	1	BIURET	184	INTEGRA	93	ROCHE	17	2.988	0.137	4.57	2.700	3.200
	2025-392	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	32	3.072	0.087	2.85	2.800	3.300
	2025-392	1	BIURET	191	RX-SERIES	126	RANDOX	27	3.092	0.092	2.96	2.800	3.300
	2025-392	1	BIURET	194	BIOLIS-24S	154	(IDG)	10	3.320	0.125	3.76	3.100	3.600
	2025-392	1	BIURET	197	ARCHITECT	1	ABBOTT	19	3.100	0.121	3.92	2.900	3.300
	2025-392	1	BIURET	203	ROCHE	93	ROCHE	47	3.102	0.084	2.70	2.900	3.400
	2025-392	1	BIURET	219	ATELLICA	143	SIEMENS	22	3.077	0.095	3.09	2.800	3.300

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-392		1	BIURET	220	Medica E.	130	MEDICA	13	2.975	0.109	3.66	2.700	3.200
2025-392		3	BIURET COL	203	ROCHE	93	ROCHE	17	3.106	0.043	1.38	2.900	3.400
024 TOTAL PROTEIN				CLIA TEST ID #: 485				EVALUATION CRITERIA: TARGET VALUE 8 %					
2025-393		1	BIURET	38	SIEMENS DI	143	SIEMENS	81	3.989	0.104	2.61	3.700	4.300
2025-393		1	BIURET	165	VITROS	63	KODAK	134	4.012	0.105	2.61	3.700	4.300
2025-393		1	BIURET	165	VITROS	63	KODAK	134	3.800	0.082	2.15	3.500	4.100
2025-393		1	BIURET	184	INTEGRA	93	ROCHE	17	3.747	0.109	2.91	3.400	4.000
2025-393		1	BIURET	186	BECK. COUL	76	AU-BECKMAN	32	3.844	0.103	2.68	3.500	4.200
2025-393		1	BIURET	191	RX-SERIES	126	RANDOX	27	3.830	0.124	3.24	3.500	4.100
2025-393		1	BIURET	194	BIOLIS-24S	154	(IDG)	10	4.190	0.158	3.77	3.900	4.500
2025-393		1	BIURET	197	ARCHITECT	1	ABBOTT	19	3.947	0.114	2.89	3.600	4.300
2025-393		1	BIURET	203	ROCHE	93	ROCHE	47	3.891	0.116	2.99	3.600	4.200
2025-393		1	BIURET	219	ATELLICA	143	SIEMENS	22	3.886	0.118	3.03	3.600	4.200
2025-393		1	BIURET	220	Medica E.	130	MEDICA	13	3.669	0.267	7.28	3.400	4.000
2025-393		3	BIURET COL	203	ROCHE	93	ROCHE	17	3.906	0.073	1.86	3.600	4.200
2025-394		1	BIURET	38	SIEMENS DI	143	SIEMENS	81	8.651	0.207	2.40	8.000	9.300
2025-394		1	BIURET	165	VITROS	63	KODAK	134	8.633	0.047	0.55	7.900	9.300
2025-394		1	BIURET	165	VITROS	63	KODAK	134	8.376	0.232	2.77	7.700	9.000
2025-394		1	BIURET	184	INTEGRA	93	ROCHE	17	8.047	0.197	2.45	7.400	8.700
2025-394		1	BIURET	186	BECK. COUL	76	AU-BECKMAN	32	8.384	0.259	3.09	7.700	9.100
2025-394		1	BIURET	191	RX-SERIES	126	RANDOX	27	8.307	0.248	2.98	7.600	9.000
2025-394		1	BIURET	194	BIOLIS-24S	154	(IDG)	10	9.040	0.262	2.89	8.300	9.800
2025-394		1	BIURET	197	ARCHITECT	1	ABBOTT	19	8.653	0.327	3.78	8.000	9.300
2025-394		1	BIURET	203	ROCHE	93	ROCHE	47	8.270	0.204	2.47	7.600	8.900
2025-394		1	BIURET	219	ATELLICA	143	SIEMENS	22	8.276	0.211	2.55	7.600	8.900
2025-394		1	BIURET	220	Medica E.	130	MEDICA	13	7.962	0.334	4.20	7.300	8.600
2025-394		3	BIURET COL	203	ROCHE	93	ROCHE	17	8.318	0.158	1.90	7.700	9.000
2025-395		1	BIURET	38	SIEMENS DI	143	SIEMENS	81	7.291	0.189	2.59	6.700	7.900

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE						
ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-395	1	BIURET	165	VITROS	63	KODAK	134	6.998	0.163	2.33	6.400	7.600
2025-395	1	BIURET	165	VITROS	63	KODAK	134	7.233	0.047	0.65	6.700	7.800
2025-395	1	BIURET	184	INTEGRA	93	ROCHE	17	6.841	0.168	2.46	6.300	7.400
2025-395	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	32	7.061	0.168	2.38	6.500	7.600
2025-395	1	BIURET	191	RX-SERIES	126	RANDOX	27	7.069	0.190	2.68	6.500	7.600
2025-395	1	BIURET	194	BIOLIS-24S	154	(IDG)	10	7.660	0.224	2.93	7.000	8.300
2025-395	1	BIURET	197	ARCHITECT	1	ABBOTT	19	7.289	0.159	2.18	6.700	7.900
2025-395	1	BIURET	203	ROCHE	93	ROCHE	47	7.051	0.199	2.82	6.500	7.600
2025-395	1	BIURET	219	ATELLICA	143	SIEMENS	22	7.086	0.194	2.73	6.500	7.700
2025-395	1	BIURET	220	Medica E.	130	MEDICA	13	6.762	0.300	4.44	6.200	7.300
2025-395	3	BIURET COL	203	ROCHE	93	ROCHE	17	7.088	0.108	1.52	6.500	7.700
025 TRIGLYCERIDES			CLIA TEST ID #: 495			EVALUATION CRITERIA: TARGET VALUE 15 %						
2025-391	2	ENZ. COLO.	165	VITROS	63	KODAK	135	180.188	5.296	2.94	153.000	207.000
2025-391	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	13	152.154	5.112	3.36	129.000	175.000
2025-391	2	ENZ. COLO.	203	ROCHE	93	ROCHE	34	152.848	3.066	2.01	130.000	176.000
2025-391	2	ENZ. COLO.	220	Medica E.	130	MEDICA	13	143.462	6.488	4.52	122.000	165.000
2025-391	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	80	146.050	3.731	2.55	124.000	168.000
2025-391	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	146.333	2.838	1.94	124.000	168.000
2025-391	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	33	154.788	6.148	3.97	132.000	178.000
2025-391	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	28	149.071	5.351	3.59	127.000	171.000
2025-391	10	ENZY. GPO	184	INTEGRA	93	ROCHE	14	152.143	4.274	2.81	129.000	175.000
2025-391	10	ENZY. GPO	203	ROCHE	93	ROCHE	25	152.920	3.783	2.47	130.000	176.000
2025-391	10	ENZY. GPO	219	ATELLICA	143	SIEMENS	22	160.409	4.849	3.02	136.000	184.000
2025-392	2	ENZ. COLO.	165	VITROS	63	KODAK	135	91.662	3.290	3.59	78.000	105.000
2025-392	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	13	85.000	3.374	3.97	72.000	98.000
2025-392	2	ENZ. COLO.	203	ROCHE	93	ROCHE	34	83.588	1.734	2.07	71.000	96.000
2025-392	2	ENZ. COLO.	220	Medica E.	130	MEDICA	13	80.538	4.107	5.10	68.000	93.000
2025-392	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	80	72.013	2.670	3.71	61.000	83.000
2025-392	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	76.667	1.972	2.57	65.000	88.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-392	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	33	82.303	3.631	4.41	70.000	95.000	
2025-392	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	28	83.321	3.263	3.92	71.000	96.000	
2025-392	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	14	84.286	2.962	3.51	72.000	97.000	
2025-392	10	ENZYM. GPO	203	ROCHE	93	ROCHE	25	83.500	1.803	2.16	71.000	96.000	
2025-392	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	22	86.591	2.774	3.20	74.000	100.000	
025 TRIGLYCERIDES			CLIA TEST ID #: 495			EVALUATION CRITERIA: TARGET VALUE 15 %							
2025-393	2	ENZ. COLO.	165	VITROS	63	KODAK	135	116.549	4.075	3.50	99.000	134.000	
2025-393	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	13	104.615	3.952	3.78	89.000	120.000	
2025-393	2	ENZ. COLO.	203	ROCHE	93	ROCHE	34	104.471	2.145	2.05	89.000	120.000	
2025-393	2	ENZ. COLO.	220	Medica E.	130	MEDICA	13	98.154	5.157	5.25	83.000	113.000	
2025-393	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	80	93.304	3.140	3.36	79.000	107.000	
2025-393	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	96.833	1.624	1.68	82.000	111.000	
2025-393	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	33	103.000	4.134	4.01	88.000	118.000	
2025-393	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	28	101.815	3.712	3.65	87.000	117.000	
2025-393	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	14	104.786	2.596	2.48	89.000	121.000	
2025-393	10	ENZYM. GPO	203	ROCHE	93	ROCHE	25	104.360	2.667	2.56	89.000	120.000	
2025-393	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	22	108.364	3.405	3.14	92.000	125.000	
2025-394	2	ENZ. COLO.	165	VITROS	63	KODAK	135	268.541	8.070	3.01	228.000	309.000	
2025-394	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	13	211.846	9.105	4.30	180.000	244.000	
2025-394	2	ENZ. COLO.	203	ROCHE	93	ROCHE	34	212.147	4.634	2.18	180.000	244.000	
2025-394	2	ENZ. COLO.	220	Medica E.	130	MEDICA	13	195.615	9.834	5.03	166.000	225.000	
2025-394	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	80	214.263	5.993	2.80	182.000	246.000	
2025-394	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	210.583	5.377	2.55	179.000	242.000	
2025-394	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	33	224.156	8.371	3.73	191.000	258.000	
2025-394	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	28	210.036	8.906	4.24	179.000	242.000	
2025-394	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	14	209.071	5.650	2.70	178.000	240.000	
2025-394	10	ENZYM. GPO	203	ROCHE	93	ROCHE	25	211.920	4.078	1.92	180.000	244.000	
2025-394	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	22	227.545	7.620	3.35	193.000	262.000	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
025 TRIGLYCERIDES				CLIA TEST ID #: 495				EVALUATION CRITERIA: TARGET VALUE 15 %					
2025-395	2	ENZ. COLO.	165	VITROS	63	KODAK	135	223.541	6.855	3.07	190.000	257.000	
2025-395	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	13	182.615	7.302	4.00	155.000	210.000	
2025-395	2	ENZ. COLO.	203	ROCHE	93	ROCHE	34	183.059	3.804	2.08	156.000	211.000	
2025-395	2	ENZ. COLO.	220	Medica E.	130	MEDICA	13	167.769	7.040	4.20	143.000	193.000	
2025-395	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	80	179.388	5.522	3.08	152.000	206.000	
2025-395	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	178.167	2.939	1.65	151.000	205.000	
2025-395	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	33	189.121	8.824	4.67	161.000	217.000	
2025-395	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	28	178.630	7.543	4.22	152.000	205.000	
2025-395	10	ENZY. GPO	184	INTEGRA	93	ROCHE	14	180.500	4.895	2.71	153.000	208.000	
2025-395	10	ENZY. GPO	203	ROCHE	93	ROCHE	25	182.208	3.488	1.91	155.000	210.000	
2025-395	10	ENZY. GPO	219	ATELLICA	143	SIEMENS	22	194.500	5.590	2.87	165.000	224.000	
026 UREA NITROGEN (BUN)				CLIA TEST ID #: 505				EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}					
2025-391	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	83	24.434	1.244	5.09	22.000	27.000	
2025-391	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	83	24.143	1.552	6.43	22.000	26.000	
2025-391	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	31	23.968	0.861	3.59	22.000	26.000	
2025-391	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	35	24.647	0.836	3.39	22.000	27.000	
2025-391	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	27	23.000	1.038	4.51	21.000	25.000	
2025-391	2	UREAS.GLDH	194	BIOLIS-24S	154	(IDG)	10	24.000	1.414	5.89	22.000	26.000	
2025-391	2	UREAS.GLDH	203	ROCHE	93	ROCHE	62	24.311	0.736	3.03	22.000	26.000	
2025-391	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	22	24.227	0.849	3.50	22.000	26.000	
2025-391	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	12	24.417	0.862	3.53	22.000	27.000	
2025-391	8	UREASE QUI	165	VITROS	63	KODAK	151	21.993	0.695	3.16	20.000	24.000	
2025-391	10	UREASE 37	220	Medica E.	130	MEDICA	16	23.563	0.609	2.59	21.000	26.000	
2025-392	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	83	6.857	0.350	5.10	5.000	9.000	
2025-392	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	83	6.699	0.787	11.76	5.000	9.000	
2025-392	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	31	6.935	0.435	6.27	5.000	9.000	
2025-392	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	35	7.229	0.539	7.46	5.000	9.000	
2025-392	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	27	7.423	0.968	13.04	5.000	9.000	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
	2025-392	2	UREAS.GLDH	194	BIOLIS-24S	154 (IDG)	10	7.000	0.447	6.39	5.000	9.000	
	2025-392	2	UREAS.GLDH	203	ROCHE	93 ROCHE	62	6.967	0.256	3.68	5.000	9.000	
	2025-392	2	UREAS.GLDH	219	ATELLICA	143 SIEMENS	22	7.045	0.475	6.74	5.000	9.000	
	2025-392	5	CHROMATOG.	197	ARCHITECT	1 ABBOTT	12	7.083	0.493	6.96	5.000	9.000	
	2025-392	8	UREASE QUI	165	VITROS	63 KODAK	151	5.651	0.543	9.60	4.000	8.000	
	2025-392	10	UREASE 37	220	Medica E.	130 MEDICA	16	7.000	0.354	5.05	5.000	9.000	
026 UREA NITROGEN (BUN)				CLIA	TEST ID #: 505		EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}						
	2025-393	2	UREAS.GLDH	38	SIEMENS DI	143 SIEMENS	83	11.819	1.031	8.73	10.000	14.000	
	2025-393	2	UREAS.GLDH	38	SIEMENS DI	143 SIEMENS	83	11.857	0.639	5.39	10.000	14.000	
	2025-393	2	UREAS.GLDH	184	INTEGRA	93 ROCHE	31	11.935	0.435	3.65	10.000	14.000	
	2025-393	2	UREAS.GLDH	186	BECK. COUL	76 AU-BECKMAN	35	12.343	0.583	4.72	10.000	14.000	
	2025-393	2	UREAS.GLDH	191	RX-SERIES	126 RANDOX	27	12.111	1.227	10.13	10.000	14.000	
	2025-393	2	UREAS.GLDH	194	BIOLIS-24S	154 (IDG)	10	12.400	0.490	3.95	10.000	14.000	
	2025-393	2	UREAS.GLDH	203	ROCHE	93 ROCHE	62	12.097	0.429	3.55	10.000	14.000	
	2025-393	2	UREAS.GLDH	219	ATELLICA	143 SIEMENS	22	12.273	0.686	5.59	10.000	14.000	
	2025-393	5	CHROMATOG.	197	ARCHITECT	1 ABBOTT	12	11.917	0.493	4.14	10.000	14.000	
	2025-393	8	UREASE QUI	165	VITROS	63 KODAK	151	10.583	0.580	5.48	9.000	13.000	
	2025-393	10	UREASE 37	220	Medica E.	130 MEDICA	16	12.000	0.500	4.17	10.000	14.000	
	2025-394	2	UREAS.GLDH	38	SIEMENS DI	143 SIEMENS	83	40.000	1.927	4.82	36.000	44.000	
	2025-394	2	UREAS.GLDH	38	SIEMENS DI	143 SIEMENS	83	41.537	1.829	4.40	38.000	45.000	
	2025-394	2	UREAS.GLDH	184	INTEGRA	93 ROCHE	31	41.033	1.140	2.78	37.000	45.000	
	2025-394	2	UREAS.GLDH	186	BECK. COUL	76 AU-BECKMAN	35	41.571	1.337	3.22	38.000	45.000	
	2025-394	2	UREAS.GLDH	191	RX-SERIES	126 RANDOX	27	38.519	2.455	6.37	35.000	42.000	
	2025-394	2	UREAS.GLDH	194	BIOLIS-24S	154 (IDG)	10	41.200	1.077	2.61	37.000	45.000	
	2025-394	2	UREAS.GLDH	203	ROCHE	93 ROCHE	62	40.968	1.135	2.77	37.000	45.000	
	2025-394	2	UREAS.GLDH	219	ATELLICA	143 SIEMENS	22	39.864	1.575	3.95	36.000	43.000	
	2025-394	5	CHROMATOG.	197	ARCHITECT	1 ABBOTT	12	42.000	1.581	3.76	38.000	46.000	
	2025-394	8	UREASE QUI	165	VITROS	63 KODAK	151	38.000	1.062	2.79	35.000	41.000	
	2025-394	10	UREASE 37	220	Medica E.	130 MEDICA	16	38.938	1.029	2.64	35.000	42.000	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
026 UREA NITROGEN (BUN)				CLIA TEST ID #: 505				EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}					
2025-395	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	83	33.048	1.686	5.10	30.000	36.000	
2025-395	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	83	32.286	1.030	3.19	29.000	35.000	
2025-395	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	31	32.645	1.258	3.86	30.000	36.000	
2025-395	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	35	32.853	1.115	3.39	30.000	36.000	
2025-395	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	27	31.111	1.969	6.33	28.000	34.000	
2025-395	2	UREAS.GLDH	194	BIOLIS-24S	154	(IDG)	10	32.600	1.200	3.68	30.000	36.000	
2025-395	2	UREAS.GLDH	203	ROCHE	93	ROCHE	62	32.645	0.952	2.92	30.000	36.000	
2025-395	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	22	32.000	1.168	3.65	29.000	35.000	
2025-395	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	12	33.083	1.187	3.59	30.000	36.000	
2025-395	8	UREASE QUI	165	VITROS	63	KODAK	151	29.848	0.867	2.90	27.000	33.000	
2025-395	10	UREASE 37	220	Medica E.	130	MEDICA	16	31.438	0.864	2.75	29.000	34.000	
027 URIC ACID				CLIA TEST ID #: 515				EVALUATION CRITERIA: TARGET VALUE 10 %					
2025-391	2	URICASE	38	SIEMENS DI	143	SIEMENS	44	6.461	0.182	2.82	5.800	7.100	
2025-391	2	URICASE	165	VITROS	63	KODAK	91	6.477	0.154	2.38	5.800	7.100	
2025-391	2	URICASE	184	INTEGRA	93	ROCHE	10	6.450	0.216	3.34	5.800	7.100	
2025-391	2	URICASE	203	ROCHE	93	ROCHE	36	6.328	0.154	2.43	5.700	7.000	
2025-391	2	URICASE	219	ATELLICA	143	SIEMENS	18	6.700	0.213	3.19	6.000	7.400	
2025-391	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	20	6.595	0.186	2.82	5.900	7.300	
2025-391	6	ENZY. COL	203	ROCHE	93	ROCHE	19	6.374	0.168	2.64	5.700	7.000	
2025-392	2	URICASE	38	SIEMENS DI	143	SIEMENS	44	1.786	0.081	4.56	1.600	2.000	
2025-392	2	URICASE	165	VITROS	63	KODAK	91	1.749	0.064	3.63	1.600	1.900	
2025-392	2	URICASE	184	INTEGRA	93	ROCHE	10	1.730	0.046	2.65	1.600	1.900	
2025-392	2	URICASE	203	ROCHE	93	ROCHE	36	1.669	0.046	2.78	1.500	1.800	
2025-392	2	URICASE	219	ATELLICA	143	SIEMENS	18	1.867	0.088	4.72	1.700	2.100	
2025-392	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	20	1.895	0.074	3.90	1.700	2.100	
2025-392	6	ENZY. COL	203	ROCHE	93	ROCHE	19	1.684	0.049	2.90	1.500	1.900	
2025-393	2	URICASE	38	SIEMENS DI	143	SIEMENS	44	3.125	0.119	3.81	2.800	3.400	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-393	2	URICASE	165	VITROS	63	KODAK	91	3.037	0.078	2.58	2.700	3.300	
2025-393	2	URICASE	184	INTEGRA	93	ROCHE	10	3.110	0.054	1.73	2.800	3.400	
2025-393	2	URICASE	203	ROCHE	93	ROCHE	36	3.029	0.074	2.44	2.700	3.300	
2025-393	2	URICASE	219	ATELLICA	143	SIEMENS	18	3.272	0.093	2.85	2.900	3.600	
2025-393	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	20	3.285	0.101	3.09	3.000	3.600	
2025-393	6	ENZY. COL	203	ROCHE	93	ROCHE	19	3.063	0.093	3.03	2.800	3.400	
027 URIC ACID			CLIA TEST ID #: 515		EVALUATION CRITERIA: TARGET VALUE 10 %								
2025-394	2	URICASE	38	SIEMENS DI	143	SIEMENS	44	10.858	0.308	2.84	9.800	11.900	
2025-394	2	URICASE	165	VITROS	63	KODAK	91	11.266	0.375	3.33	10.100	12.400	
2025-394	2	URICASE	184	INTEGRA	93	ROCHE	10	10.880	0.451	4.15	9.800	12.000	
2025-394	2	URICASE	203	ROCHE	93	ROCHE	36	10.633	0.336	3.16	9.600	11.700	
2025-394	2	URICASE	219	ATELLICA	143	SIEMENS	18	11.256	0.403	3.58	10.100	12.400	
2025-394	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	20	11.050	0.383	3.46	9.900	12.200	
2025-394	6	ENZY. COL	203	ROCHE	93	ROCHE	19	10.774	0.299	2.77	9.700	11.900	
2025-395	2	URICASE	38	SIEMENS DI	143	SIEMENS	44	8.666	0.241	2.78	7.800	9.500	
2025-395	2	URICASE	165	VITROS	63	KODAK	91	8.812	0.225	2.55	7.900	9.700	
2025-395	2	URICASE	184	INTEGRA	93	ROCHE	10	8.680	0.331	3.81	7.800	9.500	
2025-395	2	URICASE	203	ROCHE	93	ROCHE	36	8.542	0.211	2.47	7.700	9.400	
2025-395	2	URICASE	219	ATELLICA	143	SIEMENS	18	8.967	0.348	3.88	8.100	9.900	
2025-395	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	20	8.800	0.268	3.05	7.900	9.700	
2025-395	6	ENZY. COL	203	ROCHE	93	ROCHE	19	8.616	0.221	2.56	7.800	9.500	
135 GGT (GAMMA GLU. TRA)			CLIA TEST ID #: 411		EVALUATION CRITERIA: TARGET VALUE 15 % OR 5.00 {GREATER}								
2025-391	5	KINETIC 37	165	VITROS	63	KODAK	26	347.346	8.695	2.50	295.000	399.000	
2025-391	5	KINETIC 37	219	ATELLICA	143	SIEMENS	11	250.091	5.384	2.15	213.000	288.000	
2025-392	5	KINETIC 37	165	VITROS	63	KODAK	26	19.280	1.001	5.19	14.000	24.000	
2025-392	5	KINETIC 37	219	ATELLICA	143	SIEMENS	11	15.455	1.076	6.96	10.000	20.000	
2025-393	5	KINETIC 37	165	VITROS	63	KODAK	26	127.320	4.249	3.34	108.000	146.000	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-393		5	KINETIC 37	219	ATELLICA	143	SIEMENS	11	85.091	2.778	3.27	72.000	98.000
135 GGT (GAMMA GLU. TRA)				CLIA TEST ID #: 411		EVALUATION CRITERIA: TARGET VALUE 15 % OR 5.00 {GREATER}							
2025-394		5	KINETIC 37	165	VITROS	63	KODAK	26	591.115	21.165	3.58	502.000	680.000
2025-394		5	KINETIC 37	219	ATELLICA	143	SIEMENS	11	473.909	16.747	3.53	403.000	545.000
2025-395		5	KINETIC 37	165	VITROS	63	KODAK	26	469.280	11.952	2.55	399.000	540.000
2025-395		5	KINETIC 37	219	ATELLICA	143	SIEMENS	11	364.818	10.769	2.95	310.000	420.000
136 LACTIC ACID				CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 %							
2025-391		1	LACTATE-P.	165	VITROS	63	KODAK	26	2.936	0.062	2.13	2.300	3.500
2025-392		1	LACTATE-P.	165	VITROS	63	KODAK	26	0.504	0.020	3.89	0.400	0.600
2025-393		1	LACTATE-P.	165	VITROS	63	KODAK	26	0.848	0.050	5.89	0.700	1.000
2025-394		1	LACTATE-P.	165	VITROS	63	KODAK	26	5.662	0.182	3.22	4.500	6.800
2025-395		1	LACTATE-P.	165	VITROS	63	KODAK	26	4.300	0.089	2.08	3.400	5.200
137 LIPASE													
2025-391		1	COLORIMET.	203	ROCHE	93	ROCHE	18	52.056	2.321	4.46	42.000	62.000
2025-391		1	COLORIMET.	219	ATELLICA	143	SIEMENS	13	58.615	2.371	4.04	47.000	70.000
2025-391		2	ENZIMATIC	165	VITROS	63	KODAK	82	380.840	16.182	4.25	305.000	457.000
2025-391		4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	49.000	2.608	5.32	39.000	59.000
2025-391		4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	53.714	3.534	6.58	43.000	64.000
2025-391		4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	66.800	6.210	9.30	53.000	80.000
2025-391		4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	51.571	1.450	2.81	41.000	62.000
2025-391		5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	13	51.077	1.774	3.47	41.000	61.000
2025-392		1	COLORIMET.	203	ROCHE	93	ROCHE	18	16.833	0.764	4.54	13.000	20.000
2025-392		1	COLORIMET.	219	ATELLICA	143	SIEMENS	13	19.231	2.326	12.09	15.000	23.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-392	2	ENZIMATIC	165	VITROS	63	KODAK	82	63.854	3.973	6.22	51.000	77.000
2025-392	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	17.200	0.400	2.33	14.000	21.000
2025-392	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	21.600	2.059	9.53	17.000	26.000
2025-392	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	14.643	1.540	10.52	12.000	18.000
2025-392	4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	17.143	0.639	3.73	14.000	21.000
2025-392	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	13	18.154	0.948	5.22	15.000	22.000
137 LIPASE		CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-393	1	COLORIMET.	203	ROCHE	93	ROCHE	18	27.222	1.436	5.27	22.000	33.000
2025-393	1	COLORIMET.	219	ATELLICA	143	SIEMENS	13	31.385	2.237	7.13	25.000	38.000
2025-393	2	ENZIMATIC	165	VITROS	63	KODAK	82	166.247	7.610	4.58	133.000	199.000
2025-393	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	26.700	0.900	3.37	21.000	32.000
2025-393	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	26.800	2.286	8.53	21.000	32.000
2025-393	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	35.600	3.200	8.99	28.000	43.000
2025-393	4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	26.714	0.700	2.62	21.000	32.000
2025-393	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	13	27.923	1.206	4.32	22.000	34.000
2025-394	1	COLORIMET.	203	ROCHE	93	ROCHE	18	84.500	4.610	5.46	68.000	101.000
2025-394	1	COLORIMET.	219	ATELLICA	143	SIEMENS	13	94.615	4.764	5.04	76.000	114.000
2025-394	2	ENZIMATIC	165	VITROS	63	KODAK	82	622.988	35.365	5.68	498.000	748.000
2025-394	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	77.800	5.016	6.45	62.000	93.000
2025-394	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	101.200	4.534	4.48	81.000	121.000
2025-394	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	89.714	7.823	8.72	72.000	108.000
2025-394	4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	82.929	2.738	3.30	66.000	100.000
2025-394	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	13	82.462	2.469	2.99	66.000	99.000
2025-395	1	COLORIMET.	203	ROCHE	93	ROCHE	18	68.611	4.192	6.11	55.000	82.000
2025-395	1	COLORIMET.	219	ATELLICA	143	SIEMENS	13	76.923	2.556	3.32	62.000	92.000
2025-395	2	ENZIMATIC	165	VITROS	63	KODAK	82	508.488	23.862	4.69	407.000	610.000
2025-395	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	63.600	3.774	5.93	51.000	76.000
2025-395	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	71.000	4.766	6.71	57.000	85.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-395		4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	78.200	2.040	2.61	63.000	94.000
2025-395		4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	67.071	2.052	3.06	54.000	80.000
2025-395		5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	13	67.154	2.476	3.69	54.000	81.000
138 PHOSPHORUS			CLIA TEST ID #: 460			EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}							
2025-391		1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	44	4.056	0.095	2.34	3.700	4.500
2025-391		1	PHOSPHOMO.	165	VITROS	63	KODAK	90	3.977	0.118	2.98	3.600	4.400
2025-391		1	PHOSPHOMO.	165	VITROS	63	KODAK	90	4.650	0.300	6.45	4.200	5.100
2025-391		1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	13	3.846	0.101	2.62	3.500	4.200
2025-391		1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	21	3.910	0.134	3.43	3.500	4.300
2025-391		1	PHOSPHOMO.	203	ROCHE	93	ROCHE	50	3.882	0.091	2.34	3.500	4.300
2025-391		1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	19	3.953	0.127	3.22	3.600	4.300
2025-392		1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	44	1.569	0.083	5.29	1.300	1.900
2025-392		1	PHOSPHOMO.	165	VITROS	63	KODAK	90	2.063	0.187	9.05	1.800	2.400
2025-392		1	PHOSPHOMO.	165	VITROS	63	KODAK	90	1.744	0.083	4.78	1.400	2.000
2025-392		1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	13	1.508	0.100	6.61	1.200	1.800
2025-392		1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	21	1.486	0.083	5.61	1.200	1.800
2025-392		1	PHOSPHOMO.	203	ROCHE	93	ROCHE	50	1.466	0.068	4.65	1.200	1.800
2025-392		1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	19	1.474	0.064	4.32	1.200	1.800
2025-393		1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	44	2.336	0.117	5.01	2.000	2.600
2025-393		1	PHOSPHOMO.	165	VITROS	63	KODAK	90	2.913	0.220	7.57	2.600	3.200
2025-393		1	PHOSPHOMO.	165	VITROS	63	KODAK	90	2.476	0.102	4.13	2.200	2.800
2025-393		1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	13	2.262	0.108	4.76	2.000	2.600
2025-393		1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	21	2.243	0.105	4.68	1.900	2.500
2025-393		1	PHOSPHOMO.	203	ROCHE	93	ROCHE	50	2.214	0.072	3.26	1.900	2.500
2025-393		1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	19	2.242	0.099	4.42	1.900	2.500
2025-394		1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	44	6.155	0.178	2.89	5.500	6.800
2025-394		1	PHOSPHOMO.	165	VITROS	63	KODAK	90	6.054	0.216	3.56	5.400	6.700

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
	2025-394	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	7.025	0.311	4.43	6.300	7.700
	2025-394	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	13	5.862	0.227	3.88	5.300	6.400
	2025-394	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	21	6.030	0.233	3.86	5.400	6.600
	2025-394	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	50	5.931	0.137	2.32	5.300	6.500
	2025-394	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	19	6.022	0.178	2.96	5.400	6.600
138	PHOSPHORUS		CLIA	TEST ID #: 460		EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}							
	2025-395	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	44	5.118	0.132	2.58	4.600	5.600
	2025-395	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	5.813	0.276	4.75	5.200	6.400
	2025-395	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	4.993	0.148	2.97	4.500	5.500
	2025-395	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	13	4.892	0.121	2.47	4.400	5.400
	2025-395	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	21	5.000	0.198	3.95	4.500	5.500
	2025-395	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	50	4.914	0.123	2.50	4.400	5.400
	2025-395	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	19	5.037	0.163	3.23	4.500	5.500
169	C02		CLIA	TEST ID #: 351		EVALUATION CRITERIA: TARGET VALUE 20 %							
	2025-391	1	Generic Me	184	INTEGRA	93	ROCHE	10	13.400	2.577	19.23	11.000	16.000
	2025-391	1	Generic Me	184	INTEGRA	93	ROCHE	10	16.000	1.183	7.40	13.000	19.000
	2025-391	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	16.172	2.069	12.79	13.000	19.000
	2025-391	1	Generic Me	203	ROCHE	93	ROCHE	23	15.609	1.581	10.13	12.000	19.000
	2025-391	1	Generic Me	203	ROCHE	93	ROCHE	23	13.400	2.577	19.23	11.000	16.000
	2025-391	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	65	19.338	2.269	11.73	15.000	23.000
	2025-391	2	ENZYMATIC	165	VITROS	63	KODAK	53	14.698	1.899	12.92	12.000	18.000
	2025-391	2	ENZYMATIC	165	VITROS	63	KODAK	53	13.000	6.377	49.05	10.000	16.000
	2025-391	2	ENZYMATIC	165	VITROS	156	Kit 32	80	14.813	1.696	11.45	12.000	18.000
	2025-391	2	ENZYMATIC	165	VITROS	156	Kit 32	80	13.000	6.377	49.05	10.000	16.000
	2025-391	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	20	17.550	2.269	12.93	14.000	21.000
	2025-392	1	Generic Me	184	INTEGRA	93	ROCHE	10	11.200	1.720	15.36	9.000	13.000
	2025-392	1	Generic Me	184	INTEGRA	93	ROCHE	10	10.000	1.414	14.14	8.000	12.000
	2025-392	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	11.310	1.206	10.67	9.000	14.000
	2025-392	1	Generic Me	203	ROCHE	93	ROCHE	23	10.000	1.414	14.14	8.000	12.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-392	1	Generic Me	203	ROCHE	93	ROCHE	23	10.696	1.458	13.63	9.000	13.000	
2025-392	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	65	13.813	1.722	12.47	11.000	17.000	
2025-392	2	ENZYMATIC	165	VITROS	63	KODAK	53	8.667	5.437	62.73	7.000	10.000	
2025-392	2	ENZYMATIC	165	VITROS	63	KODAK	53	9.904	1.260	12.72	8.000	12.000	
2025-392	2	ENZYMATIC	165	VITROS	156	Kit 32	80	8.667	5.437	62.73	7.000	10.000	
2025-392	2	ENZYMATIC	165	VITROS	156	Kit 32	80	10.050	1.359	13.52	8.000	12.000	
2025-392	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	20	12.600	1.934	15.35	10.000	15.000	
169 C02			CLIA TEST ID #: 351		EVALUATION CRITERIA: TARGET VALUE 20 %								
2025-393	1	Generic Me	184	INTEGRA	93	ROCHE	10	9.800	1.939	19.79	8.000	12.000	
2025-393	1	Generic Me	184	INTEGRA	93	ROCHE	10	11.800	1.661	14.08	9.000	14.000	
2025-393	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	11.966	1.474	12.31	10.000	14.000	
2025-393	1	Generic Me	203	ROCHE	93	ROCHE	23	11.435	2.123	18.57	9.000	14.000	
2025-393	1	Generic Me	203	ROCHE	93	ROCHE	23	9.800	1.939	19.79	8.000	12.000	
2025-393	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	65	14.547	1.952	13.42	12.000	17.000	
2025-393	2	ENZYMATIC	165	VITROS	63	KODAK	53	10.673	1.410	13.21	9.000	13.000	
2025-393	2	ENZYMATIC	165	VITROS	63	KODAK	53	10.667	6.182	57.96	9.000	13.000	
2025-393	2	ENZYMATIC	165	VITROS	156	Kit 32	80	10.367	1.519	14.66	8.000	12.000	
2025-393	2	ENZYMATIC	165	VITROS	156	Kit 32	80	10.667	6.182	57.96	9.000	13.000	
2025-393	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	20	13.550	1.910	14.09	11.000	16.000	
2025-394	1	Generic Me	184	INTEGRA	93	ROCHE	10	20.100	1.300	6.47	16.000	24.000	
2025-394	1	Generic Me	184	INTEGRA	93	ROCHE	10	20.000	2.449	12.25	16.000	24.000	
2025-394	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	22.759	2.416	10.62	18.000	27.000	
2025-394	1	Generic Me	203	ROCHE	93	ROCHE	23	20.000	2.449	12.25	16.000	24.000	
2025-394	1	Generic Me	203	ROCHE	93	ROCHE	23	20.261	2.288	11.29	16.000	24.000	
2025-394	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	65	24.892	2.192	8.80	20.000	30.000	
2025-394	2	ENZYMATIC	165	VITROS	63	KODAK	53	19.333	9.741	50.38	15.000	23.000	
2025-394	2	ENZYMATIC	165	VITROS	63	KODAK	53	19.679	1.911	9.71	16.000	24.000	
2025-394	2	ENZYMATIC	165	VITROS	156	Kit 32	80	19.333	9.741	50.38	15.000	23.000	
2025-394	2	ENZYMATIC	165	VITROS	156	Kit 32	80	20.250	1.813	8.95	16.000	24.000	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-394		2	ENZYMATIC	219	ATELLICA	143	SIEMENS	20	23.600	2.200	9.32	19.000	28.000
169 C02				CLIA TEST ID #: 351		EVALUATION CRITERIA: TARGET VALUE 20 %							
2025-395		1	Generic Me	184	INTEGRA	93	ROCHE	10	16.400	2.577	15.71	13.000	20.000
2025-395		1	Generic Me	184	INTEGRA	93	ROCHE	10	17.600	2.010	11.42	14.000	21.000
2025-395		1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	19.034	2.076	10.91	15.000	23.000
2025-395		1	Generic Me	203	ROCHE	93	ROCHE	23	17.261	2.110	12.23	14.000	21.000
2025-395		1	Generic Me	203	ROCHE	93	ROCHE	23	16.400	2.577	15.71	13.000	20.000
2025-395		2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	65	21.365	1.897	8.88	17.000	26.000
2025-395		2	ENZYMATIC	165	VITROS	63	KODAK	53	16.491	1.798	10.90	13.000	20.000
2025-395		2	ENZYMATIC	165	VITROS	63	KODAK	53	16.000	7.789	48.68	13.000	19.000
2025-395		2	ENZYMATIC	165	VITROS	156	Kit 32	80	16.886	1.676	9.93	14.000	20.000
2025-395		2	ENZYMATIC	165	VITROS	156	Kit 32	80	16.000	7.789	48.68	13.000	19.000
2025-395		2	ENZYMATIC	219	ATELLICA	143	SIEMENS	20	20.150	1.768	8.78	16.000	24.000
170 DIRECT BILIRUBIN				CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}							
2025-391		4	JEND. -GROG	38	SIEMENS DI	143	SIEMENS	43	0.724	0.057	7.87	0.600	0.900
2025-391		5	JEND. -GROG	197	ARCHITECT	1	ABBOTT	12	1.200	0.108	9.00	0.900	1.500
2025-391		11	SPECT. WIT	165	VITROS	63	KODAK	69	0.445	0.162	36.50	0.000	0.900
2025-391		13	AZOBIL.W/D	203	ROCHE	93	ROCHE	19	0.789	0.197	24.96	0.200	1.400
2025-391		14	VANADATE 0	219	ATELLICA	143	SIEMENS	18	1.383	0.130	9.41	1.000	1.800
2025-392		4	JEND. -GROG	38	SIEMENS DI	143	SIEMENS	43	0.070	0.046	65.83	0	0.200
2025-392		5	JEND. -GROG	197	ARCHITECT	1	ABBOTT	12	0.100	0.000	0.00	0.100	0.100
2025-392		11	SPECT. WIT	165	VITROS	63	KODAK	69	0.000	0.000	0.00	0.000	0.000
2025-392		13	AZOBIL.W/D	203	ROCHE	93	ROCHE	19	0.163	0.058	35.63	0.000	0.300
2025-392		14	VANADATE 0	219	ATELLICA	143	SIEMENS	18	0.100	0.000	0.00	0.100	0.100
2025-393		4	JEND. -GROG	38	SIEMENS DI	143	SIEMENS	43	0.274	0.044	15.90	0.100	0.400
2025-393		5	JEND. -GROG	197	ARCHITECT	1	ABBOTT	12	0.417	0.037	8.94	0.300	0.500
2025-393		11	SPECT. WIT	165	VITROS	63	KODAK	69	0.039	0.104	266.97	0	0.300
2025-393		13	AZOBIL.W/D	203	ROCHE	93	ROCHE	19	0.300	0.079	26.49	0.100	0.500

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-393		14	VANADATE O	219	ATELLICA	143	SIEMENS	18	0.528	0.045	8.49	0.400	0.700
170 DIRECT BILIRUBIN				CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}							
2025-394		4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	43	1.149	0.080	6.96	0.900	1.400
2025-394		5	JEND.-GROG	197	ARCHITECT	1	ABBOTT	12	1.700	0.115	6.79	1.400	2.000
2025-394		11	SPECT. WIT	165	VITROS	63	KODAK	69	1.026	0.269	26.18	0.200	1.800
2025-394		13	AZOBIL.W/D	203	ROCHE	93	ROCHE	19	1.211	0.342	28.22	0.200	2.200
2025-394		14	VANADATE O	219	ATELLICA	143	SIEMENS	18	2.053	0.138	6.71	1.600	2.500
2025-395		4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	43	0.961	0.058	6.03	0.800	1.200
2025-395		5	JEND.-GROG	197	ARCHITECT	1	ABBOTT	12	1.458	0.086	5.91	1.200	1.800
2025-395		11	SPECT. WIT	165	VITROS	63	KODAK	69	0.749	0.184	24.52	0.200	1.300
2025-395		13	AZOBIL.W/D	203	ROCHE	93	ROCHE	19	0.979	0.337	34.37	0.000	2.000
2025-395		14	VANADATE O	219	ATELLICA	143	SIEMENS	18	1.861	0.180	9.67	1.300	2.400

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 15 WHOLE BLOOD GLUCOSE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
157 WHOLE BLOOD GLUCOSE				EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}									
2025-491		23	ABBOTT PRE					25	165.333	18.311	11.08	149.000	182.000
2025-491		27	STAT SRIP.					92	140.363	4.929	3.51	126.000	154.000
2025-491		33	AC.CHEK II					34	160.441	4.258	2.65	144.000	176.000
2025-491		34	FREE STYL					35	180.343	12.373	6.86	162.000	198.000
2025-492		23	ABBOTT PRE					25	363.760	28.556	7.85	327.000	400.000
2025-492		27	STAT SRIP.					92	282.678	13.315	4.71	254.000	311.000
2025-492		33	AC.CHEK II					34	347.294	11.276	3.25	313.000	382.000
2025-492		34	FREE STYL					35	400.514	31.311	7.82	360.000	441.000
2025-493		23	ABBOTT PRE					25	101.840	7.170	7.04	92.000	112.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 15 WHOLE BLOOD GLUCOSE				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-493	27	STAT SRIP.		92	84.033	4.020	4.78	76.000	92.000	
2025-493	33	AC.CHEK II		34	86.853	3.079	3.54	78.000	96.000	
2025-493	34	FREE STYL		35	105.829	8.091	7.64	95.000	116.000	
157 WHOLE BLOOD GLUCOSE			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}						
2025-494	23	ABBOTT PRE		25	365.520	26.181	7.16	329.000	402.000	
2025-494	27	STAT SRIP.		92	281.272	13.788	4.90	253.000	309.000	
2025-494	33	AC.CHEK II		34	348.059	11.837	3.40	313.000	383.000	
2025-494	34	FREE STYL		35	391.086	36.971	9.45	352.000	430.000	
2025-495	23	ABBOTT PRE		25	100.920	5.939	5.89	91.000	111.000	
2025-495	27	STAT SRIP.		92	83.565	4.124	4.93	75.000	92.000	
2025-495	33	AC.CHEK II		34	87.088	3.275	3.76	78.000	96.000	
2025-495	34	FREE STYL		35	107.441	5.473	5.09	97.000	118.000	
SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
007 BLOOD GASES-pCO2			CLIA TEST ID #: 335	EVALUATION CRITERIA: TARGET VALUE 8 % OR 5.00 {GREATER}						
2025-441	256	GEM PREMI.		10	65.600	1.908	2.91	60.400	70.800	
2025-441	265	ROCHE COBA		33	65.866	1.268	1.93	60.600	71.100	
2025-442	256	GEM PREMI.		10	40.600	0.917	2.26	35.600	45.600	
2025-442	265	ROCHE COBA		33	42.618	0.729	1.71	37.600	47.600	
2025-443	256	GEM PREMI.		10	21.600	0.917	4.24	16.600	26.600	
2025-443	265	ROCHE COBA		33	23.518	0.625	2.66	18.500	28.500	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES				
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
007 BLOOD GASES-pCO2			CLIA TEST ID #: 335	EVALUATION CRITERIA: TARGET VALUE 8 % OR 5.00 {GREATER}						
2025-444	256	GEM PREMI.			10	53.100	1.578	2.97	48.100	58.100
2025-444	265	ROCHE COBA			33	54.347	1.977	3.64	49.300	59.300
2025-445	256	GEM PREMI.			10	40.400	1.020	2.52	35.400	45.400
2025-445	265	ROCHE COBA			33	42.373	0.712	1.68	37.400	47.400
008 BLOOD GASES-pH			CLIA TEST ID #: 315	EVALUATION CRITERIA: TARGET VALUE 0.04						
2025-441	265	ROCHE COBA			35	7.176	0.009	0.13	7.136	7.216
2025-442	265	ROCHE COBA			35	7.418	0.008	0.11	7.378	7.458
2025-443	265	ROCHE COBA			35	7.567	0.007	0.09	7.527	7.607
2025-444	265	ROCHE COBA			35	7.227	0.007	0.10	7.187	7.267
2025-445	265	ROCHE COBA			35	7.416	0.007	0.10	7.376	7.456
009 BLOOD GASES-pO2			CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE 15 % OR 15.00 {GREATER}						
2025-441	265	ROCHE COBA			35	52.588	6.964	13.24	37.600	67.600
2025-441	265	ROCHE COBA			35	65.060	9.192	14.13	50.100	80.100
2025-442	265	ROCHE COBA			35	116.380	15.749	13.53	98.900	133.800
2025-442	265	ROCHE COBA			35	107.484	3.535	3.29	91.400	123.600
2025-443	265	ROCHE COBA			35	183.672	5.428	2.96	156.100	211.200
2025-443	265	ROCHE COBA			35	196.820	27.558	14.00	167.300	226.300
2025-444	265	ROCHE COBA			35	297.780	36.170	12.15	253.100	342.400
2025-444	265	ROCHE COBA			35	283.350	33.780	11.92	240.800	325.900

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 20 BLOOD GASES		GRP: 30 BLOOD GASES					
ANALYTE						NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
SAMPLE	METHOD		SYST/INST		REAGENTS						
009 BLOOD GASES-p02			CLIA TEST ID #: 325			EVALUATION CRITERIA: TARGET VALUE 15 % OR 15.00 {GREATER}					
2025-445	265	ROCHE COBA				35	105.025	4.861	4.63	89.300	120.800
2025-445	265	ROCHE COBA				35	112.960	9.679	8.57	96.000	129.900
SPEC: 10 CHEMISTRY				SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE						NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
SAMPLE	METHOD		SYST/INST		REAGENTS						
029 FOLL. STIM. HOR.-FSH			CLIA TEST ID #: 542			EVALUATION CRITERIA: TARGET VALUE 18 % OR 2.00 {GREATER}					
2025-421	116	ROCHE COBA				17	24.294	1.485	6.11	19.900	28.700
2025-421	125	B.C.ACCESS				10	26.160	1.569	6.00	21.500	30.900
2025-421	149	ARC i2000s				11	22.044	0.548	2.49	18.100	26.000
2025-421	149	ARC i2000s				11	21.920	1.543	7.04	18.000	25.900
2025-421	169	ATELLICA				10	26.020	1.417	5.45	21.300	30.700
2025-422	116	ROCHE COBA				17	39.588	1.608	4.06	32.500	46.700
2025-422	125	B.C.ACCESS				10	41.740	3.450	8.27	34.200	49.300
2025-422	149	ARC i2000s				11	38.733	1.020	2.63	31.800	45.700
2025-422	149	ARC i2000s				11	37.820	3.548	9.38	31.000	44.600
2025-422	169	ATELLICA				10	41.160	2.020	4.91	33.800	48.600
2025-423	116	ROCHE COBA				17	23.694	1.349	5.69	19.400	28.000
2025-423	125	B.C.ACCESS				10	25.030	1.614	6.45	20.500	29.500
2025-423	149	ARC i2000s				11	23.150	1.570	6.78	19.000	27.300
2025-423	149	ARC i2000s				11	19.478	0.710	3.64	16.000	23.000
2025-423	169	ATELLICA				10	25.110	0.744	2.96	20.600	29.600
2025-424	116	ROCHE COBA				17	6.618	0.430	6.50	4.600	8.600
2025-424	125	B.C.ACCESS				10	6.870	0.668	9.72	4.900	8.900
2025-424	149	ARC i2000s				11	4.611	0.456	9.88	2.600	6.600

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-424	149	ARC i2000s		11	5.810	0.650	11.19	3.800	7.800	
2025-424	169	ATELLICA		10	12.990	18.938	145.79	10.700	15.300	
029 FOLL. STIM. HOR.-FSH		CLIA TEST ID #: 542	EVALUATION CRITERIA: TARGET VALUE 18 % OR 2.00 {GREATER}							
2025-425	116	ROCHE COBA		17	32.547	1.828	5.62	26.700	38.400	
2025-425	125	B.C.ACCESS		10	33.870	2.029	5.99	27.800	40.000	
2025-425	149	ARC i2000s		11	30.278	0.656	2.17	24.800	35.700	
2025-425	149	ARC i2000s		11	29.710	2.607	8.78	24.400	35.100	
2025-425	169	ATELLICA		10	31.190	8.250	26.45	25.600	36.800	
030 FREE THYROXINE		CLIA TEST ID #: 545	EVALUATION CRITERIA: TARGET VALUE 15 % OR 0.30 {GREATER}							
2025-421	115	VITROS ECI		47	4.713	0.197	4.19	4.000	5.400	
2025-421	116	ROCHE COBA		50	2.024	0.082	4.06	1.700	2.300	
2025-421	125	B.C.ACCESS		40	1.600	0.000	0.00	1.300	1.900	
2025-421	125	B.C.ACCESS		40	1.662	0.105	6.34	1.400	2.000	
2025-421	149	ARC i2000s		22	1.877	0.108	5.78	1.600	2.200	
2025-421	160	SIEMENS EX		45	2.031	0.121	5.95	1.700	2.300	
2025-421	169	ATELLICA		18	1.689	0.081	4.79	1.400	2.000	
2025-422	115	VITROS ECI		47	6.762	0.158	2.33	5.700	7.800	
2025-422	116	ROCHE COBA		50	3.038	0.143	4.70	2.600	3.500	
2025-422	125	B.C.ACCESS		40	2.369	0.150	6.35	2.000	2.700	
2025-422	125	B.C.ACCESS		40	2.367	0.125	5.27	2.000	2.700	
2025-422	149	ARC i2000s		22	2.577	0.219	8.51	2.200	3.000	
2025-422	160	SIEMENS EX		45	3.102	0.163	5.24	2.600	3.600	
2025-422	169	ATELLICA		18	2.472	0.080	3.25	2.100	2.800	
2025-423	115	VITROS ECI		47	1.683	0.078	4.64	1.400	2.000	
2025-423	116	ROCHE COBA		50	1.456	0.067	4.59	1.200	1.800	
2025-423	125	B.C.ACCESS		40	0.900	0.000	0.00	0.600	1.200	
2025-423	125	B.C.ACCESS		40	0.918	0.084	9.19	0.600	1.200	
2025-423	149	ARC i2000s		22	1.332	0.047	3.50	1.000	1.600	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-423	160	SIEMENS EX		45	1.193	0.071	5.96	0.900	1.500	
2025-423	169	ATELLICA		18	1.350	0.069	5.09	1.100	1.700	
030 FREE THYROXINE		CLIA TEST ID #: 545			EVALUATION CRITERIA: TARGET VALUE 15 % OR 0.30 {GREATER}					
2025-424	115	VITROS ECI		47	1.389	0.067	4.80	1.100	1.700	
2025-424	116	ROCHE COBA		50	0.790	0.046	5.80	0.500	1.100	
2025-424	125	B.C.ACCESS		40	0.756	0.081	10.71	0.500	1.100	
2025-424	125	B.C.ACCESS		40	0.800	0.000	0.00	0.500	1.100	
2025-424	149	ARC i2000s		22	0.782	0.049	6.26	0.500	1.100	
2025-424	160	SIEMENS EX		45	0.873	0.065	7.40	0.600	1.200	
2025-424	169	ATELLICA		18	0.712	0.032	4.53	0.400	1.000	
2025-425	115	VITROS ECI		47	5.913	0.216	3.65	5.000	6.800	
2025-425	116	ROCHE COBA		50	2.541	0.107	4.20	2.200	2.900	
2025-425	125	B.C.ACCESS		40	2.033	0.125	6.13	1.700	2.300	
2025-425	125	B.C.ACCESS		40	2.055	0.180	8.77	1.700	2.400	
2025-425	149	ARC i2000s		22	2.291	0.144	6.30	1.900	2.600	
2025-425	160	SIEMENS EX		45	2.544	0.156	6.12	2.200	2.900	
2025-425	169	ATELLICA		18	2.072	0.099	4.77	1.800	2.400	
032 hCG-QUANTITATIVE		CLIA TEST ID #: 555			EVALUATION CRITERIA: TARGET VALUE 18 % OR 3.00 {GREATER}					
2025-421	115	VITROS ECI		23	310.277	15.070	4.86	254.400	366.100	
2025-421	116	ROCHE COBA		17	338.553	19.242	5.68	277.600	399.500	
2025-421	125	B.C.ACCESS		10	407.740	22.126	5.43	334.300	481.100	
2025-422	115	VITROS ECI		23	602.052	30.916	5.14	493.700	710.400	
2025-422	116	ROCHE COBA		17	659.247	38.751	5.88	540.600	777.900	
2025-422	125	B.C.ACCESS		10	779.920	35.479	4.55	639.500	920.300	
2025-423	115	VITROS ECI		23	4.004	0.410	10.24	1.000	7.000	
2025-423	116	ROCHE COBA		17	3.141	0.295	9.40	0.100	6.100	
2025-423	125	B.C.ACCESS		10	4.230	0.100	2.38	1.200	7.200	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE											
SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
032 hCG-QUANTITATIVE			CLIA TEST ID #: 555			EVALUATION CRITERIA: TARGET VALUE 18 % OR 3.00 {GREATER}					
2025-424	115	VITROS ECI				23	2.400	0.000	0.00	0	5.400
2025-424	116	ROCHE COBA				17	1.253	0.217	17.34	0	4.300
2025-424	125	B.C.ACCESS				10	2.120	0.087	4.11	0	5.100
2025-425	115	VITROS ECI				23	454.170	23.429	5.16	372.400	535.900
2025-425	116	ROCHE COBA				17	502.065	30.196	6.01	411.700	592.400
2025-425	125	B.C.ACCESS				10	594.070	33.292	5.60	487.100	701.000
035 PROLACTIN			CLIA TEST ID #: 563			EVALUATION CRITERIA: TARGET VALUE 20 %					
2025-421	116	ROCHE COBA				17	14.653	0.790	5.39	11.700	17.600
2025-421	125	B.C.ACCESS				10	21.040	1.173	5.58	16.800	25.200
2025-421	169	ATELLICA				10	13.860	0.535	3.86	11.100	16.600
2025-422	116	ROCHE COBA				17	27.924	1.744	6.24	22.300	33.500
2025-422	125	B.C.ACCESS				10	36.190	1.449	4.00	29.000	43.400
2025-422	169	ATELLICA				10	25.260	1.279	5.06	20.200	30.300
2025-423	116	ROCHE COBA				17	10.365	0.615	5.94	8.300	12.400
2025-423	125	B.C.ACCESS				10	8.830	0.568	6.43	7.100	10.600
2025-423	169	ATELLICA				10	6.990	0.266	3.81	5.600	8.400
2025-424	116	ROCHE COBA				17	1.688	0.090	5.33	1.400	2.000
2025-424	125	B.C.ACCESS				10	1.840	0.169	9.16	1.500	2.200
2025-424	169	ATELLICA				10	1.590	0.122	7.68	1.300	1.900
2025-425	116	ROCHE COBA				17	21.388	1.068	4.99	17.100	25.700
2025-425	125	B.C.ACCESS				10	29.530	1.095	3.71	23.600	35.400
2025-425	169	ATELLICA				10	19.340	0.873	4.51	15.500	23.200
037 TESTOSTERONE			CLIA TEST ID #: 570			EVALUATION CRITERIA: TARGET VALUE 30 % OR 0.20 {GREATER}					
2025-421	116	ROCHE COBA				10	812.610	48.560	5.98	568.800	1056.400

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-421	149	ARC i2000s			10	813.300	45.305	5.57	569.300	1057.300
037 TESTOSTERONE			CLIA TEST ID #: 570		EVALUATION CRITERIA: TARGET VALUE 30 % OR 0.20 {GREATER}					
2025-422	116	ROCHE COBA			10	1321.900	62.001	4.69	925.300	1718.500
2025-422	149	ARC i2000s			10	1440.000	146.356	10.16	1008.000	1872.000
2025-423	116	ROCHE COBA			10	195.420	5.969	3.05	136.800	254.000
2025-423	149	ARC i2000s			10	222.990	15.118	6.78	156.100	289.900
2025-424	116	ROCHE COBA			10	108.390	4.793	4.42	75.900	140.900
2025-424	149	ARC i2000s			10	103.580	5.713	5.52	72.500	134.700
2025-425	116	ROCHE COBA			10	1071.200	41.482	3.87	749.800	1392.600
2025-425	149	ARC i2000s			10	1133.850	67.181	5.93	793.700	1474.000
039 THYRO. STI. HOR.-TSH			CLIA TEST ID #: 585		EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}					
2025-421	106	TOSOH AIA			10	5.530	0.564	10.20	4.400	6.600
2025-421	115	VITROS ECI			54	5.379	0.181	3.36	4.300	6.500
2025-421	116	ROCHE COBA			56	4.413	0.222	5.02	3.500	5.300
2025-421	125	B.C.ACCESS			51	4.020	0.188	4.67	3.200	4.800
2025-421	149	ARC i2000s			24	3.665	0.152	4.15	2.900	4.400
2025-421	160	SIEMENS EX			70	3.162	0.180	5.70	2.500	3.800
2025-421	169	ATELLICA			20	4.045	0.199	4.91	3.200	4.900
2025-422	106	TOSOH AIA			10	9.790	1.165	11.90	7.800	11.700
2025-422	115	VITROS ECI			54	9.426	0.395	4.19	7.500	11.300
2025-422	116	ROCHE COBA			56	7.382	0.324	4.38	5.900	8.900
2025-422	125	B.C.ACCESS			51	7.233	0.325	4.49	5.800	8.700
2025-422	149	ARC i2000s			24	6.633	0.313	4.72	5.300	8.000
2025-422	160	SIEMENS EX			70	5.490	0.315	5.74	4.400	6.600
2025-422	169	ATELLICA			20	6.915	0.400	5.79	5.500	8.300

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 55 (124)
DATE : 7/22/2025
TIME : 12:51:16

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE		METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
039 THYRO. STI. HOR.-TSH			CLIA TEST ID #: 585		EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}						
2025-423	106	TOSOH AIA			10	2.340	0.185	7.93	1.900	2.800	
2025-423	115	VITROS ECI			54	2.026	0.113	5.55	1.600	2.400	
2025-423	116	ROCHE COBA			56	2.307	0.108	4.66	1.800	2.800	
2025-423	125	B.C.ACCESS			51	2.171	0.121	5.57	1.700	2.600	
2025-423	149	ARC i2000s			24	1.883	0.103	5.46	1.500	2.300	
2025-423	160	SIEMENS EX			70	1.977	0.134	6.79	1.600	2.400	
2025-423	169	ATELLICA			20	2.005	0.092	4.59	1.600	2.400	
2025-424	106	TOSOH AIA			10	0.660	0.066	10.05	0.500	0.900	
2025-424	115	VITROS ECI			54	0.526	0.044	8.33	0.300	0.700	
2025-424	116	ROCHE COBA			56	0.743	0.053	7.15	0.500	0.900	
2025-424	125	B.C.ACCESS			51	0.576	0.042	7.36	0.400	0.800	
2025-424	149	ARC i2000s			24	0.500	0.000	0.00	0.300	0.700	
2025-424	160	SIEMENS EX			70	0.550	0.053	9.60	0.400	0.800	
2025-424	169	ATELLICA			20	0.565	0.048	8.44	0.400	0.800	
2025-425	106	TOSOH AIA			10	7.490	0.836	11.16	6.000	9.000	
2025-425	115	VITROS ECI			54	7.489	0.284	3.79	6.000	9.000	
2025-425	116	ROCHE COBA			56	5.947	0.274	4.60	4.800	7.100	
2025-425	125	B.C.ACCESS			51	5.643	0.271	4.80	4.500	6.800	
2025-425	149	ARC i2000s			24	5.063	0.189	3.73	4.100	6.100	
2025-425	160	SIEMENS EX			70	4.362	0.268	6.13	3.500	5.200	
2025-425	169	ATELLICA			20	5.550	0.266	4.78	4.400	6.700	
040 THYROXINE (T4)			CLIA TEST ID #: 595		EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}						
2025-421	32	SIEM DIME.			43	10.342	0.502	4.85	8.300	12.400	
2025-421	115	VITROS ECI			43	8.670	0.377	4.35	6.900	10.400	
2025-421	116	ROCHE COBA			47	9.243	0.578	6.26	7.400	11.100	
2025-421	125	B.C.ACCESS			40	8.723	0.563	6.46	7.000	10.500	
2025-421	149	ARC i2000s			22	8.000	0.439	5.49	6.400	9.600	

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 56 (124)
DATE : 7/22/2025
TIME : 12:51:16

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-421	149	ARC i2000s		22	9.052	0.564	6.23	7.200	10.900
2025-421	169	ATELLICA		18	10.111	0.514	5.08	8.100	12.100
040 THYROXINE (T4)		CLIA TEST ID #: 595	EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}						
2025-422	32	SIEM DIME.		43	16.986	0.857	5.05	13.600	20.400
2025-422	115	VITROS ECI		43	12.881	0.522	4.06	10.300	15.500
2025-422	116	ROCHE COBA		47	14.600	0.943	6.46	11.700	17.500
2025-422	125	B.C.ACCESS		40	13.218	1.101	8.33	10.600	15.900
2025-422	149	ARC i2000s		22	12.586	0.702	5.58	10.100	15.100
2025-422	149	ARC i2000s		22	15.073	1.459	9.68	12.100	18.100
2025-422	169	ATELLICA		18	13.878	0.675	4.86	11.100	16.700
2025-423	32	SIEM DIME.		43	11.590	0.682	5.89	9.300	13.900
2025-423	115	VITROS ECI		43	8.231	0.341	4.14	6.600	9.900
2025-423	116	ROCHE COBA		47	10.547	0.780	7.40	8.400	12.700
2025-423	125	B.C.ACCESS		40	8.955	0.754	8.42	7.200	10.700
2025-423	149	ARC i2000s		22	10.295	0.872	8.46	8.200	12.400
2025-423	149	ARC i2000s		22	8.500	0.616	7.25	6.800	10.200
2025-423	169	ATELLICA		18	9.678	0.402	4.16	7.700	11.600
2025-424	32	SIEM DIME.		43	3.342	0.433	12.96	2.300	4.300
2025-424	115	VITROS ECI		43	3.179	0.123	3.87	2.200	4.200
2025-424	116	ROCHE COBA		47	3.435	0.242	7.06	2.400	4.400
2025-424	125	B.C.ACCESS		40	2.825	0.317	11.21	1.800	3.800
2025-424	149	ARC i2000s		22	2.200	0.191	8.66	1.200	3.200
2025-424	149	ARC i2000s		22	2.757	0.292	10.59	1.800	3.800
2025-424	169	ATELLICA		18	3.711	0.247	6.65	2.700	4.700
2025-425	32	SIEM DIME.		43	13.560	0.645	4.76	10.800	16.300
2025-425	115	VITROS ECI		43	10.907	0.476	4.36	8.700	13.100
2025-425	116	ROCHE COBA		47	11.993	0.678	5.65	9.600	14.400

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-425	125	B.C.ACCESS		40	10.928	0.841	7.69	8.700	13.100
2025-425	149	ARC i2000s		22	12.300	0.730	5.93	9.800	14.800
2025-425	149	ARC i2000s		22	10.400	0.316	3.04	8.300	12.500
2025-425	169	ATELLICA		18	12.328	0.672	5.45	9.900	14.800
141 FOLATE		CLIA TEST ID #: 541	EVALUATION CRITERIA: TARGET VALUE 30 % OR 1.00 {GREATER}						
2025-421	115	VITROS ECI		16	5.173	0.503	9.72	3.600	6.700
2025-421	116	ROCHE COBA		25	4.452	0.630	14.15	3.100	5.800
2025-421	125	B.C.ACCESS		11	6.836	0.296	4.33	4.800	8.900
2025-421	149	ARC i2000s		13	6.300	0.932	14.79	4.400	8.200
2025-421	169	ATELLICA		10	4.700	0.338	7.18	3.300	6.100
2025-422	115	VITROS ECI		16	10.747	1.438	13.39	7.500	14.000
2025-422	116	ROCHE COBA		25	9.944	1.176	11.83	7.000	12.900
2025-422	125	B.C.ACCESS		11	12.864	0.391	3.04	9.000	16.700
2025-422	149	ARC i2000s		13	12.838	1.771	13.79	9.000	16.700
2025-422	169	ATELLICA		10	12.990	3.928	30.24	9.100	16.900
2025-423	115	VITROS ECI		16	0.575	0.401	69.70	0	1.600
2025-423	116	ROCHE COBA		25	2.000	0.000	0.00	1.000	3.000
2025-423	125	B.C.ACCESS		11	1.800	0.135	7.49	0.800	2.800
2025-423	149	ARC i2000s		13	1.554	0.708	45.55	0.600	2.600
2025-423	169	ATELLICA		10	0.980	0.376	38.40	0.000	2.000
2025-424	115	VITROS ECI		16	0.833	0.101	12.13	0	1.800
2025-424	116	ROCHE COBA		25	2.000	0.000	0.00	1.000	3.000
2025-424	125	B.C.ACCESS		11	0.909	0.124	13.64	0	1.900
2025-424	149	ARC i2000s		13	1.092	0.814	74.50	0.100	2.100
2025-424	169	ATELLICA		10	0.520	0.178	34.19	0	1.500
2025-425	115	VITROS ECI		16	8.100	0.771	9.52	5.700	10.500

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-425	116	ROCHE COBA			25	6.980	0.881	12.63	4.900	9.100
2025-425	125	B.C.ACCESS			11	9.973	0.322	3.23	7.000	13.000
2025-425	149	ARC i2000s			13	9.315	1.097	11.77	6.500	12.100
2025-425	169	ATELLICA			10	8.750	1.264	14.45	6.100	11.400
142 hLH (HUMAN LUT. HOR)			CLIA TEST ID #: 560	EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-421	116	ROCHE COBA			15	21.513	0.865	4.02	17.200	25.800
2025-421	125	B.C.ACCESS			10	21.410	1.687	7.88	17.100	25.700
2025-421	149	ARC i2000s			10	12.770	0.714	5.59	10.200	15.300
2025-421	169	ATELLICA			10	18.360	1.063	5.79	14.700	22.000
2025-422	116	ROCHE COBA			15	36.467	1.422	3.90	29.200	43.800
2025-422	125	B.C.ACCESS			10	35.620	2.399	6.73	28.500	42.700
2025-422	149	ARC i2000s			10	22.560	2.009	8.91	18.000	27.100
2025-422	169	ATELLICA			10	29.490	1.937	6.57	23.600	35.400
2025-423	116	ROCHE COBA			15	16.240	0.745	4.59	13.000	19.500
2025-423	125	B.C.ACCESS			10	13.090	0.724	5.53	10.500	15.700
2025-423	149	ARC i2000s			10	9.850	0.684	6.95	7.900	11.800
2025-423	169	ATELLICA			10	12.670	0.608	4.80	10.100	15.200
2025-424	116	ROCHE COBA			15	4.187	0.212	5.08	3.300	5.000
2025-424	125	B.C.ACCESS			10	3.000	0.100	3.33	2.400	3.600
2025-424	149	ARC i2000s			10	2.180	0.133	6.09	1.700	2.600
2025-424	169	ATELLICA			10	2.980	0.189	6.33	2.400	3.600
2025-425	116	ROCHE COBA			15	29.487	1.257	4.26	23.600	35.400
2025-425	125	B.C.ACCESS			10	28.330	1.428	5.04	22.700	34.000
2025-425	149	ARC i2000s			10	17.920	0.993	5.54	14.300	21.500
2025-425	169	ATELLICA			10	24.420	1.249	5.11	19.500	29.300

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 59 (124)
DATE : 7/22/2025
TIME : 12:51:16

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)							
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
031 hCG-QUALITATIVE														
2025-421	113	BIO-SIGN			002	002	002	002		002 - POSITIVE	19	19	19	100
2025-421	142	INSTANT VI			002	002	002	002		002 - POSITIVE	23	23	23	100
2025-421	150	AIM STEP			002	002	002	002		002 - POSITIVE	112	112	112	100
2025-421	164	HCG Alere			002	002	002	002		002 - POSITIVE	76	76	76	100
2025-421	165	Osom HCG C			002	002	002	002		001 - NEGATIVE	13	1	12	0
2025-421	165	Osom HCG C			002	002	002	002		002 - POSITIVE	13	12	12	100
2025-421	166	FaStep			002	002	002	002		002 - POSITIVE	15	15	15	100
2025-421	167	Tanner Sci			002	002	002	002		002 - POSITIVE	10	10	10	100
2025-421	168	STANBIO 20			002	002	002	002		002 - POSITIVE	16	16	16	100
2025-422	113	BIO-SIGN			002	002	002	002		002 - POSITIVE	19	19	19	100
2025-422	142	INSTANT VI			002	002	002	002		002 - POSITIVE	23	23	23	100
2025-422	150	AIM STEP			002	002	002	002		002 - POSITIVE	112	112	112	100
2025-422	164	HCG Alere			002	002	002	002		002 - POSITIVE	76	76	76	100
2025-422	165	Osom HCG C			002	002	002	002		002 - POSITIVE	13	13	13	100
2025-422	166	FaStep			002	002	002	002		002 - POSITIVE	15	15	15	100
2025-422	167	Tanner Sci			002	002	002	002		002 - POSITIVE	10	10	10	100
2025-422	168	STANBIO 20			002	002	002	002		002 - POSITIVE	16	16	16	100
2025-423	113	BIO-SIGN			001	001	001	001		001 - NEGATIVE	19	18	18	100
2025-423	113	BIO-SIGN			001	001	001	001		002 - POSITIVE	19	1	18	0
2025-423	142	INSTANT VI			001	001	001	001		001 - NEGATIVE	23	20	20	100
2025-423	142	INSTANT VI			001	001	001	001		002 - POSITIVE	23	3	20	0
2025-423	150	AIM STEP					001	001		001 - NEGATIVE	112	89	89	100
2025-423	150	AIM STEP					001	001		002 - POSITIVE	112	23	89	0
2025-423	164	HCG Alere			001	001	001	001		001 - NEGATIVE	76	64	64	100
2025-423	164	HCG Alere			001	001	001	001		002 - POSITIVE	76	12	64	0
2025-423	165	Osom HCG C			001	001	001	001		001 - NEGATIVE	13	11	11	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-423	165	Osom HCG C		001	001	001	001			002 - POSITIVE	13	2	11	0
2025-423	166	FaStep		001	001	001	001			001 - NEGATIVE	15	15	15	100
2025-423	167	Tanner Sci		001	001	001	001			001 - NEGATIVE	10	10	10	100
2025-423	168	STANBIO 20				001	001			001 - NEGATIVE	16	12	12	100
2025-423	168	STANBIO 20				001	001			002 - POSITIVE	16	4	12	0
031 hCG-QUALITATIVE														
2025-424	113	BIO-SIGN		001	001	001	001			001 - NEGATIVE	19	19	19	100
2025-424	142	INSTANT VI		001	001	001	001			001 - NEGATIVE	23	23	23	100
2025-424	150	AIM STEP		001	001	001	001			001 - NEGATIVE	112	112	112	100
2025-424	164	HCG Alere		001	001	001	001			001 - NEGATIVE	76	76	76	100
2025-424	165	Osom HCG C		001	001	001	001			001 - NEGATIVE	13	12	12	100
2025-424	165	Osom HCG C		001	001	001	001			002 - POSITIVE	13	1	12	0
2025-424	166	FaStep		001	001	001	001			001 - NEGATIVE	15	15	15	100
2025-424	167	Tanner Sci		001	001	001	001			001 - NEGATIVE	10	10	10	100
2025-424	168	STANBIO 20		001	001	001	001			001 - NEGATIVE	16	16	16	100
2025-425	113	BIO-SIGN		002	002	002	002			001 - NEGATIVE	19	1	18	0
2025-425	113	BIO-SIGN		002	002	002	002			002 - POSITIVE	19	18	18	100
2025-425	142	INSTANT VI		002	002	002	002			002 - POSITIVE	23	23	23	100
2025-425	150	AIM STEP		002	002	002	002			002 - POSITIVE	112	112	112	100
2025-425	164	HCG Alere		002	002	002	002			001 - NEGATIVE	76	1	75	0
2025-425	164	HCG Alere		002	002	002	002			002 - POSITIVE	76	75	75	100
2025-425	165	Osom HCG C		002	002	002	002			001 - NEGATIVE	13	1	12	0
2025-425	165	Osom HCG C		002	002	002	002			002 - POSITIVE	13	12	12	100
2025-425	166	FaStep		002	002	002	002			002 - POSITIVE	15	15	15	100
2025-425	167	Tanner Sci		002	002	002	002			002 - POSITIVE	10	10	10	100
2025-425	168	STANBIO 20		002	002	002	002			002 - POSITIVE	16	16	16	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 61 (124)
DATE : 7/22/2025
TIME : 12:51:16

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFeree LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
151 hCG ONLY QUALITATIVE													
2025-411	018	BIO SIGN			001	001	001	001	001 - NEGATIVE	26	26	26	100
2025-411	114	INSTANT VI			001	001	001	001	001 - NEGATIVE	61	61	61	100
2025-411	118	AIM STEP			001	001	001	001	001 - NEGATIVE	232	232	232	100
2025-411	130	ALERE HCG			001	001	001	001	001 - NEGATIVE	103	103	103	100
2025-411	131	OSOM HCG			001	001	001	001	001 - NEGATIVE	23	23	23	100
2025-411	133	FaStep			001	001	001	001	001 - NEGATIVE	29	29	29	100
2025-411	134	Tanner Sc.			001	001	001	001	001 - NEGATIVE	54	54	54	100
2025-411	136	CLARITY			001	001	001	001	001 - NEGATIVE	21	21	21	100
2025-411	137	CARDINAL			001	001	001	001	001 - NEGATIVE	12	12	12	100
2025-412	018	BIO SIGN			002	002	002	002	002 - POSITIVE	26	26	26	100
2025-412	114	INSTANT VI			002	002	002	002	002 - POSITIVE	61	61	61	100
2025-412	118	AIM STEP			002	002	002	002	002 - POSITIVE	232	232	232	100
2025-412	130	ALERE HCG			002	002	002	002	002 - POSITIVE	103	103	103	100
2025-412	131	OSOM HCG			002	002	002	002	002 - POSITIVE	23	23	23	100
2025-412	133	FaStep			002	002	002	002	002 - POSITIVE	29	29	29	100
2025-412	134	Tanner Sc.			002	002	002	002	002 - POSITIVE	54	54	54	100
2025-412	136	CLARITY			002	002	002	002	002 - POSITIVE	21	21	21	100
2025-412	137	CARDINAL			002	002	002	002	002 - POSITIVE	12	12	12	100
2025-413	018	BIO SIGN			002	002	002	002	002 - POSITIVE	26	26	26	100
2025-413	114	INSTANT VI			002	002	002	002	002 - POSITIVE	61	61	61	100
2025-413	118	AIM STEP			002	002	002	002	002 - POSITIVE	232	232	232	100
2025-413	130	ALERE HCG			002	002	002	002	001 - NEGATIVE	103	1	102	0
2025-413	130	ALERE HCG			002	002	002	002	002 - POSITIVE	103	102	102	100
2025-413	131	OSOM HCG			002	002	002	002	002 - POSITIVE	23	23	23	100
2025-413	133	FaStep			002	002	002	002	002 - POSITIVE	29	29	29	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFeree LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-413	134	Tanner Sc.			002	002	002	002		002 - POSITIVE	54	54	54	100
2025-413	136	CLARITY			002	002	002	002		002 - POSITIVE	21	21	21	100
2025-413	137	CARDINAL			002	002	002	002		002 - POSITIVE	12	12	12	100
151 hCG ONLY QUALITATIVE														
2025-414	018	BIO SIGN			002	002	002	002		002 - POSITIVE	26	26	26	100
2025-414	114	INSTANT VI			002	002	002	002		002 - POSITIVE	61	61	61	100
2025-414	118	AIM STEP			002	002	002	002		002 - POSITIVE	232	232	232	100
2025-414	130	ALERE HCG			002	002	002	002		001 - NEGATIVE	103	1	102	0
2025-414	130	ALERE HCG			002	002	002	002		002 - POSITIVE	103	102	102	100
2025-414	131	OSOM HCG			002	002	002	002		002 - POSITIVE	23	23	23	100
2025-414	133	FaStep			002	002	002	002		002 - POSITIVE	29	29	29	100
2025-414	134	Tanner Sc.			002	002	002	002		002 - POSITIVE	54	54	54	100
2025-414	136	CLARITY			002	002	002	002		002 - POSITIVE	21	21	21	100
2025-414	137	CARDINAL			002	002	002	002		002 - POSITIVE	12	12	12	100
2025-415	018	BIO SIGN			001	001	001	001		001 - NEGATIVE	26	26	26	100
2025-415	114	INSTANT VI			001	001	001	001		001 - NEGATIVE	61	61	61	100
2025-415	118	AIM STEP			001	001	001	001		001 - NEGATIVE	232	232	232	100
2025-415	130	ALERE HCG			001	001	001	001		001 - NEGATIVE	103	102	102	100
2025-415	130	ALERE HCG			001	001	001	001		002 - POSITIVE	103	1	102	0
2025-415	131	OSOM HCG			001	001	001	001		001 - NEGATIVE	23	23	23	100
2025-415	133	FaStep			001	001	001	001		001 - NEGATIVE	29	29	29	100
2025-415	134	Tanner Sc.			001	001	001	001		001 - NEGATIVE	54	54	54	100
2025-415	136	CLARITY			001	001	001	001		001 - NEGATIVE	21	21	21	100
2025-415	137	CARDINAL			001	001	001	001		001 - NEGATIVE	12	12	12	100

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 55 ENDO.(T3 UPTAKE)						
ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
173 T3 UPTAKE			CLIA TEST ID #: 565		EVALUATION CRITERIA: TARGET VALUE		18 %					
2025-421	1	%U	84	VITROS ECI	1	25-35	36	45.368	1.986	4.38	37.200	53.530
2025-421	1	%U	91	B.C.ACCESS	2	35-45	21	46.505	2.858	6.15	38.130	54.880
2025-421	2	TUV	95	Arc i2000s	3	0.7 - 1.2	17	1.000	0.065	6.49	0.820	1.180
2025-421	4	%	32	DIMENSION	2	35-45	44	38.650	1.647	4.26	31.690	45.610
2025-421	4	%	91	B.C.ACCESS	2	35-45	11	48.218	2.445	5.07	39.540	56.900
2025-421	4	%	106	ATELLICA	1	25-35	15	38.359	2.030	5.29	31.450	45.260
2025-421	5	TBI	98	ROCHE COBA	4	0.8-1.3	42	0.748	0.045	5.97	0.610	0.880
2025-422	1	%U	84	VITROS ECI	1	25-35	36	40.947	2.308	5.64	33.580	48.320
2025-422	1	%U	91	B.C.ACCESS	2	35-45	21	44.629	2.634	5.90	36.600	52.660
2025-422	2	TUV	95	Arc i2000s	3	0.7 - 1.2	17	1.212	0.073	6.02	0.990	1.430
2025-422	4	%	32	DIMENSION	2	35-45	44	39.432	1.642	4.16	32.330	46.530
2025-422	4	%	91	B.C.ACCESS	2	35-45	11	44.173	2.952	6.68	36.220	52.120
2025-422	4	%	106	ATELLICA	1	25-35	15	33.558	2.014	6.00	27.520	39.600
2025-422	5	TBI	98	ROCHE COBA	4	0.8-1.3	42	0.612	0.043	7.09	0.500	0.720
2025-423	1	%U	84	VITROS ECI	1	25-35	36	24.276	1.113	4.58	19.910	28.650
2025-423	1	%U	91	B.C.ACCESS	2	35-45	21	34.710	1.884	5.43	28.460	40.960
2025-423	2	TUV	95	Arc i2000s	3	0.7 - 1.2	17	1.424	0.085	5.98	1.170	1.680
2025-423	4	%	32	DIMENSION	2	35-45	44	30.329	1.635	5.39	24.870	35.790
2025-423	4	%	91	B.C.ACCESS	2	35-45	11	34.900	1.621	4.65	28.620	41.180
2025-423	4	%	106	ATELLICA	1	25-35	15	21.936	1.305	5.95	17.990	25.880
2025-423	5	TBI	98	ROCHE COBA	4	0.8-1.3	42	1.079	0.042	3.86	0.880	1.270
2025-424	1	%U	84	VITROS ECI	1	25-35	36	51.988	2.005	3.86	42.630	61.350
2025-424	1	%U	91	B.C.ACCESS	2	35-45	21	52.529	2.428	4.62	43.070	61.980
2025-424	2	TUV	95	Arc i2000s	3	0.7 - 1.2	17	0.689	0.045	6.57	0.560	0.810
2025-424	4	%	32	DIMENSION	2	35-45	44	38.469	1.991	5.18	31.540	45.390
2025-424	4	%	91	B.C.ACCESS	2	35-45	11	52.145	2.905	5.57	42.760	61.530

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)					
ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE		METHOD		SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-424		4	%	106	ATELLICA	1	25-35	15	50.825	3.100	6.10	41.680	59.970
2025-424		5	TBI	98	ROCHE COBA	4	0.8-1.3	42	0.910	0.046	5.00	0.750	1.070
173 T3 UPTAKE				CLIA TEST ID #: 565				EVALUATION CRITERIA: TARGET VALUE 18 %					
2025-425		1	%U	84	VITROS ECI	1	25-35	36	43.051	2.061	4.79	35.300	50.800
2025-425		1	%U	91	B.C.ACCESS	2	35-45	21	46.338	3.038	6.56	38.000	54.680
2025-425		2	TUV	95	Arc i2000s	3	0.7 - 1.2	17	1.112	0.065	5.89	0.910	1.310
2025-425		4	%	32	DIMENSION	2	35-45	44	39.150	1.838	4.70	32.100	46.200
2025-425		4	%	91	B.C.ACCESS	2	35-45	11	45.873	2.888	6.30	37.620	54.130
2025-425		4	%	106	ATELLICA	1	25-35	15	35.342	1.895	5.36	28.980	41.700
2025-425		5	TBI	98	ROCHE COBA	4	0.8-1.3	42	0.679	0.044	6.46	0.560	0.800

SPEC: 10 CHEMISTRY				SUB: 40 TOXICOLOGY				GRP: 60 TOXICOLOGY					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
043 DIGOXIN				CLIA TEST ID #: 645				EVALUATION CRITERIA: TARGET VALUE 15 % OR 0.20 {GREATER}					
2025-421		50	VITROS					16	1.375	0.103	7.50	1.200	1.600
2025-422		50	VITROS					16	2.281	0.163	7.14	1.900	2.600
2025-423		50	VITROS					16	0.400	0.000	0.00	0.200	0.600
2025-424		50	VITROS					16	0.613	0.093	15.14	0.400	0.800

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 40 TOXICOLOGY		GRP: 60 TOXICOLOGY						
ANALYTE											
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
043 DIGOXIN			CLIA TEST ID #: 645	EVALUATION CRITERIA: TARGET VALUE 15 % OR 0.20 {GREATER}							
2025-425	50	VITROS			16	1.850	0.122	6.62	1.600	2.100	
045 FERRITIN			CLIA TEST ID #: 410	EVALUATION CRITERIA: TARGET VALUE 20 %							
2025-421	50	VITROS			22	92.433	4.694	5.08	73.900	110.900	
2025-421	50	VITROS			22	91.305	4.987	5.46	73.000	109.600	
2025-421	90	ROCHE COBA			18	161.078	11.530	7.16	128.900	193.300	
2025-421	105	ATELLICA			12	108.683	7.213	6.64	86.900	130.400	
2025-422	50	VITROS			22	169.795	8.873	5.23	135.800	203.800	
2025-422	50	VITROS			22	172.400	5.842	3.39	137.900	206.900	
2025-422	90	ROCHE COBA			18	289.928	15.389	5.31	231.900	347.900	
2025-422	105	ATELLICA			12	201.292	15.774	7.84	161.000	241.600	
2025-423	50	VITROS			22	59.633	2.451	4.11	47.700	71.600	
2025-423	50	VITROS			22	60.195	5.362	8.91	48.200	72.200	
2025-423	90	ROCHE COBA			18	103.944	8.105	7.80	83.200	124.700	
2025-423	105	ATELLICA			12	67.225	4.173	6.21	53.800	80.700	
2025-424	50	VITROS			22	17.795	1.142	6.42	14.200	21.400	
2025-424	50	VITROS			22	16.600	0.535	3.23	13.300	19.900	
2025-424	90	ROCHE COBA			18	31.344	2.231	7.12	25.100	37.600	
2025-424	105	ATELLICA			12	18.233	1.107	6.07	14.600	21.900	
2025-425	50	VITROS			22	146.600	12.639	8.62	117.300	175.900	
2025-425	50	VITROS			22	130.250	8.423	6.47	104.200	156.300	
2025-425	90	ROCHE COBA			18	228.911	15.634	6.83	183.100	274.700	
2025-425	105	ATELLICA			12	151.364	10.265	6.78	121.100	181.600	
046 GENTAMICIN			CLIA TEST ID #: 665	EVALUATION CRITERIA: TARGET VALUE 25 %							
2025-421	50	VITROS			16	7.273	0.311	4.27	5.500	9.100	
2025-421	50	VITROS			16	8.817	3.383	38.38	6.600	11.000	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 40 TOXICOLOGY			GRP: 60 TOXICOLOGY					
ANALYTE											
SAMPLE		METHOD	SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
046 GENTAMICIN			CLIA TEST ID #: 665			EVALUATION CRITERIA: TARGET VALUE 25 %					
2025-422		50 VITROS				16	17.400	6.301	36.21	13.100	21.800
2025-422		50 VITROS				16	14.747	0.919	6.23	11.100	18.400
2025-423		50 VITROS				16	0.607	0.025	4.11	0.500	0.800
2025-423		50 VITROS				16	0.367	0.205	56.04	0.300	0.500
2025-424		50 VITROS				16	0.267	0.094	35.36	0.200	0.300
2025-424		50 VITROS				16	0.525	0.198	37.80	0.400	0.700
2025-425		50 VITROS				16	10.880	0.700	6.43	8.200	13.600
2025-425		50 VITROS				16	13.000	5.025	38.65	9.800	16.300
050 PHENYTOIN			CLIA TEST ID #: 695			EVALUATION CRITERIA: TARGET VALUE 15 % OR 2.00 {GREATER}					
2025-421		50 VITROS				16	13.669	0.611	4.47	11.600	15.700
2025-422		50 VITROS				16	26.825	0.992	3.70	22.800	30.800
2025-423		50 VITROS				16	7.338	0.549	7.48	5.300	9.300
2025-424		50 VITROS				16	2.438	1.580	64.82	0.400	4.400
2025-425		50 VITROS				16	20.544	0.771	3.75	17.500	23.600
054 THEOPHYLLINE			CLIA TEST ID #: 735			EVALUATION CRITERIA: TARGET VALUE 20 %					
2025-421		50 VITROS				13	29.854	1.143	3.83	23.900	35.800
2025-422		50 VITROS				13	52.115	4.265	8.18	41.700	62.500
2025-423		50 VITROS				13	22.369	1.098	4.91	17.900	26.800

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 67 (124)
DATE : 7/22/2025
TIME : 12:51:16

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 40 TOXICOLOGY		GRP: 60 TOXICOLOGY							
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
054 THEOPHYLLINE				CLIA TEST ID #: 735		EVALUATION CRITERIA: TARGET VALUE 20 %							
2025-424		50	VITROS					13	3.008	0.345	11.48	2.400	3.600
2025-425		50	VITROS					13	39.646	1.308	3.30	31.700	47.600
127 VANCOMYCIN				CLIA TEST ID #: 756		EVALUATION CRITERIA: TARGET VALUE 15 % OR 2.00 {GREATER}							
2025-421		50	VITROS					21	24.110	0.883	3.66	20.500	27.700
2025-421		92	ROCHE COBA					11	25.420	0.978	3.85	21.600	29.200
2025-422		50	VITROS					21	50.038	1.845	3.69	42.500	57.500
2025-422		92	ROCHE COBA					11	47.491	2.094	4.41	40.400	54.600
2025-423		50	VITROS					21	5.000	0.000	0.00	3.000	7.000
2025-423		92	ROCHE COBA					11	4.000	0.000	0.00	2.000	6.000
2025-424		50	VITROS					21	5.000	0.000	0.00	3.000	7.000
2025-424		92	ROCHE COBA					11	4.000	0.000	0.00	2.000	6.000
2025-425		50	VITROS					21	37.714	1.463	3.88	32.100	43.400
2025-425		92	ROCHE COBA					11	36.855	1.252	3.40	31.300	42.400
SPEC: 10 CHEMISTRY				SUB: 50 URINALYSIS		GRP: 70 URINALYSIS							
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
065 URINA-PROTEIN QUANT.				CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}							
2025-451		58	VITROS					43	155.070	12.065	7.78	116.300	193.800
2025-451		62	SIEM DIM.					46	118.149	2.902	2.46	88.600	147.700
2025-451		79	BECK. COUL					21	108.185	3.376	3.12	81.100	135.200
2025-451		93	ARCHITECT					17	106.312	2.629	2.47	79.700	132.900
2025-451		113	ROCHE COBA					42	99.085	2.220	2.24	74.300	123.900

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 68 (124)
DATE : 7/22/2025
TIME : 12:51:16

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST		REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-451	146	ATELLICA				15	115.793	2.932	2.53	86.800	144.700
065 URINA-PROTEIN QUANT.			CLIA TEST ID #: 0			EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
2025-452	58	VITROS				43	159.023	9.922	6.24	119.300	198.800
2025-452	62	SIEM DIM.				46	115.611	1.945	1.68	86.700	144.500
2025-452	79	BECK. COUL				21	101.770	2.869	2.82	76.300	127.200
2025-452	93	ARCHITECT				17	97.365	2.554	2.62	73.000	121.700
2025-452	113	ROCHE COBA				42	91.331	1.979	2.17	68.500	114.200
2025-452	146	ATELLICA				15	113.073	2.402	2.12	84.800	141.300
2025-453	58	VITROS				43	5.048	0.213	4.22	0.000	10.000
2025-453	62	SIEM DIM.				46	23.391	1.183	5.06	17.500	29.200
2025-453	79	BECK. COUL				21	5.595	0.624	11.16	0.600	10.600
2025-453	93	ARCHITECT				17	6.806	0.056	0.82	1.800	11.800
2025-453	113	ROCHE COBA				42	4.041	0.987	24.42	0	9.000
2025-453	146	ATELLICA				15	24.307	1.771	7.29	18.200	30.400
2025-454	58	VITROS				43	5.000	0.000	0.00	0.000	10.000
2025-454	62	SIEM DIM.				46	15.127	1.155	7.64	10.100	20.100
2025-454	79	BECK. COUL				21	4.890	0.217	4.43	0	9.900
2025-454	93	ARCHITECT				17	6.825	0.090	1.32	1.800	11.800
2025-454	113	ROCHE COBA				42	4.295	0.821	19.11	0	9.300
2025-454	146	ATELLICA				15	15.887	2.303	14.49	10.900	20.900
2025-455	58	VITROS				43	173.093	10.018	5.79	129.800	216.400
2025-455	62	SIEM DIM.				46	121.335	2.321	1.91	91.000	151.700
2025-455	79	BECK. COUL				21	102.430	2.486	2.43	76.800	128.000
2025-455	93	ARCHITECT				17	104.565	3.617	3.46	78.400	130.700
2025-455	113	ROCHE COBA				42	99.149	1.942	1.96	74.400	123.900
2025-455	146	ATELLICA				15	120.107	1.683	1.40	90.100	150.100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 69 (124)
DATE : 7/22/2025
TIME : 12:51:16

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
067 URI-SPECIFIC GRAVITY			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD							
2025-451	11	AMES NM10S			33	1.024	0.002	0.20	1.018	1.030	
2025-451	13	BAYER CLI			20	1.023	0.003	0.24	1.015	1.030	
2025-451	67	URISCAN			55	1.021	0.004	0.35	1.011	1.032	
2025-451	72	URS-9-TECO			57	1.021	0.005	0.46	1.006	1.035	
2025-451	80	ROCHE (CHE			36	1.016	0.002	0.20	1.010	1.022	
2025-451	89	AIMSTRIP			154	1.022	0.003	0.25	1.014	1.030	
2025-451	94	CLINITEK			108	1.024	0.002	0.24	1.016	1.031	
2025-451	102	ACON LAB			120	1.021	0.002	0.20	1.015	1.027	
2025-451	131	iCHEM VELO			36	1.025	0.001	0.07	1.023	1.027	
2025-451	140	MISSION A			39	1.022	0.003	0.30	1.013	1.031	
2025-451	145	CLINITEK			42	1.031	0.001	0.07	1.028	1.033	
2025-451	147	Mission120			37	1.023	0.003	0.26	1.015	1.031	
2025-451	148	Mission500			138	1.020	0.000	0.00	1.020	1.020	
2025-451	151	Clari. Uro			23	1.022	0.003	0.28	1.013	1.031	
2025-452	11	AMES NM10S			33	1.020	0.003	0.33	1.010	1.031	
2025-452	13	BAYER CLI			20	1.020	0.002	0.24	1.012	1.027	
2025-452	67	URISCAN			55	1.018	0.003	0.31	1.008	1.027	
2025-452	72	URS-9-TECO			57	1.019	0.005	0.45	1.005	1.032	
2025-452	80	ROCHE (CHE			36	1.013	0.002	0.25	1.005	1.020	
2025-452	89	AIMSTRIP			154	1.019	0.003	0.26	1.011	1.027	
2025-452	94	CLINITEK			108	1.021	0.002	0.24	1.014	1.028	
2025-452	102	ACON LAB			120	1.019	0.002	0.23	1.012	1.026	
2025-452	131	iCHEM VELO			36	1.026	0.001	0.09	1.023	1.029	
2025-452	140	MISSION A			39	1.018	0.002	0.25	1.010	1.025	
2025-452	145	CLINITEK			42	1.028	0.001	0.09	1.025	1.030	
2025-452	147	Mission120			37	1.021	0.002	0.24	1.013	1.028	
2025-452	148	Mission500			138	1.019	0.002	0.18	1.014	1.025	
2025-452	151	Clari. Uro			23	1.017	0.002	0.25	1.010	1.025	

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 70 (124)
DATE : 7/22/2025
TIME : 12:51:16

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY				SUB: 50 URINALYSIS		GRP: 70 URINALYSIS				
ANALYTE										
SAMPLE		METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
067 URI-SPECIFIC GRAVITY			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD						
2025-453	11	AMES NM10S			33	1.012	0.003	0.32	1.003	1.022
2025-453	13	BAYER CLI			20	1.012	0.003	0.28	1.003	1.020
2025-453	67	URISCAN			55	1.009	0.003	0.26	1.001	1.017
2025-453	72	URS-9-TECO			57	1.012	0.004	0.43	0.999	1.025
2025-453	80	ROCHE (CHE			36	1.010	0.003	0.30	1.001	1.019
2025-453	89	AIMSTRIP			154	1.012	0.004	0.37	1.001	1.023
2025-453	94	CLINITEK			108	1.012	0.003	0.26	1.004	1.020
2025-453	102	ACON LAB			120	1.011	0.003	0.25	1.003	1.019
2025-453	131	iCHEM VELO			36	1.026	0.001	0.07	1.024	1.028
2025-453	140	MISSION A			39	1.012	0.004	0.36	1.001	1.023
2025-453	145	CLINITEK			42	1.032	0.001	0.08	1.029	1.034
2025-453	147	Mission120			37	1.015	0.002	0.21	1.008	1.021
2025-453	148	Mission500			138	1.012	0.003	0.31	1.003	1.022
2025-453	151	Clari. Uro			23	1.010	0.002	0.21	1.004	1.016
2025-454	11	AMES NM10S			33	1.021	0.003	0.27	1.013	1.029
2025-454	13	BAYER CLI			20	1.019	0.003	0.33	1.009	1.029
2025-454	67	URISCAN			55	1.021	0.003	0.31	1.011	1.030
2025-454	72	URS-9-TECO			57	1.018	0.006	0.56	1.001	1.035
2025-454	80	ROCHE (CHE			36	1.017	0.002	0.24	1.010	1.024
2025-454	89	AIMSTRIP			154	1.021	0.003	0.33	1.011	1.031
2025-454	94	CLINITEK			108	1.020	0.004	0.37	1.009	1.032
2025-454	102	ACON LAB			120	1.020	0.003	0.25	1.012	1.028
2025-454	131	iCHEM VELO			36	1.028	0.001	0.07	1.026	1.030
2025-454	140	MISSION A			39	1.020	0.002	0.24	1.013	1.027
2025-454	145	CLINITEK			42	1.034	0.001	0.10	1.031	1.038
2025-454	147	Mission120			37	1.021	0.002	0.15	1.016	1.025
2025-454	148	Mission500			138	1.020	0.000	0.00	1.020	1.020
2025-454	151	Clari. Uro			23	1.021	0.003	0.32	1.011	1.031

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
067 URI-SPECIFIC GRAVITY			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD							
2025-455	11	AMES NM10S			33	1.015	0.004	0.36		1.004	1.026
2025-455	13	BAYER CLI			20	1.015	0.003	0.27		1.006	1.023
2025-455	67	URISCAN			55	1.011	0.003	0.31		1.001	1.020
2025-455	72	URS-9-TECO			57	1.014	0.005	0.46		1.000	1.028
2025-455	80	ROCHE (CHE			36	1.012	0.002	0.24		1.005	1.019
2025-455	89	AIMSTRIP			154	1.015	0.004	0.41		1.002	1.027
2025-455	94	CLINITEK			108	1.015	0.003	0.30		1.006	1.025
2025-455	102	ACON LAB			120	1.015	0.004	0.40		1.003	1.027
2025-455	131	iCHEM VELO			36	1.028	0.001	0.09		1.025	1.031
2025-455	140	MISSION A			39	1.014	0.005	0.44		1.001	1.028
2025-455	145	CLINITEK			42	1.032	0.001	0.08		1.029	1.034
2025-455	147	Mission120			37	1.018	0.003	0.27		1.010	1.026
2025-455	148	Mission500			138	1.017	0.003	0.31		1.008	1.027
2025-455	151	Clari. Uro			23	1.012	0.002	0.24		1.005	1.019
166 MICROALBUMIN				EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}							
2025-451	58	VITROS			53	952.004	39.265	4.12		714.000	1190.000
2025-451	62	SIEM DIM.			73	917.752	66.307	7.22		688.300	1147.200
2025-451	79	BECK. COUL			21	828.748	132.782	16.02		621.600	1035.900
2025-451	85	Rx DAYTONA			11	756.791	104.929	13.86		567.600	946.000
2025-451	93	ARCHITECT			20	924.850	28.452	3.08		693.600	1156.100
2025-451	95	INTEGRA			20	932.450	42.242	4.53		699.300	1165.600
2025-451	113	ROCHE COBA			49	876.323	52.283	5.97		657.200	1095.400
2025-451	113	ROCHE COBA			49	897.600	48.181	5.37		673.200	1122.000
2025-451	146	ATELLICA			20	768.053	22.631	2.95		576.000	960.100
2025-451	154	CS400DIRUI			12	692.642	212.815	30.73		519.500	865.800
2025-452	58	VITROS			53	872.502	37.576	4.31		654.400	1090.600
2025-452	62	SIEM DIM.			73	855.545	46.000	5.38		641.700	1069.400
2025-452	79	BECK. COUL			21	790.152	113.813	14.40		592.600	987.700

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 72 (124)
DATE : 7/22/2025
TIME : 12:51:16

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
	SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
166 MICROALBUMIN	2025-452	85	Rx DAYTONA		11	704.200	90.712	12.88	528.200	880.300
	2025-452	93	ARCHITECT		20	845.040	25.520	3.02	633.800	1056.300
	2025-452	95	INTEGRA		20	855.010	42.900	5.02	641.300	1068.800
	2025-452	113	ROCHE COBA		49	823.667	23.809	2.89	617.800	1029.600
	2025-452	113	ROCHE COBA		49	803.652	50.751	6.32	602.700	1004.600
	2025-452	146	ATELLICA		20	706.400	17.797	2.52	529.800	883.000
	2025-452	154	CS400DIRUI		12	681.667	209.440	30.72	511.300	852.100
				CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
	2025-453	58	VITROS		53	5.962	0.192	3.23	1.000	11.000
	2025-453	62	SIEM DIM.		73	2.292	1.201	52.42	0	7.300
2025-453	79	BECK. COUL		21	2.371	2.964	125.01	0	7.400	
2025-453	85	Rx DAYTONA		11	3.418	3.052	89.28	0	8.400	
2025-453	93	ARCHITECT		20	4.995	0.022	0.45	0.000	10.000	
2025-453	95	INTEGRA		20	2.785	1.303	46.79	0	7.800	
2025-453	113	ROCHE COBA		49	3.400	2.404	70.71	0	8.400	
2025-453	113	ROCHE COBA		49	10.537	3.917	37.18	5.500	15.500	
2025-453	146	ATELLICA		20	3.000	0.000	0.00	0	8.000	
2025-453	154	CS400DIRUI		12	4.625	3.681	79.58	0	9.600	
2025-454	58	VITROS		53	5.962	0.192	3.23	1.000	11.000	
2025-454	62	SIEM DIM.		73	3.242	1.249	38.54	0	8.200	
2025-454	79	BECK. COUL		21	2.343	2.977	127.09	0	7.300	
2025-454	85	Rx DAYTONA		11	3.345	2.736	81.77	0	8.300	
2025-454	93	ARCHITECT		20	5.000	0.000	0.00	0.000	10.000	
2025-454	95	INTEGRA		20	2.585	1.198	46.35	0	7.600	
2025-454	113	ROCHE COBA		49	3.400	2.404	70.71	0	8.400	
2025-454	113	ROCHE COBA		49	10.537	3.917	37.18	5.500	15.500	
2025-454	146	ATELLICA		20	3.000	0.000	0.00	0	8.000	
2025-454	154	CS400DIRUI		12	4.925	3.714	75.42	0	9.900	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
166 MICROALBUMIN			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}							
2025-455	58	VITROS				53	878.811	33.554	3.82	659.100	1098.500
2025-455	62	SIEM DIM.				73	879.779	49.817	5.66	659.800	1099.700
2025-455	79	BECK. COUL				21	810.848	123.875	15.28	608.100	1013.600
2025-455	85	Rx DAYTONA				11	726.927	109.756	15.10	545.200	908.700
2025-455	93	ARCHITECT				20	856.568	20.551	2.40	642.400	1070.700
2025-455	95	INTEGRA				20	875.205	47.718	5.45	656.400	1094.000
2025-455	113	ROCHE COBA				49	824.085	43.743	5.31	618.100	1030.100
2025-455	113	ROCHE COBA				49	822.833	30.442	3.70	617.100	1028.500
2025-455	146	ATELLICA				20	719.850	21.516	2.99	539.900	899.800
2025-455	154	CS400DIRUI				12	717.636	81.325	11.33	538.200	897.000
167 CREATININE											
2025-451	58	VITROS				61	3.214	0.104	3.24	0	8.200
2025-451	62	SIEM DIM.				73	8.895	5.653	63.56	3.900	13.900
2025-451	79	BECK. COUL				22	0.486	0.406	83.64	0	5.500
2025-451	85	Rx DAYTONA				10	1.280	1.101	85.99	0	6.300
2025-451	93	ARCHITECT				19	5.000	0.000	0.00	0.000	10.000
2025-451	95	INTEGRA				21	0.405	0.304	75.09	0	5.400
2025-451	113	ROCHE COBA				49	3.394	1.478	43.54	0	8.400
2025-451	146	ATELLICA				19	3.000	0.000	0.00	0	8.000
2025-451	154	CS400DIRUI				11	0.955	0.891	93.31	0	6.000
2025-452	58	VITROS				61	247.673	7.814	3.15	185.800	309.600
2025-452	62	SIEM DIM.				73	252.381	8.045	3.19	189.300	315.500
2025-452	79	BECK. COUL				22	224.427	8.394	3.74	168.300	280.500
2025-452	85	Rx DAYTONA				10	246.590	23.287	9.44	184.900	308.200
2025-452	93	ARCHITECT				19	245.547	6.094	2.48	184.200	306.900
2025-452	95	INTEGRA				21	256.245	9.320	3.64	192.200	320.300
2025-452	113	ROCHE COBA				49	257.073	8.678	3.38	192.800	321.300
2025-452	146	ATELLICA				19	236.006	11.657	4.94	177.000	295.000

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST		REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-452	154	CS400DIRUI				11	243.955	27.061	11.09	183.000	304.900
167 CREATININE			CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}						
2025-453	58	VITROS				61	258.462	13.317	5.15	193.800	323.100
2025-453	62	SIEM DIM.				73	251.674	6.966	2.77	188.800	314.600
2025-453	79	BECK. COUL				22	225.441	8.822	3.91	169.100	281.800
2025-453	85	Rx DAYTONA				10	241.900	21.966	9.08	181.400	302.400
2025-453	93	ARCHITECT				19	248.095	5.051	2.04	186.100	310.100
2025-453	95	INTEGRA				21	257.329	11.123	4.32	193.000	321.700
2025-453	113	ROCHE COBA				49	257.231	8.874	3.45	192.900	321.500
2025-453	146	ATELLICA				19	235.089	6.482	2.76	176.300	293.900
2025-453	154	CS400DIRUI				11	243.864	25.951	10.64	182.900	304.800
2025-454	58	VITROS				61	3.105	0.705	22.71	0	8.100
2025-454	62	SIEM DIM.				73	8.877	5.674	63.92	3.900	13.900
2025-454	79	BECK. COUL				22	0.424	0.459	108.23	0	5.400
2025-454	85	Rx DAYTONA				10	0.250	0.410	164.20	0	5.300
2025-454	93	ARCHITECT				19	5.000	0.000	0.00	0.000	10.000
2025-454	95	INTEGRA				21	0.225	0.378	167.99	0	5.200
2025-454	113	ROCHE COBA				49	3.478	1.312	37.72	0	8.500
2025-454	146	ATELLICA				19	3.000	0.000	0.00	0	8.000
2025-454	154	CS400DIRUI				11	1.700	2.581	151.85	0	6.700
2025-455	58	VITROS				61	261.325	8.041	3.08	196.000	326.700
2025-455	62	SIEM DIM.				73	254.356	7.440	2.92	190.800	317.900
2025-455	79	BECK. COUL				22	212.257	7.032	3.31	159.200	265.300
2025-455	85	Rx DAYTONA				10	248.850	22.499	9.04	186.600	311.100
2025-455	93	ARCHITECT				19	249.779	5.699	2.28	187.300	312.200
2025-455	95	INTEGRA				21	257.045	10.007	3.89	192.800	321.300
2025-455	113	ROCHE COBA				49	260.051	8.714	3.35	195.000	325.100
2025-455	146	ATELLICA				19	237.453	4.857	2.05	178.100	296.800

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 75 (124)
DATE : 7/22/2025
TIME : 12:51:16

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS								
ANALYTE														
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-455		154	CS400DIRUI						11	238.727	19.931	8.35	179.000	298.400

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
057 URINALYSIS-BILIRUBIN													
2025-451	011	AMES NM10S			057	057	057	057	057 - NEGATIVE	33	33	33	100
2025-451	013	BAYER CLI			057	057	057	057	057 - NEGATIVE	20	20	20	100
2025-451	067	URISCAN			057	057	057	057	057 - NEGATIVE	55	55	55	100
2025-451	072	URS-9-TECO			057	057	057	057	057 - NEGATIVE	58	58	58	100
2025-451	080	ROCHE (CHE			057	057	057	057	057 - NEGATIVE	35	35	35	100
2025-451	089	AIMSTRIP			057	057	057	057	057 - NEGATIVE	151	151	151	100
2025-451	094	CLINITEK			057	057	057	057	057 - NEGATIVE	108	108	108	100
2025-451	102	ACON LAB			057	057	057	057	057 - NEGATIVE	115	115	115	100
2025-451	131	iCHEM VELO			057	057	057	057	057 - NEGATIVE	36	36	36	100
2025-451	140	MISSION A			057	057	057	057	057 - NEGATIVE	36	36	36	100
2025-451	145	CLINITEK			057	057	057	057	057 - NEGATIVE	42	42	42	100
2025-451	147	Mission120			057	057	057	057	057 - NEGATIVE	39	39	39	100
2025-451	148	Mission500			057	057	057	057	057 - NEGATIVE	143	143	143	100
2025-451	151	Clari. Uro			057	057	057	057	057 - NEGATIVE	25	25	25	100
2025-452	011	AMES NM10S			057	057	057	057	057 - NEGATIVE	33	33	33	100
2025-452	013	BAYER CLI			057	057	057	057	057 - NEGATIVE	20	20	20	100
2025-452	067	URISCAN			057	057	057	057	057 - NEGATIVE	55	55	55	100
2025-452	072	URS-9-TECO			057	057	057	057	057 - NEGATIVE	58	58	58	100
2025-452	080	ROCHE (CHE			057	057	057	057	057 - NEGATIVE	35	35	35	100
2025-452	089	AIMSTRIP			057	057	057	057	057 - NEGATIVE	151	151	151	100
2025-452	094	CLINITEK			057	057	057	057	057 - NEGATIVE	108	108	108	100
2025-452	102	ACON LAB			057	057	057	057	057 - NEGATIVE	115	115	115	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-452	131	iCHEM VELO			057	057	057	057		057 - NEGATIVE	36	36	36	100
2025-452	140	MISSION A			057	057	057	057		057 - NEGATIVE	36	36	36	100
2025-452	145	CLINITEK			057	057	057	057		057 - NEGATIVE	42	42	42	100
2025-452	147	Mission120			057	057	057	057		057 - NEGATIVE	39	39	39	100
2025-452	148	Mission500			057	057	057	057		057 - NEGATIVE	143	143	143	100
2025-452	151	Clari. Uro			057	057	057	057		057 - NEGATIVE	25	25	25	100
057 URINALYSIS-BILIRUBIN														
2025-453	011	AMES NM10S			057	057	057	057		057 - NEGATIVE	33	33	33	100
2025-453	013	BAYER CLI			057	057	057	057		057 - NEGATIVE	20	20	20	100
2025-453	067	URISCAN			057	057	057	057		057 - NEGATIVE	55	55	55	100
2025-453	072	URS-9-TECO			057	057	057	057		057 - NEGATIVE	58	58	58	100
2025-453	080	ROCHE (CHE			057	057	057	057		057 - NEGATIVE	35	35	35	100
2025-453	089	AIMSTRIP			057	057	057	057		057 - NEGATIVE	151	151	151	100
2025-453	094	CLINITEK			057	057	057	057		057 - NEGATIVE	108	108	108	100
2025-453	102	ACON LAB			057	057	057	057		057 - NEGATIVE	115	115	115	100
2025-453	131	iCHEM VELO			057	057	057	057		057 - NEGATIVE	36	36	36	100
2025-453	140	MISSION A			057	057	057	057		057 - NEGATIVE	36	36	36	100
2025-453	145	CLINITEK			057	057	057	057		057 - NEGATIVE	42	42	42	100
2025-453	147	Mission120			057	057	057	057		057 - NEGATIVE	39	39	39	100
2025-453	148	Mission500			057	057	057	057		057 - NEGATIVE	143	143	143	100
2025-453	151	Clari. Uro			057	057	057	057		057 - NEGATIVE	25	25	25	100
2025-454	011	AMES NM10S			057	057	057	057		057 - NEGATIVE	33	33	33	100
2025-454	013	BAYER CLI			057	057	057	057		057 - NEGATIVE	20	20	20	100
2025-454	067	URISCAN			057	057	057	057		057 - NEGATIVE	55	55	55	100
2025-454	072	URS-9-TECO			057	057	057	057		057 - NEGATIVE	58	58	58	100
2025-454	080	ROCHE (CHE			057	057	057	057		057 - NEGATIVE	35	35	35	100
2025-454	089	AIMSTRIP			057	057	057	057		057 - NEGATIVE	151	151	151	100
2025-454	094	CLINITEK			057	057	057	057		057 - NEGATIVE	108	108	108	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-454	102	ACON LAB			057	057	057	057		057 - NEGATIVE	115	115	115	100
2025-454	131	iCHEM VELO			057	057	057	057		057 - NEGATIVE	36	36	36	100
2025-454	140	MISSION A			057	057	057	057		057 - NEGATIVE	36	36	36	100
2025-454	145	CLINITEK			057	057	057	057		057 - NEGATIVE	42	42	42	100
2025-454	147	Mission120			057	057	057	057		057 - NEGATIVE	39	39	39	100
2025-454	148	Mission500			057	057	057	057		057 - NEGATIVE	143	142	142	100
2025-454	148	Mission500			057	057	057	057		060 - 3+	143	1	142	0
2025-454	151	Clari. Uro			057	057	057	057		057 - NEGATIVE	25	25	25	100
057 URINALYSIS-BILIRUBIN														
2025-455	011	AMES NM10S			058	060	057	059		058 - TRACES, 1+	33	6	33	100
2025-455	011	AMES NM10S			058	060	057	059		059 - 2+	33	23	33	100
2025-455	011	AMES NM10S			058	060	057	059		060 - 3+	33	4	33	100
2025-455	013	BAYER CLI			058	060	057	059		058 - TRACES, 1+	20	3	20	100
2025-455	013	BAYER CLI			058	060	057	059		059 - 2+	20	16	20	100
2025-455	013	BAYER CLI			058	060	057	059		060 - 3+	20	1	20	100
2025-455	067	URISCAN			057	059	057	059		057 - NEGATIVE	55	18	54	100
2025-455	067	URISCAN			057	059	057	059		058 - TRACES, 1+	55	35	54	100
2025-455	067	URISCAN			057	059	057	059		059 - 2+	55	1	54	100
2025-455	067	URISCAN			057	059	057	059		060 - 3+	55	1	54	0
2025-455	072	URS-9-TECO			057	059	057	059		057 - NEGATIVE	58	1	49	100
2025-455	072	URS-9-TECO			057	059	057	059		058 - TRACES, 1+	58	24	49	100
2025-455	072	URS-9-TECO			057	059	057	059		059 - 2+	58	24	49	100
2025-455	072	URS-9-TECO			057	059	057	059		060 - 3+	58	9	49	0
2025-455	080	ROCHE (CHE			057	059	057	059		057 - NEGATIVE	35	1	33	100
2025-455	080	ROCHE (CHE			057	059	057	059		058 - TRACES, 1+	35	29	33	100
2025-455	080	ROCHE (CHE			057	059	057	059		059 - 2+	35	3	33	100
2025-455	080	ROCHE (CHE			057	059	057	059		060 - 3+	35	2	33	0
2025-455	089	AIMSTRIP			057	059	057	059		057 - NEGATIVE	151	3	147	100
2025-455	089	AIMSTRIP			057	059	057	059		058 - TRACES, 1+	151	112	147	100
2025-455	089	AIMSTRIP			057	059	057	059		059 - 2+	151	32	147	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS								
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-455	089	AIMSTRIP					057	059	057	059	060 - 3+	151	4	147	0
2025-455	094	CLINITEK					058	060	057	059	058 - TRACES, 1+	108	23	108	100
2025-455	094	CLINITEK					058	060	057	059	059 - 2+	108	84	108	100
2025-455	094	CLINITEK					058	060	057	059	060 - 3+	108	1	108	100
2025-455	102	ACON LAB					057	059	057	059	058 - TRACES, 1+	115	78	109	100
2025-455	102	ACON LAB					057	059	057	059	059 - 2+	115	31	109	100
2025-455	102	ACON LAB					057	059	057	059	060 - 3+	115	6	109	0
2025-455	131	iCHEM VELO					057	057	057	059	057 - NEGATIVE	36	36	36	100
2025-455	140	MISSION A					057	059	057	059	058 - TRACES, 1+	36	25	35	100
2025-455	140	MISSION A					057	059	057	059	059 - 2+	36	10	35	100
2025-455	140	MISSION A					057	059	057	059	060 - 3+	36	1	35	0
2025-455	145	CLINITEK					057	057	057	059	057 - NEGATIVE	42	42	42	100
2025-455	147	Mission120					057	059	057	059	058 - TRACES, 1+	39	26	38	100
2025-455	147	Mission120					057	059	057	059	059 - 2+	39	12	38	100
2025-455	147	Mission120					057	059	057	059	060 - 3+	39	1	38	0
2025-455	148	Mission500					057	059	057	059	058 - TRACES, 1+	143	118	140	100
2025-455	148	Mission500					057	059	057	059	059 - 2+	143	22	140	100
2025-455	148	Mission500					057	059	057	059	060 - 3+	143	3	140	0
2025-455	151	Clari. Uro					057	059	057	059	058 - TRACES, 1+	25	20	24	100
2025-455	151	Clari. Uro					057	059	057	059	059 - 2+	25	4	24	100
2025-455	151	Clari. Uro					057	059	057	059	060 - 3+	25	1	24	0
058 URINALYSIS-GLUCOSE															
2025-451	011	AMES NM10S					076	078	076	078	076 - 500mg/dl2+	32	5	32	100
2025-451	011	AMES NM10S					076	078	076	078	077 - 1000mg/dl	32	25	32	100
2025-451	011	AMES NM10S					076	078	076	078	078 - 2000mg/dl	32	2	32	100
2025-451	013	BAYER CLI					076	078	076	078	076 - 500mg/dl2+	20	7	20	100
2025-451	013	BAYER CLI					076	078	076	078	077 - 1000mg/dl	20	13	20	100
2025-451	067	URISCAN					077	078	076	078	076 - 500mg/dl2+	55	3	55	100
2025-451	067	URISCAN					077	078	076	078	077 - 1000mg/dl	55	16	55	100
2025-451	067	URISCAN					077	078	076	078	078 - 2000mg/dl	55	36	55	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-451	072	URS-9-TECO				076	078	076	078	073 - NEGATIVE	58	1	56	0
2025-451	072	URS-9-TECO				076	078	076	078	075 - 250mg/dl-+	58	1	56	0
2025-451	072	URS-9-TECO				076	078	076	078	076 - 500mg/dl2+	58	19	56	100
2025-451	072	URS-9-TECO				076	078	076	078	077 - 1000mg/dl	58	32	56	100
2025-451	072	URS-9-TECO				076	078	076	078	078 - 2000mg/dl	58	5	56	100
2025-451	080	ROCHE (CHE				076	078	076	078	075 - 250mg/dl-+	36	1	35	0
2025-451	080	ROCHE (CHE				076	078	076	078	077 - 1000mg/dl	36	32	35	100
2025-451	080	ROCHE (CHE				076	078	076	078	078 - 2000mg/dl	36	3	35	100
2025-451	089	AIMSTRIP				076	078	076	078	073 - NEGATIVE	153	1	148	0
2025-451	089	AIMSTRIP				076	078	076	078	075 - 250mg/dl-+	153	4	148	0
2025-451	089	AIMSTRIP				076	078	076	078	076 - 500mg/dl2+	153	52	148	100
2025-451	089	AIMSTRIP				076	078	076	078	077 - 1000mg/dl	153	94	148	100
2025-451	089	AIMSTRIP				076	078	076	078	078 - 2000mg/dl	153	2	148	100
2025-451	094	CLINITEK				076	078	076	078	075 - 250mg/dl-+	108	5	103	0
2025-451	094	CLINITEK				076	078	076	078	076 - 500mg/dl2+	108	32	103	100
2025-451	094	CLINITEK				076	078	076	078	077 - 1000mg/dl	108	70	103	100
2025-451	094	CLINITEK				076	078	076	078	078 - 2000mg/dl	108	1	103	100
2025-451	102	ACON LAB				076	078	076	078	075 - 250mg/dl-+	118	2	116	0
2025-451	102	ACON LAB				076	078	076	078	076 - 500mg/dl2+	118	49	116	100
2025-451	102	ACON LAB				076	078	076	078	077 - 1000mg/dl	118	59	116	100
2025-451	102	ACON LAB				076	078	076	078	078 - 2000mg/dl	118	8	116	100
2025-451	131	iCHEM VELO				075	077	076	078	076 - 500mg/dl2+	36	33	36	100
2025-451	131	iCHEM VELO				075	077	076	078	077 - 1000mg/dl	36	3	36	100
2025-451	140	MISSION A				076	078	076	078	076 - 500mg/dl2+	39	9	39	100
2025-451	140	MISSION A				076	078	076	078	077 - 1000mg/dl	39	22	39	100
2025-451	140	MISSION A				076	078	076	078	078 - 2000mg/dl	39	8	39	100
2025-451	145	CLINITEK				076	078	076	078	075 - 250mg/dl-+	42	1	41	0
2025-451	145	CLINITEK				076	078	076	078	076 - 500mg/dl2+	42	2	41	100
2025-451	145	CLINITEK				076	078	076	078	077 - 1000mg/dl	42	37	41	100
2025-451	145	CLINITEK				076	078	076	078	078 - 2000mg/dl	42	2	41	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-451	147	Mission120			076	078	076	078		075 - 250mg/dl-+	36	1	35	0
2025-451	147	Mission120			076	078	076	078		076 - 500mg/dl2+	36	3	35	100
2025-451	147	Mission120			076	078	076	078		077 - 1000mg/dl	36	16	35	100
2025-451	147	Mission120			076	078	076	078		078 - 2000mg/dl	36	16	35	100
2025-451	148	Mission500			076	078	076	078		076 - 500mg/dl2+	142	37	142	100
2025-451	148	Mission500			076	078	076	078		077 - 1000mg/dl	142	65	142	100
2025-451	148	Mission500			076	078	076	078		078 - 2000mg/dl	142	40	142	100
2025-451	151	Clari. Uro			076	078	076	078		076 - 500mg/dl2+	24	5	24	100
2025-451	151	Clari. Uro			076	078	076	078		077 - 1000mg/dl	24	18	24	100
2025-451	151	Clari. Uro			076	078	076	078		078 - 2000mg/dl	24	1	24	100
058 URINALYSIS-GLUCOSE														
2025-452	011	AMES NM10S			073	073	073	073		073 - NEGATIVE	32	32	32	100
2025-452	013	BAYER CLI			073	073	073	073		073 - NEGATIVE	20	20	20	100
2025-452	067	URISCAN			073	073	073	073		073 - NEGATIVE	55	53	53	100
2025-452	067	URISCAN			073	073	073	073		074 - TRACES	55	1	53	0
2025-452	067	URISCAN			073	073	073	073		075 - 250mg/dl-+	55	1	53	0
2025-452	072	URS-9-TECO			073	073	073	073		073 - NEGATIVE	58	58	58	100
2025-452	080	ROCHE (CHE			073	073	073	073		073 - NEGATIVE	36	36	36	100
2025-452	089	AIMSTRIP			073	073	073	073		073 - NEGATIVE	153	152	152	100
2025-452	089	AIMSTRIP			073	073	073	073		074 - TRACES	153	1	152	0
2025-452	094	CLINITEK			073	073	073	073		073 - NEGATIVE	108	106	106	100
2025-452	094	CLINITEK			073	073	073	073		074 - TRACES	108	1	106	0
2025-452	094	CLINITEK			073	073	073	073		075 - 250mg/dl-+	108	1	106	0
2025-452	102	ACON LAB			073	073	073	073		073 - NEGATIVE	118	118	118	100
2025-452	131	iCHEM VELO			073	073	073	073		073 - NEGATIVE	36	36	36	100
2025-452	140	MISSION A			073	073	073	073		073 - NEGATIVE	39	39	39	100
2025-452	145	CLINITEK			073	073	073	073		073 - NEGATIVE	42	42	42	100
2025-452	147	Mission120			073	073	073	073		073 - NEGATIVE	36	36	36	100
2025-452	148	Mission500			073	073	073	073		073 - NEGATIVE	142	142	142	100
2025-452	151	Clari. Uro			073	073	073	073		073 - NEGATIVE	24	24	24	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 81 (124)
DATE : 7/22/2025
TIME : 12:51:16

Participant Summary**MONTH 5 OF YEAR 2025**

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS				
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFeree LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
058 URINALYSIS-GLUCOSE												
2025-453	011	AMES NM10S			076	078	075 077	076 - 500mg/dl2+	32	7	32	100
2025-453	011	AMES NM10S			076	078	075 077	077 - 1000mg/dl	32	22	32	100
2025-453	011	AMES NM10S			076	078	075 077	078 - 2000mg/dl	32	3	32	100
2025-453	013	BAYER CLI			076	078	075 077	076 - 500mg/dl2+	20	6	20	100
2025-453	013	BAYER CLI			076	078	075 077	077 - 1000mg/dl	20	14	20	100
2025-453	067	URISCAN			077	078	075 077	076 - 500mg/dl2+	55	1	55	100
2025-453	067	URISCAN			077	078	075 077	077 - 1000mg/dl	55	17	55	100
2025-453	067	URISCAN			077	078	075 077	078 - 2000mg/dl	55	37	55	100
2025-453	072	URS-9-TECO			076	078	075 077	074 - TRACES	58	1	57	0
2025-453	072	URS-9-TECO			076	078	075 077	075 - 250mg/dl-+	58	2	57	100
2025-453	072	URS-9-TECO			076	078	075 077	076 - 500mg/dl2+	58	23	57	100
2025-453	072	URS-9-TECO			076	078	075 077	077 - 1000mg/dl	58	28	57	100
2025-453	072	URS-9-TECO			076	078	075 077	078 - 2000mg/dl	58	4	57	100
2025-453	080	ROCHE (CHE			076	078	075 077	075 - 250mg/dl-+	36	1	36	100
2025-453	080	ROCHE (CHE			076	078	075 077	077 - 1000mg/dl	36	32	36	100
2025-453	080	ROCHE (CHE			076	078	075 077	078 - 2000mg/dl	36	3	36	100
2025-453	089	AIMSTRIP			076	078	075 077	073 - NEGATIVE	153	2	151	0
2025-453	089	AIMSTRIP			076	078	075 077	075 - 250mg/dl-+	153	4	151	100
2025-453	089	AIMSTRIP			076	078	075 077	076 - 500mg/dl2+	153	44	151	100
2025-453	089	AIMSTRIP			076	078	075 077	077 - 1000mg/dl	153	102	151	100
2025-453	089	AIMSTRIP			076	078	075 077	078 - 2000mg/dl	153	1	151	100
2025-453	094	CLINITEK			076	078	075 077	075 - 250mg/dl-+	108	2	108	100
2025-453	094	CLINITEK			076	078	075 077	076 - 500mg/dl2+	108	30	108	100
2025-453	094	CLINITEK			076	078	075 077	077 - 1000mg/dl	108	75	108	100
2025-453	094	CLINITEK			076	078	075 077	078 - 2000mg/dl	108	1	108	100
2025-453	102	ACON LAB			076	078	075 077	075 - 250mg/dl-+	118	3	118	100
2025-453	102	ACON LAB			076	078	075 077	076 - 500mg/dl2+	118	44	118	100
2025-453	102	ACON LAB			076	078	075 077	077 - 1000mg/dl	118	66	118	100
2025-453	102	ACON LAB			076	078	075 077	078 - 2000mg/dl	118	5	118	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-453	131	iCHEM VELO			075	077	075	077		076 - 500mg/dl2+	36	33	36	100
2025-453	131	iCHEM VELO			075	077	075	077		077 - 1000mg/dl	36	3	36	100
2025-453	140	MISSION A			076	078	075	077		076 - 500mg/dl2+	39	6	39	100
2025-453	140	MISSION A			076	078	075	077		077 - 1000mg/dl	39	25	39	100
2025-453	140	MISSION A			076	078	075	077		078 - 2000mg/dl	39	8	39	100
2025-453	145	CLINITEK			075	077	075	077		075 - 250mg/dl-+	42	1	41	100
2025-453	145	CLINITEK			075	077	075	077		076 - 500mg/dl2+	42	31	41	100
2025-453	145	CLINITEK			075	077	075	077		077 - 1000mg/dl	42	9	41	100
2025-453	145	CLINITEK			075	077	075	077		078 - 2000mg/dl	42	1	41	0
2025-453	147	Mission120			076	078	075	077		075 - 250mg/dl-+	36	1	36	100
2025-453	147	Mission120			076	078	075	077		076 - 500mg/dl2+	36	4	36	100
2025-453	147	Mission120			076	078	075	077		077 - 1000mg/dl	36	18	36	100
2025-453	147	Mission120			076	078	075	077		078 - 2000mg/dl	36	13	36	100
2025-453	148	Mission500			076	078	075	077		075 - 250mg/dl-+	142	1	142	100
2025-453	148	Mission500			076	078	075	077		076 - 500mg/dl2+	142	31	142	100
2025-453	148	Mission500			076	078	075	077		077 - 1000mg/dl	142	63	142	100
2025-453	148	Mission500			076	078	075	077		078 - 2000mg/dl	142	47	142	100
2025-453	151	Clari. Uro			076	078	075	077		076 - 500mg/dl2+	24	4	24	100
2025-453	151	Clari. Uro			076	078	075	077		077 - 1000mg/dl	24	20	24	100
058 URINALYSIS-GLUCOSE														
2025-454	011	AMES NM10S			073	075	074	076		074 - TRACES	32	21	32	100
2025-454	011	AMES NM10S			073	075	074	076		075 - 250mg/dl-+	32	11	32	100
2025-454	013	BAYER CLI			073	075	074	076		074 - TRACES	20	11	20	100
2025-454	013	BAYER CLI			073	075	074	076		075 - 250mg/dl-+	20	8	20	100
2025-454	013	BAYER CLI			073	075	074	076		076 - 500mg/dl2+	20	1	20	100
2025-454	067	URISCAN					074	076		073 - NEGATIVE	55	6	40	0
2025-454	067	URISCAN					074	076		074 - TRACES	55	4	40	100
2025-454	067	URISCAN					074	076		075 - 250mg/dl-+	55	21	40	100
2025-454	067	URISCAN					074	076		076 - 500mg/dl2+	55	15	40	100
2025-454	067	URISCAN					074	076		077 - 1000mg/dl	55	9	40	0

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS											
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH		COMMER LOW/HIGH		REPORTED VALUE		PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-454	072	URS-9-TECO					073	075	074	076				073 - NEGATIVE	58	16	58	100
2025-454	072	URS-9-TECO					073	075	074	076				074 - TRACES	58	25	58	100
2025-454	072	URS-9-TECO					073	075	074	076				075 - 250mg/dl-+	58	17	58	100
2025-454	080	ROCHE (CHE					076	078	074	076				077 - 1000mg/dl	36	33	36	100
2025-454	080	ROCHE (CHE					076	078	074	076				078 - 2000mg/dl	36	3	36	100
2025-454	089	AIMSTRIP					074	076	074	076				073 - NEGATIVE	153	12	141	0
2025-454	089	AIMSTRIP					074	076	074	076				074 - TRACES	153	36	141	100
2025-454	089	AIMSTRIP					074	076	074	076				075 - 250mg/dl-+	153	103	141	100
2025-454	089	AIMSTRIP					074	076	074	076				076 - 500mg/dl2+	153	2	141	100
2025-454	094	CLINITEK					073	075	074	076				073 - NEGATIVE	108	1	107	100
2025-454	094	CLINITEK					073	075	074	076				074 - TRACES	108	67	107	100
2025-454	094	CLINITEK					073	075	074	076				075 - 250mg/dl-+	108	39	107	100
2025-454	094	CLINITEK					073	075	074	076				077 - 1000mg/dl	108	1	107	0
2025-454	102	ACON LAB					074	076	074	076				073 - NEGATIVE	118	3	115	0
2025-454	102	ACON LAB					074	076	074	076				074 - TRACES	118	22	115	100
2025-454	102	ACON LAB					074	076	074	076				075 - 250mg/dl-+	118	92	115	100
2025-454	102	ACON LAB					074	076	074	076				076 - 500mg/dl2+	118	1	115	100
2025-454	131	iCHEM VELO					075	077	074	076				076 - 500mg/dl2+	36	33	36	100
2025-454	131	iCHEM VELO					075	077	074	076				077 - 1000mg/dl	36	3	36	100
2025-454	140	MISSION A					074	076	074	076				074 - TRACES	39	8	39	100
2025-454	140	MISSION A					074	076	074	076				075 - 250mg/dl-+	39	30	39	100
2025-454	140	MISSION A					074	076	074	076				076 - 500mg/dl2+	39	1	39	100
2025-454	145	CLINITEK					076	078	074	076				076 - 500mg/dl2+	42	9	42	100
2025-454	145	CLINITEK					076	078	074	076				077 - 1000mg/dl	42	32	42	100
2025-454	145	CLINITEK					076	078	074	076				078 - 2000mg/dl	42	1	42	100
2025-454	147	Mission120					074	076	074	076				074 - TRACES	36	10	36	100
2025-454	147	Mission120					074	076	074	076				075 - 250mg/dl-+	36	26	36	100
2025-454	148	Mission500					074	076	074	076				074 - TRACES	142	15	142	100
2025-454	148	Mission500					074	076	074	076				075 - 250mg/dl-+	142	127	142	100
2025-454	151	Clari. Uro					074	076	074	076				073 - NEGATIVE	24	1	23	0

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-454	151	Clari. Uro		074	076	074	076			074 - TRACES	24	3	23	100
2025-454	151	Clari. Uro		074	076	074	076			075 - 250mg/dl-+	24	20	23	100
058 URINALYSIS-GLUCOSE														
2025-455	011	AMES NM10S		073	073	073	073			073 - NEGATIVE	32	32	32	100
2025-455	013	BAYER CLI		073	073	073	073			073 - NEGATIVE	20	20	20	100
2025-455	067	URISCAN		073	073	073	073			073 - NEGATIVE	55	55	55	100
2025-455	072	URS-9-TECO		073	073	073	073			073 - NEGATIVE	58	58	58	100
2025-455	080	ROCHE (CHE		073	073	073	073			073 - NEGATIVE	36	36	36	100
2025-455	089	AIMSTRIP		073	073	073	073			073 - NEGATIVE	153	151	151	100
2025-455	089	AIMSTRIP		073	073	073	073			077 - 1000mg/dl	153	2	151	0
2025-455	094	CLINITEK		073	073	073	073			073 - NEGATIVE	108	108	108	100
2025-455	102	ACON LAB		073	073	073	073			073 - NEGATIVE	118	117	117	100
2025-455	102	ACON LAB		073	073	073	073			074 - TRACES	118	1	117	0
2025-455	131	iCHEM VELO		073	073	073	073			073 - NEGATIVE	36	36	36	100
2025-455	140	MISSION A		073	073	073	073			073 - NEGATIVE	39	39	39	100
2025-455	145	CLINITEK		073	073	073	073			073 - NEGATIVE	42	42	42	100
2025-455	147	Mission120		073	073	073	073			073 - NEGATIVE	36	36	36	100
2025-455	148	Mission500		073	073	073	073			073 - NEGATIVE	142	141	141	100
2025-455	148	Mission500		073	073	073	073			076 - 500mg/dl2+	142	1	141	0
2025-455	151	Clari. Uro		073	073	073	073			073 - NEGATIVE	24	24	24	100
059 URINALYS.HG.OR BLOOD														
2025-451	011	AMES NM10S		068	069	068	069			068 - POS.(1-2+)	32	2	32	100
2025-451	011	AMES NM10S		068	069	068	069			069 - POS.(3+)	32	30	32	100
2025-451	013	BAYER CLI		068	069	068	069			068 - POS.(1-2+)	20	2	20	100
2025-451	013	BAYER CLI		068	069	068	069			069 - POS.(3+)	20	18	20	100
2025-451	067	URISCAN		068	069	068	069			068 - POS.(1-2+)	55	7	55	100
2025-451	067	URISCAN		068	069	068	069			069 - POS.(3+)	55	48	55	100
2025-451	072	URS-9-TECO		068	069	068	069			068 - POS.(1-2+)	58	3	58	100
2025-451	072	URS-9-TECO		068	069	068	069			069 - POS.(3+)	58	55	58	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 85 (124)
DATE : 7/22/2025
TIME : 12:51:16

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-451	080	ROCHE (CHE			068	069	068	069	069 - POS.(3+)	36	36	36	100
2025-451	089	AIMSTRIP			068	069	068	069	066 - NEGATIVE	152	1	151	0
2025-451	089	AIMSTRIP			068	069	068	069	068 - POS.(1-2+)	152	3	151	100
2025-451	089	AIMSTRIP			068	069	068	069	069 - POS.(3+)	152	148	151	100
2025-451	094	CLINITEK			068	069	068	069	068 - POS.(1-2+)	108	2	108	100
2025-451	094	CLINITEK			068	069	068	069	069 - POS.(3+)	108	106	108	100
2025-451	102	ACON LAB			068	069	068	069	068 - POS.(1-2+)	120	2	120	100
2025-451	102	ACON LAB			068	069	068	069	069 - POS.(3+)	120	118	120	100
2025-451	131	iCHEM VELO			068	069	068	069	068 - POS.(1-2+)	36	2	36	100
2025-451	131	iCHEM VELO			068	069	068	069	069 - POS.(3+)	36	34	36	100
2025-451	140	MISSION A			068	069	068	069	068 - POS.(1-2+)	37	2	37	100
2025-451	140	MISSION A			068	069	068	069	069 - POS.(3+)	37	35	37	100
2025-451	145	CLINITEK			068	069	068	069	068 - POS.(1-2+)	42	1	42	100
2025-451	145	CLINITEK			068	069	068	069	069 - POS.(3+)	42	41	42	100
2025-451	147	Mission120			068	069	068	069	068 - POS.(1-2+)	38	1	38	100
2025-451	147	Mission120			068	069	068	069	069 - POS.(3+)	38	37	38	100
2025-451	148	Mission500			068	069	068	069	069 - POS.(3+)	140	140	140	100
2025-451	151	Clari. Uro			068	069	068	069	069 - POS.(3+)	24	24	24	100
059 URINALYS.HG.OR BLOOD													
2025-452	011	AMES NM10S			068	069	068	069	068 - POS.(1-2+)	32	3	32	100
2025-452	011	AMES NM10S			068	069	068	069	069 - POS.(3+)	32	29	32	100
2025-452	013	BAYER CLI			068	069	068	069	069 - POS.(3+)	20	20	20	100
2025-452	067	URISCAN			068	069	068	069	068 - POS.(1-2+)	55	6	55	100
2025-452	067	URISCAN			068	069	068	069	069 - POS.(3+)	55	49	55	100
2025-452	072	URS-9-TECO			068	069	068	069	068 - POS.(1-2+)	58	7	58	100
2025-452	072	URS-9-TECO			068	069	068	069	069 - POS.(3+)	58	51	58	100
2025-452	080	ROCHE (CHE			068	069	068	069	069 - POS.(3+)	36	36	36	100
2025-452	089	AIMSTRIP			068	069	068	069	066 - NEGATIVE	152	1	151	0
2025-452	089	AIMSTRIP			068	069	068	069	068 - POS.(1-2+)	152	2	151	100
2025-452	089	AIMSTRIP			068	069	068	069	069 - POS.(3+)	152	149	151	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-452	094	CLINITEK					068 069	068 069		068 - POS.(1-2+)	108	1	108	100
2025-452	094	CLINITEK					068 069	068 069		069 - POS.(3+)	108	107	108	100
2025-452	102	ACON LAB					068 069	068 069		069 - POS.(3+)	120	120	120	100
2025-452	131	iCHEM VELO					068 069	068 069		068 - POS.(1-2+)	36	2	36	100
2025-452	131	iCHEM VELO					068 069	068 069		069 - POS.(3+)	36	34	36	100
2025-452	140	MISSION A					068 069	068 069		068 - POS.(1-2+)	37	2	37	100
2025-452	140	MISSION A					068 069	068 069		069 - POS.(3+)	37	35	37	100
2025-452	145	CLINITEK					068 069	068 069		068 - POS.(1-2+)	42	2	42	100
2025-452	145	CLINITEK					068 069	068 069		069 - POS.(3+)	42	40	42	100
2025-452	147	Mission120					068 069	068 069		069 - POS.(3+)	38	38	38	100
2025-452	148	Mission500					068 069	068 069		069 - POS.(3+)	140	140	140	100
2025-452	151	Clari. Uro					068 069	068 069		069 - POS.(3+)	24	24	24	100
059 URINALYS.HG.OR BLOOD														
2025-453	011	AMES NM10S					066 066	066 066		066 - NEGATIVE	32	32	32	100
2025-453	013	BAYER CLI					066 066	066 066		066 - NEGATIVE	20	20	20	100
2025-453	067	URISCAN					066 066	066 066		066 - NEGATIVE	55	55	55	100
2025-453	072	URS-9-TECO					066 066	066 066		066 - NEGATIVE	58	58	58	100
2025-453	080	ROCHE (CHE					066 066	066 066		066 - NEGATIVE	36	36	36	100
2025-453	089	AIMSTRIP					066 066	066 066		066 - NEGATIVE	152	151	151	100
2025-453	089	AIMSTRIP					066 066	066 066		069 - POS.(3+)	152	1	151	0
2025-453	094	CLINITEK					066 066	066 066		066 - NEGATIVE	108	108	108	100
2025-453	102	ACON LAB					066 066	066 066		066 - NEGATIVE	120	120	120	100
2025-453	131	iCHEM VELO					066 066	066 066		066 - NEGATIVE	36	35	35	100
2025-453	131	iCHEM VELO					066 066	066 066		068 - POS.(1-2+)	36	1	35	0
2025-453	140	MISSION A					066 066	066 066		066 - NEGATIVE	37	37	37	100
2025-453	145	CLINITEK					066 066	066 066		066 - NEGATIVE	42	42	42	100
2025-453	147	Mission120					066 066	066 066		066 - NEGATIVE	38	38	38	100
2025-453	148	Mission500					066 066	066 066		066 - NEGATIVE	140	140	140	100
2025-453	151	Clari. Uro					066 066	066 066		066 - NEGATIVE	24	24	24	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
059 URINALYS.HG.OR BLOOD													
2025-454	011	AMES NM10S			066	066	066	066	066 - NEGATIVE	32	32	32	100
2025-454	013	BAYER CLI			066	066	066	066	066 - NEGATIVE	20	20	20	100
2025-454	067	URISCAN			066	066	066	066	066 - NEGATIVE	55	53	53	100
2025-454	067	URISCAN			066	066	066	066	067 - TRACES	55	2	53	0
2025-454	072	URS-9-TECO			066	066	066	066	066 - NEGATIVE	58	56	56	100
2025-454	072	URS-9-TECO			066	066	066	066	067 - TRACES	58	1	56	0
2025-454	072	URS-9-TECO			066	066	066	066	068 - POS.(1-2+)	58	1	56	0
2025-454	080	ROCHE (CHE			066	066	066	066	066 - NEGATIVE	36	36	36	100
2025-454	089	AIMSTRIP			066	066	066	066	066 - NEGATIVE	152	152	152	100
2025-454	094	CLINITEK			066	066	066	066	066 - NEGATIVE	108	108	108	100
2025-454	102	ACON LAB			066	066	066	066	066 - NEGATIVE	120	120	120	100
2025-454	131	iCHEM VELO			066	066	066	066	066 - NEGATIVE	36	36	36	100
2025-454	140	MISSION A			066	066	066	066	066 - NEGATIVE	37	37	37	100
2025-454	145	CLINITEK			066	066	066	066	066 - NEGATIVE	42	42	42	100
2025-454	147	Mission120			066	066	066	066	066 - NEGATIVE	38	38	38	100
2025-454	148	Mission500			066	066	066	066	066 - NEGATIVE	140	140	140	100
2025-454	151	Clari. Uro			066	066	066	066	066 - NEGATIVE	24	24	24	100
2025-455	011	AMES NM10S			068	069	068	069	068 - POS.(1-2+)	32	8	32	100
2025-455	011	AMES NM10S			068	069	068	069	069 - POS.(3+)	32	24	32	100
2025-455	013	BAYER CLI			068	069	068	069	068 - POS.(1-2+)	20	1	20	100
2025-455	013	BAYER CLI			068	069	068	069	069 - POS.(3+)	20	19	20	100
2025-455	067	URISCAN			068	069	068	069	068 - POS.(1-2+)	55	10	55	100
2025-455	067	URISCAN			068	069	068	069	069 - POS.(3+)	55	45	55	100
2025-455	072	URS-9-TECO			068	069	068	069	068 - POS.(1-2+)	58	11	58	100
2025-455	072	URS-9-TECO			068	069	068	069	069 - POS.(3+)	58	47	58	100
2025-455	080	ROCHE (CHE			068	069	068	069	069 - POS.(3+)	36	36	36	100
2025-455	089	AIMSTRIP			068	069	068	069	067 - TRACES	152	1	151	0

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 88 (124)
DATE : 7/22/2025
TIME : 12:51:16

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-455	089	AIMSTRIP			068	069	068	069	068 - POS.(1-2+)	152	3	151	100
2025-455	089	AIMSTRIP			068	069	068	069	069 - POS.(3+)	152	148	151	100
2025-455	094	CLINITEK			068	069	068	069	068 - POS.(1-2+)	108	13	108	100
2025-455	094	CLINITEK			068	069	068	069	069 - POS.(3+)	108	95	108	100
2025-455	102	ACON LAB			068	069	068	069	066 - NEGATIVE	120	1	119	0
2025-455	102	ACON LAB			068	069	068	069	068 - POS.(1-2+)	120	3	119	100
2025-455	102	ACON LAB			068	069	068	069	069 - POS.(3+)	120	116	119	100
2025-455	131	iCHEM VELO			067	069	068	069	067 - TRACES	36	1	36	100
2025-455	131	iCHEM VELO			067	069	068	069	068 - POS.(1-2+)	36	34	36	100
2025-455	131	iCHEM VELO			067	069	068	069	069 - POS.(3+)	36	1	36	100
2025-455	140	MISSION A			068	069	068	069	068 - POS.(1-2+)	37	1	37	100
2025-455	140	MISSION A			068	069	068	069	069 - POS.(3+)	37	36	37	100
2025-455	145	CLINITEK			068	069	068	069	068 - POS.(1-2+)	42	8	42	100
2025-455	145	CLINITEK			068	069	068	069	069 - POS.(3+)	42	34	42	100
2025-455	147	Mission120			068	069	068	069	069 - POS.(3+)	38	38	38	100
2025-455	148	Mission500			068	069	068	069	068 - POS.(1-2+)	140	1	140	100
2025-455	148	Mission500			068	069	068	069	069 - POS.(3+)	140	139	140	100
2025-455	151	Clari. Uro			068	069	068	069	069 - POS.(3+)	24	24	24	100
060 URINALYSIS-KETONES													
2025-451	011	AMES NM10S			090	090	090	090	090 - NEGATIVE	32	32	32	100
2025-451	013	BAYER CLI			090	090	090	090	090 - NEGATIVE	20	20	20	100
2025-451	067	URISCAN			090	090	090	090	090 - NEGATIVE	55	55	55	100
2025-451	072	URS-9-TECO			090	090	090	090	090 - NEGATIVE	56	56	56	100
2025-451	080	ROCHE (CHE			090	090	090	090	090 - NEGATIVE	36	36	36	100
2025-451	089	AIMSTRIP			090	090	090	090	090 - NEGATIVE	154	154	154	100
2025-451	094	CLINITEK			090	090	090	090	090 - NEGATIVE	108	108	108	100
2025-451	102	ACON LAB			090	090	090	090	090 - NEGATIVE	118	118	118	100
2025-451	131	iCHEM VELO			090	090	090	090	090 - NEGATIVE	36	35	35	100
2025-451	131	iCHEM VELO			090	090	090	090	091 - TRACE	36	1	35	0
2025-451	140	MISSION A			090	090	090	090	090 - NEGATIVE	40	40	40	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-451	145	CLINITEK			090	090	090	090	090 - NEGATIVE	42	42	42	100
2025-451	147	Mission120			090	090	090	090	090 - NEGATIVE	37	37	37	100
2025-451	148	Mission500			090	090	090	090	090 - NEGATIVE	140	140	140	100
2025-451	151	Clari. Uro			090	090	090	090	090 - NEGATIVE	24	24	24	100
060 URINALYSIS-KETONES													
2025-452	011	AMES NM10S			090	090	090	090	090 - NEGATIVE	32	32	32	100
2025-452	013	BAYER CLI			090	090	090	090	090 - NEGATIVE	20	20	20	100
2025-452	067	URISCAN			090	090	090	090	090 - NEGATIVE	55	55	55	100
2025-452	072	URS-9-TECO			090	090	090	090	090 - NEGATIVE	56	56	56	100
2025-452	080	ROCHE (CHE			090	090	090	090	090 - NEGATIVE	36	36	36	100
2025-452	089	AIMSTRIP			090	090	090	090	090 - NEGATIVE	154	154	154	100
2025-452	094	CLINITEK			090	090	090	090	090 - NEGATIVE	108	108	108	100
2025-452	102	ACON LAB			090	090	090	090	090 - NEGATIVE	118	118	118	100
2025-452	131	iCHEM VELO			090	090	090	090	090 - NEGATIVE	36	36	36	100
2025-452	140	MISSION A			090	090	090	090	090 - NEGATIVE	40	40	40	100
2025-452	145	CLINITEK			090	090	090	090	090 - NEGATIVE	42	42	42	100
2025-452	147	Mission120			090	090	090	090	090 - NEGATIVE	37	37	37	100
2025-452	148	Mission500			090	090	090	090	090 - NEGATIVE	140	140	140	100
2025-452	151	Clari. Uro			090	090	090	090	090 - NEGATIVE	24	24	24	100
2025-453	011	AMES NM10S			090	090	090	090	090 - NEGATIVE	32	32	32	100
2025-453	013	BAYER CLI			090	090	090	090	090 - NEGATIVE	20	20	20	100
2025-453	067	URISCAN			090	090	090	090	090 - NEGATIVE	55	55	55	100
2025-453	072	URS-9-TECO			090	090	090	090	090 - NEGATIVE	56	56	56	100
2025-453	080	ROCHE (CHE			090	090	090	090	090 - NEGATIVE	36	36	36	100
2025-453	089	AIMSTRIP			090	090	090	090	090 - NEGATIVE	154	154	154	100
2025-453	094	CLINITEK			090	090	090	090	090 - NEGATIVE	108	108	108	100
2025-453	102	ACON LAB			090	090	090	090	090 - NEGATIVE	118	118	118	100
2025-453	131	iCHEM VELO			090	090	090	090	090 - NEGATIVE	36	36	36	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS								
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-453	140	MISSION A				090	090	090	090		090 - NEGATIVE	40	40	40	100
2025-453	145	CLINITEK				090	090	090	090		090 - NEGATIVE	42	42	42	100
2025-453	147	Mission120				090	090	090	090		090 - NEGATIVE	37	37	37	100
2025-453	148	Mission500				090	090	090	090		090 - NEGATIVE	140	140	140	100
2025-453	151	Clari. Uro				090	090	090	090		090 - NEGATIVE	24	24	24	100
060 URINALYSIS-KETONES															
2025-454	011	AMES NM10S				092	094	092	094		092 - SMALL (1+)	32	5	32	100
2025-454	011	AMES NM10S				092	094	092	094		093 - MOD. (2+)	32	19	32	100
2025-454	011	AMES NM10S				092	094	092	094		094 - LARGE-3-4+	32	8	32	100
2025-454	013	BAYER CLI				092	094	092	094		091 - TRACE	20	1	19	0
2025-454	013	BAYER CLI				092	094	092	094		092 - SMALL (1+)	20	3	19	100
2025-454	013	BAYER CLI				092	094	092	094		093 - MOD. (2+)	20	14	19	100
2025-454	013	BAYER CLI				092	094	092	094		094 - LARGE-3-4+	20	2	19	100
2025-454	067	URISCAN				092	094	092	094		092 - SMALL (1+)	55	3	55	100
2025-454	067	URISCAN				092	094	092	094		093 - MOD. (2+)	55	32	55	100
2025-454	067	URISCAN				092	094	092	094		094 - LARGE-3-4+	55	20	55	100
2025-454	072	URS-9-TECO				092	094	092	094		090 - NEGATIVE	56	1	55	0
2025-454	072	URS-9-TECO				092	094	092	094		092 - SMALL (1+)	56	4	55	100
2025-454	072	URS-9-TECO				092	094	092	094		093 - MOD. (2+)	56	32	55	100
2025-454	072	URS-9-TECO				092	094	092	094		094 - LARGE-3-4+	56	19	55	100
2025-454	080	ROCHE (CHE				092	094	092	094		090 - NEGATIVE	36	1	35	0
2025-454	080	ROCHE (CHE				092	094	092	094		092 - SMALL (1+)	36	7	35	100
2025-454	080	ROCHE (CHE				092	094	092	094		093 - MOD. (2+)	36	17	35	100
2025-454	080	ROCHE (CHE				092	094	092	094		094 - LARGE-3-4+	36	11	35	100
2025-454	089	AIMSTRIP				092	094	092	094		090 - NEGATIVE	154	1	152	0
2025-454	089	AIMSTRIP				092	094	092	094		091 - TRACE	154	1	152	0
2025-454	089	AIMSTRIP				092	094	092	094		092 - SMALL (1+)	154	12	152	100
2025-454	089	AIMSTRIP				092	094	092	094		093 - MOD. (2+)	154	72	152	100
2025-454	089	AIMSTRIP				092	094	092	094		094 - LARGE-3-4+	154	68	152	100
2025-454	094	CLINITEK				092	094	092	094		091 - TRACE	108	1	107	0

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-454	094	CLINITEK			092	094	092	094	092 - SMALL (1+)	108	14	107	100
2025-454	094	CLINITEK			092	094	092	094	093 - MOD. (2+)	108	89	107	100
2025-454	094	CLINITEK			092	094	092	094	094 - LARGE-3-4+	108	4	107	100
2025-454	102	ACON LAB			092	094	092	094	092 - SMALL (1+)	118	5	118	100
2025-454	102	ACON LAB			092	094	092	094	093 - MOD. (2+)	118	62	118	100
2025-454	102	ACON LAB			092	094	092	094	094 - LARGE-3-4+	118	51	118	100
2025-454	131	iCHEM VELO			092	094	092	094	091 - TRACE	36	1	35	0
2025-454	131	iCHEM VELO			092	094	092	094	092 - SMALL (1+)	36	12	35	100
2025-454	131	iCHEM VELO			092	094	092	094	093 - MOD. (2+)	36	18	35	100
2025-454	131	iCHEM VELO			092	094	092	094	094 - LARGE-3-4+	36	5	35	100
2025-454	140	MISSION A			093	094	092	094	092 - SMALL (1+)	40	1	40	100
2025-454	140	MISSION A			093	094	092	094	093 - MOD. (2+)	40	6	40	100
2025-454	140	MISSION A			093	094	092	094	094 - LARGE-3-4+	40	33	40	100
2025-454	145	CLINITEK			092	094	092	094	091 - TRACE	42	1	41	0
2025-454	145	CLINITEK			092	094	092	094	093 - MOD. (2+)	42	31	41	100
2025-454	145	CLINITEK			092	094	092	094	094 - LARGE-3-4+	42	10	41	100
2025-454	147	Mission120			093	094	092	094	093 - MOD. (2+)	37	4	37	100
2025-454	147	Mission120			093	094	092	094	094 - LARGE-3-4+	37	33	37	100
2025-454	148	Mission500			092	094	092	094	092 - SMALL (1+)	140	3	140	100
2025-454	148	Mission500			092	094	092	094	093 - MOD. (2+)	140	87	140	100
2025-454	148	Mission500			092	094	092	094	094 - LARGE-3-4+	140	50	140	100
2025-454	151	Clari. Uro			093	094	092	094	093 - MOD. (2+)	24	8	24	100
2025-454	151	Clari. Uro			093	094	092	094	094 - LARGE-3-4+	24	16	24	100
060 URINALYSIS-KETONES													
2025-455	011	AMES NM10S			093	094	093	094	094 - LARGE-3-4+	32	32	32	100
2025-455	013	BAYER CLI			093	094	093	094	093 - MOD. (2+)	20	1	20	100
2025-455	013	BAYER CLI			093	094	093	094	094 - LARGE-3-4+	20	19	20	100
2025-455	067	URISCAN			093	094	093	094	093 - MOD. (2+)	55	17	55	100
2025-455	067	URISCAN			093	094	093	094	094 - LARGE-3-4+	55	38	55	100
2025-455	072	URS-9-TECO			093	094	093	094	092 - SMALL (1+)	56	1	55	0

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 92 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-455	072	URS-9-TECO		093	094	093	094			093 - MOD. (2+)	56	1	55	100
2025-455	072	URS-9-TECO		093	094	093	094			094 - LARGE-3-4+	56	54	55	100
2025-455	080	ROCHE (CHE		093	094	093	094			093 - MOD. (2+)	36	2	36	100
2025-455	080	ROCHE (CHE		093	094	093	094			094 - LARGE-3-4+	36	34	36	100
2025-455	089	AIMSTRIP		093	094	093	094			092 - SMALL (1+)	154	1	153	0
2025-455	089	AIMSTRIP		093	094	093	094			093 - MOD. (2+)	154	5	153	100
2025-455	089	AIMSTRIP		093	094	093	094			094 - LARGE-3-4+	154	148	153	100
2025-455	094	CLINITEK		093	094	093	094			093 - MOD. (2+)	108	4	108	100
2025-455	094	CLINITEK		093	094	093	094			094 - LARGE-3-4+	108	104	108	100
2025-455	102	ACON LAB		093	094	093	094			093 - MOD. (2+)	118	2	118	100
2025-455	102	ACON LAB		093	094	093	094			094 - LARGE-3-4+	118	116	118	100
2025-455	131	iCHEM VELO		092	094	093	094			093 - MOD. (2+)	36	20	36	100
2025-455	131	iCHEM VELO		092	094	093	094			094 - LARGE-3-4+	36	16	36	100
2025-455	140	MISSION A		093	094	093	094			093 - MOD. (2+)	40	2	40	100
2025-455	140	MISSION A		093	094	093	094			094 - LARGE-3-4+	40	38	40	100
2025-455	145	CLINITEK		093	094	093	094			092 - SMALL (1+)	42	1	41	0
2025-455	145	CLINITEK		093	094	093	094			094 - LARGE-3-4+	42	41	41	100
2025-455	147	Mission120		093	094	093	094			094 - LARGE-3-4+	37	37	37	100
2025-455	148	Mission500		093	094	093	094			090 - NEGATIVE	140	1	139	0
2025-455	148	Mission500		093	094	093	094			094 - LARGE-3-4+	140	139	139	100
2025-455	151	Clari. Uro		093	094	093	094			094 - LARGE-3-4+	24	24	24	100
061 URINALYSIS-NITRATE														
2025-451	011	AMES NM10S		070	070	070	070			070 - NEGATIVE	31	31	31	100
2025-451	013	BAYER CLI		070	070	070	070			070 - NEGATIVE	20	20	20	100
2025-451	067	URISCAN		070	070	070	070			070 - NEGATIVE	55	55	55	100
2025-451	072	URS-9-TECO		070	070	070	070			070 - NEGATIVE	57	57	57	100
2025-451	080	ROCHE (CHE		070	070	070	070			070 - NEGATIVE	36	36	36	100
2025-451	089	AIMSTRIP		070	070	070	070			070 - NEGATIVE	154	154	154	100
2025-451	094	CLINITEK		070	070	070	070			070 - NEGATIVE	108	108	108	100
2025-451	102	ACON LAB		070	070	070	070			070 - NEGATIVE	118	118	118	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-451	131	iCHEM VELO				070	070	070	070	070 - NEGATIVE	36	36	36	100
2025-451	140	MISSION A				070	070	070	070	070 - NEGATIVE	38	38	38	100
2025-451	145	CLINITEK				070	070	070	070	070 - NEGATIVE	43	43	43	100
2025-451	147	Mission120				070	070	070	070	070 - NEGATIVE	38	38	38	100
2025-451	148	Mission500				070	070	070	070	070 - NEGATIVE	140	140	140	100
2025-451	151	Clari. Uro				070	070	070	070	070 - NEGATIVE	24	24	24	100
061 URINALYSIS-NITRATE														
2025-452	011	AMES NM10S				070	070	070	070	070 - NEGATIVE	31	31	31	100
2025-452	013	BAYER CLI				070	070	070	070	070 - NEGATIVE	20	20	20	100
2025-452	067	URISCAN				070	070	070	070	070 - NEGATIVE	55	55	55	100
2025-452	072	URS-9-TECO				070	070	070	070	070 - NEGATIVE	57	57	57	100
2025-452	080	ROCHE (CHE				070	070	070	070	070 - NEGATIVE	36	36	36	100
2025-452	089	AIMSTRIP				070	070	070	070	070 - NEGATIVE	154	154	154	100
2025-452	094	CLINITEK				070	070	070	070	070 - NEGATIVE	108	108	108	100
2025-452	102	ACON LAB				070	070	070	070	070 - NEGATIVE	118	118	118	100
2025-452	131	iCHEM VELO				070	070	070	070	070 - NEGATIVE	36	36	36	100
2025-452	140	MISSION A				070	070	070	070	070 - NEGATIVE	38	38	38	100
2025-452	145	CLINITEK				070	070	070	070	070 - NEGATIVE	43	43	43	100
2025-452	147	Mission120				070	070	070	070	070 - NEGATIVE	38	38	38	100
2025-452	148	Mission500				070	070	070	070	070 - NEGATIVE	140	140	140	100
2025-452	151	Clari. Uro				070	070	070	070	070 - NEGATIVE	24	24	24	100
2025-453	011	AMES NM10S				070	070	070	070	070 - NEGATIVE	31	31	31	100
2025-453	013	BAYER CLI				070	070	070	070	070 - NEGATIVE	20	20	20	100
2025-453	067	URISCAN				070	070	070	070	070 - NEGATIVE	55	55	55	100
2025-453	072	URS-9-TECO				070	070	070	070	070 - NEGATIVE	57	57	57	100
2025-453	080	ROCHE (CHE				070	070	070	070	070 - NEGATIVE	36	36	36	100
2025-453	089	AIMSTRIP				070	070	070	070	070 - NEGATIVE	154	154	154	100
2025-453	094	CLINITEK				070	070	070	070	070 - NEGATIVE	108	108	108	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-453	102	ACON LAB			070	070	070	070		070 - NEGATIVE	118	118	118	100
2025-453	131	iCHEM VELO			070	070	070	070		070 - NEGATIVE	36	36	36	100
2025-453	140	MISSION A			070	070	070	070		070 - NEGATIVE	38	38	38	100
2025-453	145	CLINITEK			070	070	070	070		070 - NEGATIVE	43	43	43	100
2025-453	147	Mission120			070	070	070	070		070 - NEGATIVE	38	38	38	100
2025-453	148	Mission500			070	070	070	070		070 - NEGATIVE	140	139	139	100
2025-453	148	Mission500			070	070	070	070		072 - POSITIVE	140	1	139	0
2025-453	151	Clari. Uro			070	070	070	070		070 - NEGATIVE	24	24	24	100
061 URINALYSIS-NITRATE														
2025-454	011	AMES NM10S			071	072	071	072		072 - POSITIVE	31	31	31	100
2025-454	013	BAYER CLI			071	072	071	072		072 - POSITIVE	20	20	20	100
2025-454	067	URISCAN			071	072	071	072		072 - POSITIVE	55	55	55	100
2025-454	072	URS-9-TECO			071	072	071	072		072 - POSITIVE	57	57	57	100
2025-454	080	ROCHE (CHE			071	072	071	072		072 - POSITIVE	36	36	36	100
2025-454	089	AIMSTRIP			071	072	071	072		071 - WEAK POS.	154	2	154	100
2025-454	089	AIMSTRIP			071	072	071	072		072 - POSITIVE	154	152	154	100
2025-454	094	CLINITEK			071	072	071	072		072 - POSITIVE	108	108	108	100
2025-454	102	ACON LAB			071	072	071	072		071 - WEAK POS.	118	1	118	100
2025-454	102	ACON LAB			071	072	071	072		072 - POSITIVE	118	117	118	100
2025-454	131	iCHEM VELO			071	072	071	072		072 - POSITIVE	36	36	36	100
2025-454	140	MISSION A			071	072	071	072		072 - POSITIVE	38	38	38	100
2025-454	145	CLINITEK			071	072	071	072		072 - POSITIVE	43	43	43	100
2025-454	147	Mission120			071	072	071	072		072 - POSITIVE	38	38	38	100
2025-454	148	Mission500			071	072	071	072		072 - POSITIVE	140	140	140	100
2025-454	151	Clari. Uro			071	072	071	072		072 - POSITIVE	24	24	24	100
2025-455	011	AMES NM10S			070	070	070	070		070 - NEGATIVE	31	31	31	100
2025-455	013	BAYER CLI			070	070	070	070		070 - NEGATIVE	20	20	20	100
2025-455	067	URISCAN			070	070	070	070		070 - NEGATIVE	55	55	55	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 95 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-455	072	URS-9-TECO			070	070	070	070		070 - NEGATIVE	57	57	57	100
2025-455	080	ROCHE (CHE			070	070	070	070		070 - NEGATIVE	36	36	36	100
2025-455	089	AIMSTRIP			070	070	070	070		070 - NEGATIVE	154	153	153	100
2025-455	089	AIMSTRIP			070	070	070	070		072 - POSITIVE	154	1	153	0
2025-455	094	CLINITEK			070	070	070	070		070 - NEGATIVE	108	108	108	100
2025-455	102	ACON LAB			070	070	070	070		070 - NEGATIVE	118	117	117	100
2025-455	102	ACON LAB			070	070	070	070		072 - POSITIVE	118	1	117	0
2025-455	131	iCHEM VELO			070	070	070	070		070 - NEGATIVE	36	36	36	100
2025-455	140	MISSION A			070	070	070	070		070 - NEGATIVE	38	37	37	100
2025-455	140	MISSION A			070	070	070	070		072 - POSITIVE	38	1	37	0
2025-455	145	CLINITEK			070	070	070	070		070 - NEGATIVE	43	42	42	100
2025-455	145	CLINITEK			070	070	070	070		072 - POSITIVE	43	1	42	0
2025-455	147	Mission120			070	070	070	070		070 - NEGATIVE	38	38	38	100
2025-455	148	Mission500			070	070	070	070		070 - NEGATIVE	140	139	139	100
2025-455	148	Mission500			070	070	070	070		072 - POSITIVE	140	1	139	0
2025-455	151	Clari. Uro			070	070	070	070		070 - NEGATIVE	24	24	24	100
062 URINALYSIS-pH														
2025-451	011	AMES NM10S			083	087	083	087		085 - 6.5	32	30	32	100
2025-451	011	AMES NM10S			083	087	083	087		086 - 7.0	32	2	32	100
2025-451	013	BAYER CLI			083	087	083	087		085 - 6.5	20	19	20	100
2025-451	013	BAYER CLI			083	087	083	087		086 - 7.0	20	1	20	100
2025-451	067	URISCAN			082	086	083	087		082 - 5.0	55	1	55	100
2025-451	067	URISCAN			082	086	083	087		083 - 5.5	55	4	55	100
2025-451	067	URISCAN			082	086	083	087		084 - 6.0	55	26	55	100
2025-451	067	URISCAN			082	086	083	087		085 - 6.5	55	24	55	100
2025-451	072	URS-9-TECO			083	087	083	087		084 - 6.0	57	9	57	100
2025-451	072	URS-9-TECO			083	087	083	087		085 - 6.5	57	47	57	100
2025-451	072	URS-9-TECO			083	087	083	087		086 - 7.0	57	1	57	100
2025-451	080	ROCHE (CHE			083	087	083	087		084 - 6.0	36	5	36	100
2025-451	080	ROCHE (CHE			083	087	083	087		085 - 6.5	36	31	36	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE		PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-451	089	AIMSTRIP		083	087	083	087			082 - 5.0		154	1	153	0
2025-451	089	AIMSTRIP		083	087	083	087			083 - 5.5		154	1	153	100
2025-451	089	AIMSTRIP		083	087	083	087			084 - 6.0		154	57	153	100
2025-451	089	AIMSTRIP		083	087	083	087			085 - 6.5		154	92	153	100
2025-451	089	AIMSTRIP		083	087	083	087			086 - 7.0		154	3	153	100
2025-451	094	CLINITEK		083	087	083	087			084 - 6.0		108	3	108	100
2025-451	094	CLINITEK		083	087	083	087			085 - 6.5		108	103	108	100
2025-451	094	CLINITEK		083	087	083	087			086 - 7.0		108	2	108	100
2025-451	102	ACON LAB		083	087	083	087			083 - 5.5		120	1	120	100
2025-451	102	ACON LAB		083	087	083	087			084 - 6.0		120	25	120	100
2025-451	102	ACON LAB		083	087	083	087			085 - 6.5		120	92	120	100
2025-451	102	ACON LAB		083	087	083	087			086 - 7.0		120	2	120	100
2025-451	131	iCHEM VELO		082	086	083	087			084 - 6.0		36	36	36	100
2025-451	140	MISSION A		083	087	083	087			084 - 6.0		39	17	39	100
2025-451	140	MISSION A		083	087	083	087			085 - 6.5		39	21	39	100
2025-451	140	MISSION A		083	087	083	087			086 - 7.0		39	1	39	100
2025-451	145	CLINITEK		083	087	083	087			085 - 6.5		42	42	42	100
2025-451	147	Mission120		083	087	083	087			084 - 6.0		37	16	37	100
2025-451	147	Mission120		083	087	083	087			085 - 6.5		37	21	37	100
2025-451	148	Mission500		083	087	083	087			084 - 6.0		138	14	138	100
2025-451	148	Mission500		083	087	083	087			085 - 6.5		138	124	138	100
2025-451	151	Clari. Uro		082	086	083	087			084 - 6.0		24	20	24	100
2025-451	151	Clari. Uro		082	086	083	087			085 - 6.5		24	3	24	100
2025-451	151	Clari. Uro		082	086	083	087			086 - 7.0		24	1	24	100
062 URINALYSIS-pH															
2025-452	011	AMES NM10S		084	088	084	088			086 - 7.0		32	30	32	100
2025-452	011	AMES NM10S		084	088	084	088			087 - 7.5		32	2	32	100
2025-452	013	BAYER CLI		084	088	084	088			086 - 7.0		20	19	20	100
2025-452	013	BAYER CLI		084	088	084	088			087 - 7.5		20	1	20	100
2025-452	067	URISCAN		084	088	084	088			085 - 6.5		55	21	55	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-452	067	URISCAN			084 088	084 088		086 - 7.0	55	34	55	100
2025-452	072	URS-9-TECO			084 088	084 088		085 - 6.5	57	3	57	100
2025-452	072	URS-9-TECO			084 088	084 088		086 - 7.0	57	52	57	100
2025-452	072	URS-9-TECO			084 088	084 088		087 - 7.5	57	2	57	100
2025-452	080	ROCHE (CHE			084 088	084 088		086 - 7.0	36	36	36	100
2025-452	089	AIMSTRIP			084 088	084 088		084 - 6.0	154	2	154	100
2025-452	089	AIMSTRIP			084 088	084 088		085 - 6.5	154	7	154	100
2025-452	089	AIMSTRIP			084 088	084 088		086 - 7.0	154	137	154	100
2025-452	089	AIMSTRIP			084 088	084 088		087 - 7.5	154	8	154	100
2025-452	094	CLINITEK			084 088	084 088		086 - 7.0	108	104	108	100
2025-452	094	CLINITEK			084 088	084 088		087 - 7.5	108	4	108	100
2025-452	102	ACON LAB			084 088	084 088		084 - 6.0	120	1	120	100
2025-452	102	ACON LAB			084 088	084 088		085 - 6.5	120	5	120	100
2025-452	102	ACON LAB			084 088	084 088		086 - 7.0	120	106	120	100
2025-452	102	ACON LAB			084 088	084 088		087 - 7.5	120	8	120	100
2025-452	131	iCHEM VELO			084 088	084 088		086 - 7.0	36	36	36	100
2025-452	140	MISSION A			084 088	084 088		085 - 6.5	39	7	39	100
2025-452	140	MISSION A			084 088	084 088		086 - 7.0	39	32	39	100
2025-452	145	CLINITEK			084 088	084 088		086 - 7.0	42	42	42	100
2025-452	147	Mission120			084 088	084 088		085 - 6.5	37	17	37	100
2025-452	147	Mission120			084 088	084 088		086 - 7.0	37	20	37	100
2025-452	148	Mission500			084 088	084 088		085 - 6.5	138	1	138	100
2025-452	148	Mission500			084 088	084 088		086 - 7.0	138	137	138	100
2025-452	151	Clari. Uro			084 088	084 088		085 - 6.5	24	2	24	100
2025-452	151	Clari. Uro			084 088	084 088		086 - 7.0	24	22	24	100
062 URINALYSIS-pH												
2025-453	011	AMES NM10S			086 088	086 088		087 - 7.5	32	9	32	100
2025-453	011	AMES NM10S			086 088	086 088		088 - 8.00R MORE	32	23	32	100
2025-453	013	BAYER CLI			085 088	086 088		087 - 7.5	20	12	20	100
2025-453	013	BAYER CLI			085 088	086 088		088 - 8.00R MORE	20	8	20	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 98 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary**MONTH 5 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS								
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-453	067	URISCAN					085	088	086	088	087 - 7.5	55	39	55	100
2025-453	067	URISCAN					085	088	086	088	088 - 8.00R MORE	55	16	55	100
2025-453	072	URS-9-TECO					085	088	086	088	086 - 7.0	57	6	57	100
2025-453	072	URS-9-TECO					085	088	086	088	087 - 7.5	57	38	57	100
2025-453	072	URS-9-TECO					085	088	086	088	088 - 8.00R MORE	57	13	57	100
2025-453	080	ROCHE (CHE					084	088	086	088	085 - 6.5	36	1	36	100
2025-453	080	ROCHE (CHE					084	088	086	088	086 - 7.0	36	27	36	100
2025-453	080	ROCHE (CHE					084	088	086	088	088 - 8.00R MORE	36	8	36	100
2025-453	089	AIMSTRIP					085	088	086	088	084 - 6.0	154	1	153	0
2025-453	089	AIMSTRIP					085	088	086	088	085 - 6.5	154	1	153	100
2025-453	089	AIMSTRIP					085	088	086	088	086 - 7.0	154	2	153	100
2025-453	089	AIMSTRIP					085	088	086	088	087 - 7.5	154	88	153	100
2025-453	089	AIMSTRIP					085	088	086	088	088 - 8.00R MORE	154	62	153	100
2025-453	094	CLINITEK					086	088	086	088	086 - 7.0	108	2	108	100
2025-453	094	CLINITEK					086	088	086	088	087 - 7.5	108	35	108	100
2025-453	094	CLINITEK					086	088	086	088	088 - 8.00R MORE	108	71	108	100
2025-453	102	ACON LAB					085	088	086	088	086 - 7.0	120	1	120	100
2025-453	102	ACON LAB					085	088	086	088	087 - 7.5	120	75	120	100
2025-453	102	ACON LAB					085	088	086	088	088 - 8.00R MORE	120	44	120	100
2025-453	131	iCHEM VELO					084	088	086	088	086 - 7.0	36	29	36	100
2025-453	131	iCHEM VELO					084	088	086	088	088 - 8.00R MORE	36	7	36	100
2025-453	140	MISSION A					085	088	086	088	087 - 7.5	39	30	39	100
2025-453	140	MISSION A					085	088	086	088	088 - 8.00R MORE	39	9	39	100
2025-453	145	CLINITEK					086	088	086	088	087 - 7.5	42	13	42	100
2025-453	145	CLINITEK					086	088	086	088	088 - 8.00R MORE	42	29	42	100
2025-453	147	Mission120					085	088	086	088	086 - 7.0	37	1	37	100
2025-453	147	Mission120					085	088	086	088	087 - 7.5	37	28	37	100
2025-453	147	Mission120					085	088	086	088	088 - 8.00R MORE	37	8	37	100
2025-453	148	Mission500					085	088	086	088	086 - 7.0	138	3	138	100
2025-453	148	Mission500					085	088	086	088	087 - 7.5	138	69	138	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-453	148	Mission500			085	088	086	088		088 - 8.00R MORE	138	66	138	100
2025-453	151	Clari. Uro			085	088	086	088		087 - 7.5	24	21	24	100
2025-453	151	Clari. Uro			085	088	086	088		088 - 8.00R MORE	24	3	24	100
062 URINALYSIS-pH														
2025-454	011	AMES NM10S			082	086	080	084		082 - 5.0	32	6	32	100
2025-454	011	AMES NM10S			082	086	080	084		083 - 5.5	32	9	32	100
2025-454	011	AMES NM10S			082	086	080	084		084 - 6.0	32	17	32	100
2025-454	013	BAYER CLI			082	086	080	084		082 - 5.0	20	6	20	100
2025-454	013	BAYER CLI			082	086	080	084		083 - 5.5	20	6	20	100
2025-454	013	BAYER CLI			082	086	080	084		084 - 6.0	20	8	20	100
2025-454	067	URISCAN			080	084	080	084		082 - 5.0	55	48	55	100
2025-454	067	URISCAN			080	084	080	084		083 - 5.5	55	7	55	100
2025-454	072	URS-9-TECO			082	086	080	084		082 - 5.0	57	12	57	100
2025-454	072	URS-9-TECO			082	086	080	084		083 - 5.5	57	9	57	100
2025-454	072	URS-9-TECO			082	086	080	084		084 - 6.0	57	34	57	100
2025-454	072	URS-9-TECO			082	086	080	084		085 - 6.5	57	2	57	100
2025-454	080	ROCHE (CHE			080	084	080	084		082 - 5.0	36	32	36	100
2025-454	080	ROCHE (CHE			080	084	080	084		083 - 5.5	36	1	36	100
2025-454	080	ROCHE (CHE			080	084	080	084		084 - 6.0	36	3	36	100
2025-454	089	AIMSTRIP			082	086	080	084		082 - 5.0	154	30	154	100
2025-454	089	AIMSTRIP			082	086	080	084		083 - 5.5	154	34	154	100
2025-454	089	AIMSTRIP			082	086	080	084		084 - 6.0	154	90	154	100
2025-454	094	CLINITEK			082	086	080	084		082 - 5.0	108	16	108	100
2025-454	094	CLINITEK			082	086	080	084		083 - 5.5	108	27	108	100
2025-454	094	CLINITEK			082	086	080	084		084 - 6.0	108	65	108	100
2025-454	102	ACON LAB			082	086	080	084		082 - 5.0	120	31	120	100
2025-454	102	ACON LAB			082	086	080	084		083 - 5.5	120	18	120	100
2025-454	102	ACON LAB			082	086	080	084		084 - 6.0	120	71	120	100
2025-454	131	iCHEM VELO			080	084	080	084		082 - 5.0	36	36	36	100
2025-454	140	MISSION A			081	085	080	084		082 - 5.0	39	7	39	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 100 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-454	140	MISSION A			081	085	080	084		083 - 5.5	39	20	39	100
2025-454	140	MISSION A			081	085	080	084		084 - 6.0	39	12	39	100
2025-454	145	CLINITEK			081	085	080	084		082 - 5.0	42	13	42	100
2025-454	145	CLINITEK			081	085	080	084		083 - 5.5	42	29	42	100
2025-454	147	Mission120			081	085	080	084		082 - 5.0	37	12	37	100
2025-454	147	Mission120			081	085	080	084		083 - 5.5	37	21	37	100
2025-454	147	Mission120			081	085	080	084		084 - 6.0	37	4	37	100
2025-454	148	Mission500			082	086	080	084		082 - 5.0	138	1	138	100
2025-454	148	Mission500			082	086	080	084		083 - 5.5	138	6	138	100
2025-454	148	Mission500			082	086	080	084		084 - 6.0	138	130	138	100
2025-454	148	Mission500			082	086	080	084		085 - 6.5	138	1	138	100
2025-454	151	Clari. Uro			082	086	080	084		082 - 5.0	24	3	24	100
2025-454	151	Clari. Uro			082	086	080	084		083 - 5.5	24	4	24	100
2025-454	151	Clari. Uro			082	086	080	084		084 - 6.0	24	17	24	100
062 URINALYSIS-pH														
2025-455	011	AMES NM10S			086	088	086	088		087 - 7.5	32	4	32	100
2025-455	011	AMES NM10S			086	088	086	088		088 - 8.00R MORE	32	28	32	100
2025-455	013	BAYER CLI			086	088	086	088		087 - 7.5	20	1	20	100
2025-455	013	BAYER CLI			086	088	086	088		088 - 8.00R MORE	20	19	20	100
2025-455	067	URISCAN			086	088	086	088		086 - 7.0	55	1	55	100
2025-455	067	URISCAN			086	088	086	088		087 - 7.5	55	24	55	100
2025-455	067	URISCAN			086	088	086	088		088 - 8.00R MORE	55	30	55	100
2025-455	072	URS-9-TECO			086	088	086	088		086 - 7.0	57	4	57	100
2025-455	072	URS-9-TECO			086	088	086	088		087 - 7.5	57	23	57	100
2025-455	072	URS-9-TECO			086	088	086	088		088 - 8.00R MORE	57	30	57	100
2025-455	080	ROCHE (CHE			086	088	086	088		086 - 7.0	36	8	36	100
2025-455	080	ROCHE (CHE			086	088	086	088		088 - 8.00R MORE	36	28	36	100
2025-455	089	AIMSTRIP			086	088	086	088		084 - 6.0	154	1	153	0
2025-455	089	AIMSTRIP			086	088	086	088		087 - 7.5	154	17	153	100
2025-455	089	AIMSTRIP			086	088	086	088		088 - 8.00R MORE	154	136	153	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 101 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-455	094	CLINITEK			086	088	086	088		087 - 7.5	108	13	108	100
2025-455	094	CLINITEK			086	088	086	088		088 - 8.00R MORE	108	95	108	100
2025-455	102	ACON LAB			086	088	086	088		086 - 7.0	120	1	120	100
2025-455	102	ACON LAB			086	088	086	088		087 - 7.5	120	12	120	100
2025-455	102	ACON LAB			086	088	086	088		088 - 8.00R MORE	120	107	120	100
2025-455	131	iCHEM VELO			086	088	086	088		086 - 7.0	36	15	36	100
2025-455	131	iCHEM VELO			086	088	086	088		088 - 8.00R MORE	36	21	36	100
2025-455	140	MISSION A			086	088	086	088		087 - 7.5	39	6	39	100
2025-455	140	MISSION A			086	088	086	088		088 - 8.00R MORE	39	33	39	100
2025-455	145	CLINITEK			086	088	086	088		087 - 7.5	42	2	42	100
2025-455	145	CLINITEK			086	088	086	088		088 - 8.00R MORE	42	40	42	100
2025-455	147	Mission120			086	088	086	088		086 - 7.0	37	1	37	100
2025-455	147	Mission120			086	088	086	088		087 - 7.5	37	10	37	100
2025-455	147	Mission120			086	088	086	088		088 - 8.00R MORE	37	26	37	100
2025-455	148	Mission500			086	088	086	088		087 - 7.5	138	5	138	100
2025-455	148	Mission500			086	088	086	088		088 - 8.00R MORE	138	133	138	100
2025-455	151	Clari. Uro			086	088	086	088		087 - 7.5	24	3	24	100
2025-455	151	Clari. Uro			086	088	086	088		088 - 8.00R MORE	24	21	24	100
064 URIN-PROTEIN QUALI.														
2025-451	011	AMES NM10S			053	055	053	055		054 - 2+	33	20	32	100
2025-451	011	AMES NM10S			053	055	053	055		053 - 1+	33	1	32	100
2025-451	011	AMES NM10S			053	055	053	055		055 - 3+	33	11	32	100
2025-451	011	AMES NM10S			053	055	053	055		056 - 4+	33	1	32	0
2025-451	013	BAYER CLI			053	055	053	055		054 - 2+	20	14	20	100
2025-451	013	BAYER CLI			053	055	053	055		055 - 3+	20	6	20	100
2025-451	067	URISCAN			053	055	053	055		054 - 2+	56	35	56	100
2025-451	067	URISCAN			053	055	053	055		053 - 1+	56	21	56	100
2025-451	072	URS-9-TECO			053	055	053	055		054 - 2+	57	35	56	100
2025-451	072	URS-9-TECO			053	055	053	055		053 - 1+	57	8	56	100
2025-451	072	URS-9-TECO			053	055	053	055		055 - 3+	57	13	56	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 102 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-451	072	URS-9-TECO		053	055	053	055			056 - 4+	57	1	56	0
2025-451	080	ROCHE (CHE		053	055	053	055			054 - 2+	36	24	35	100
2025-451	080	ROCHE (CHE		053	055	053	055			055 - 3+	36	11	35	100
2025-451	080	ROCHE (CHE		053	055	053	055			056 - 4+	36	1	35	0
2025-451	089	AIMSTRIP		053	055	053	055			054 - 2+	152	120	151	100
2025-451	089	AIMSTRIP		053	055	053	055			051 - NEGATIVE	152	1	151	0
2025-451	089	AIMSTRIP		053	055	053	055			053 - 1+	152	7	151	100
2025-451	089	AIMSTRIP		053	055	053	055			055 - 3+	152	24	151	100
2025-451	094	CLINITEK		053	055	053	055			054 - 2+	108	91	108	100
2025-451	094	CLINITEK		053	055	053	055			053 - 1+	108	1	108	100
2025-451	094	CLINITEK		053	055	053	055			055 - 3+	108	16	108	100
2025-451	102	ACON LAB		053	055	053	055			054 - 2+	120	87	120	100
2025-451	102	ACON LAB		053	055	053	055			053 - 1+	120	7	120	100
2025-451	102	ACON LAB		053	055	053	055			055 - 3+	120	26	120	100
2025-451	131	iCHEM VELO		053	055	053	055			054 - 2+	36	31	36	100
2025-451	131	iCHEM VELO		053	055	053	055			055 - 3+	36	5	36	100
2025-451	140	MISSION A		053	055	053	055			054 - 2+	38	35	38	100
2025-451	140	MISSION A		053	055	053	055			055 - 3+	38	3	38	100
2025-451	145	CLINITEK		053	055	053	055			054 - 2+	42	32	41	100
2025-451	145	CLINITEK		053	055	053	055			055 - 3+	42	9	41	100
2025-451	145	CLINITEK		053	055	053	055			056 - 4+	42	1	41	0
2025-451	147	Mission120		053	055	053	055			054 - 2+	38	33	38	100
2025-451	147	Mission120		053	055	053	055			053 - 1+	38	4	38	100
2025-451	147	Mission120		053	055	053	055			055 - 3+	38	1	38	100
2025-451	148	Mission500		053	055	053	055			054 - 2+	139	116	139	100
2025-451	148	Mission500		053	055	053	055			053 - 1+	139	10	139	100
2025-451	148	Mission500		053	055	053	055			055 - 3+	139	13	139	100
2025-451	151	Clari. Uro		053	055	053	055			054 - 2+	24	21	24	100
2025-451	151	Clari. Uro		053	055	053	055			053 - 1+	24	2	24	100
2025-451	151	Clari. Uro		053	055	053	055			055 - 3+	24	1	24	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 103 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
064 URIN-PROTEIN QUALI.													
2025-452	011	AMES NM10S			053	055	053	055	054 - 2+	33	20	33	100
2025-452	011	AMES NM10S			053	055	053	055	055 - 3+	33	13	33	100
2025-452	013	BAYER CLI			053	055	053	055	054 - 2+	20	13	20	100
2025-452	013	BAYER CLI			053	055	053	055	055 - 3+	20	7	20	100
2025-452	067	URISCAN			053	055	053	055	054 - 2+	56	41	56	100
2025-452	067	URISCAN			053	055	053	055	053 - 1+	56	13	56	100
2025-452	067	URISCAN			053	055	053	055	055 - 3+	56	2	56	100
2025-452	072	URS-9-TECO			053	055	053	055	054 - 2+	57	33	55	100
2025-452	072	URS-9-TECO			053	055	053	055	051 - NEGATIVE	57	1	55	0
2025-452	072	URS-9-TECO			053	055	053	055	053 - 1+	57	1	55	100
2025-452	072	URS-9-TECO			053	055	053	055	055 - 3+	57	21	55	100
2025-452	072	URS-9-TECO			053	055	053	055	056 - 4+	57	1	55	0
2025-452	080	ROCHE (CHE			053	055	053	055	054 - 2+	36	25	35	100
2025-452	080	ROCHE (CHE			053	055	053	055	055 - 3+	36	10	35	100
2025-452	080	ROCHE (CHE			053	055	053	055	056 - 4+	36	1	35	0
2025-452	089	AIMSTRIP			053	055	053	055	054 - 2+	152	105	151	100
2025-452	089	AIMSTRIP			053	055	053	055	051 - NEGATIVE	152	1	151	0
2025-452	089	AIMSTRIP			053	055	053	055	053 - 1+	152	3	151	100
2025-452	089	AIMSTRIP			053	055	053	055	055 - 3+	152	43	151	100
2025-452	094	CLINITEK			053	055	053	055	054 - 2+	108	86	107	100
2025-452	094	CLINITEK			053	055	053	055	052 - TRACES	108	1	107	0
2025-452	094	CLINITEK			053	055	053	055	053 - 1+	108	2	107	100
2025-452	094	CLINITEK			053	055	053	055	055 - 3+	108	19	107	100
2025-452	102	ACON LAB			053	055	053	055	054 - 2+	120	85	120	100
2025-452	102	ACON LAB			053	055	053	055	053 - 1+	120	5	120	100
2025-452	102	ACON LAB			053	055	053	055	055 - 3+	120	30	120	100
2025-452	131	iCHEM VELO			053	055	053	055	054 - 2+	36	21	35	100
2025-452	131	iCHEM VELO			053	055	053	055	055 - 3+	36	14	35	100
2025-452	131	iCHEM VELO			053	055	053	055	056 - 4+	36	1	35	0

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-452	140	MISSION A		053	055	053	055			054 - 2+	38	31	38	100
2025-452	140	MISSION A		053	055	053	055			053 - 1+	38	2	38	100
2025-452	140	MISSION A		053	055	053	055			055 - 3+	38	5	38	100
2025-452	145	CLINITEK		053	055	053	055			054 - 2+	42	28	41	100
2025-452	145	CLINITEK		053	055	053	055			053 - 1+	42	1	41	100
2025-452	145	CLINITEK		053	055	053	055			055 - 3+	42	12	41	100
2025-452	145	CLINITEK		053	055	053	055			056 - 4+	42	1	41	0
2025-452	147	Mission120		053	055	053	055			054 - 2+	38	32	38	100
2025-452	147	Mission120		053	055	053	055			053 - 1+	38	4	38	100
2025-452	147	Mission120		053	055	053	055			055 - 3+	38	2	38	100
2025-452	148	Mission500		053	055	053	055			054 - 2+	139	98	138	100
2025-452	148	Mission500		053	055	053	055			051 - NEGATIVE	139	1	138	0
2025-452	148	Mission500		053	055	053	055			053 - 1+	139	7	138	100
2025-452	148	Mission500		053	055	053	055			055 - 3+	139	33	138	100
2025-452	151	Clari. Uro		053	055	053	055			054 - 2+	24	22	24	100
2025-452	151	Clari. Uro		053	055	053	055			055 - 3+	24	2	24	100
064 URIN-PROTEIN QUALI.														
2025-453	011	AMES NM10S		051	051	051	051			051 - NEGATIVE	33	32	32	100
2025-453	011	AMES NM10S		051	051	051	051			052 - TRACES	33	1	32	0
2025-453	013	BAYER CLI		051	051	051	051			051 - NEGATIVE	20	20	20	100
2025-453	067	URISCAN		051	051	051	051			051 - NEGATIVE	56	55	55	100
2025-453	067	URISCAN		051	051	051	051			052 - TRACES	56	1	55	0
2025-453	072	URS-9-TECO		051	051	051	051			051 - NEGATIVE	57	57	57	100
2025-453	080	ROCHE (CHE				051	051			051 - NEGATIVE	36	28	28	100
2025-453	080	ROCHE (CHE				051	051			052 - TRACES	36	6	28	0
2025-453	080	ROCHE (CHE				051	051			053 - 1+	36	2	28	0
2025-453	089	AIMSTRIP		051	051	051	051			051 - NEGATIVE	152	148	148	100
2025-453	089	AIMSTRIP		051	051	051	051			052 - TRACES	152	4	148	0
2025-453	094	CLINITEK		051	051	051	051			051 - NEGATIVE	108	108	108	100
2025-453	102	ACON LAB		051	051	051	051			051 - NEGATIVE	120	119	119	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 105 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-453	102	ACON LAB			051	051	051	051	052 - TRACES	120	1	119	0
2025-453	131	iCHEM VELO			051	051	051	051	051 - NEGATIVE	36	36	36	100
2025-453	140	MISSION A			051	051	051	051	051 - NEGATIVE	38	38	38	100
2025-453	145	CLINITEK			051	051	051	051	051 - NEGATIVE	42	42	42	100
2025-453	147	Mission120			051	051	051	051	051 - NEGATIVE	38	38	38	100
2025-453	148	Mission500			051	051	051	051	054 - 2+	139	1	132	0
2025-453	148	Mission500			051	051	051	051	051 - NEGATIVE	139	132	132	100
2025-453	148	Mission500			051	051	051	051	052 - TRACES	139	4	132	0
2025-453	148	Mission500			051	051	051	051	053 - 1+	139	1	132	0
2025-453	148	Mission500			051	051	051	051	055 - 3+	139	1	132	0
2025-453	151	Clari. Uro			051	051	051	051	051 - NEGATIVE	24	24	24	100
064 URIN-PROTEIN QUALI.													
2025-454	011	AMES NM10S			051	051	051	051	051 - NEGATIVE	33	33	33	100
2025-454	013	BAYER CLI			051	051	051	051	051 - NEGATIVE	20	20	20	100
2025-454	067	URISCAN			051	051	051	051	051 - NEGATIVE	56	56	56	100
2025-454	072	URS-9-TECO			051	051	051	051	051 - NEGATIVE	57	57	57	100
2025-454	080	ROCHE (CHE			051	051	051	051	051 - NEGATIVE	36	36	36	100
2025-454	089	AIMSTRIP			051	051	051	051	051 - NEGATIVE	152	152	152	100
2025-454	094	CLINITEK			051	051	051	051	051 - NEGATIVE	108	108	108	100
2025-454	102	ACON LAB			051	051	051	051	051 - NEGATIVE	120	120	120	100
2025-454	131	iCHEM VELO			051	051	051	051	051 - NEGATIVE	36	36	36	100
2025-454	140	MISSION A			051	051	051	051	051 - NEGATIVE	38	38	38	100
2025-454	145	CLINITEK			051	051	051	051	051 - NEGATIVE	42	42	42	100
2025-454	147	Mission120			051	051	051	051	051 - NEGATIVE	38	38	38	100
2025-454	148	Mission500			051	051	051	051	051 - NEGATIVE	139	139	139	100
2025-454	151	Clari. Uro			051	051	051	051	051 - NEGATIVE	24	24	24	100
2025-455	011	AMES NM10S			053	055	054	056	054 - 2+	33	20	33	100
2025-455	011	AMES NM10S			053	055	054	056	055 - 3+	33	13	33	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 106 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS				
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-455	013	BAYER CLI			053	055	054 056	054 - 2+	20	13	20	100
2025-455	013	BAYER CLI			053	055	054 056	055 - 3+	20	7	20	100
2025-455	067	URISCAN			053	055	054 056	054 - 2+	56	44	56	100
2025-455	067	URISCAN			053	055	054 056	053 - 1+	56	5	56	100
2025-455	067	URISCAN			053	055	054 056	055 - 3+	56	7	56	100
2025-455	072	URS-9-TECO			054	056	054 056	054 - 2+	57	22	57	100
2025-455	072	URS-9-TECO			054	056	054 056	055 - 3+	57	32	57	100
2025-455	072	URS-9-TECO			054	056	054 056	056 - 4+	57	3	57	100
2025-455	080	ROCHE (CHE			053	055	054 056	054 - 2+	36	22	36	100
2025-455	080	ROCHE (CHE			053	055	054 056	053 - 1+	36	1	36	100
2025-455	080	ROCHE (CHE			053	055	054 056	055 - 3+	36	12	36	100
2025-455	080	ROCHE (CHE			053	055	054 056	056 - 4+	36	1	36	100
2025-455	089	AIMSTRIP			054	056	054 056	054 - 2+	152	69	150	100
2025-455	089	AIMSTRIP			054	056	054 056	053 - 1+	152	2	150	0
2025-455	089	AIMSTRIP			054	056	054 056	055 - 3+	152	81	150	100
2025-455	094	CLINITEK			053	055	054 056	054 - 2+	108	84	108	100
2025-455	094	CLINITEK			053	055	054 056	053 - 1+	108	1	108	100
2025-455	094	CLINITEK			053	055	054 056	055 - 3+	108	23	108	100
2025-455	102	ACON LAB			054	056	054 056	054 - 2+	120	55	115	100
2025-455	102	ACON LAB			054	056	054 056	051 - NEGATIVE	120	1	115	0
2025-455	102	ACON LAB			054	056	054 056	053 - 1+	120	4	115	0
2025-455	102	ACON LAB			054	056	054 056	055 - 3+	120	60	115	100
2025-455	131	iCHEM VELO			054	056	054 056	054 - 2+	36	15	35	100
2025-455	131	iCHEM VELO			054	056	054 056	053 - 1+	36	1	35	0
2025-455	131	iCHEM VELO			054	056	054 056	055 - 3+	36	19	35	100
2025-455	131	iCHEM VELO			054	056	054 056	056 - 4+	36	1	35	100
2025-455	140	MISSION A			053	055	054 056	054 - 2+	38	28	38	100
2025-455	140	MISSION A			053	055	054 056	055 - 3+	38	10	38	100
2025-455	145	CLINITEK			054	056	054 056	054 - 2+	42	4	42	100
2025-455	145	CLINITEK			054	056	054 056	055 - 3+	42	36	42	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS								
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-455	145	CLINITEK					054	056	054	056	056 - 4+	42	2	42	100
2025-455	147	Mission120					053	055	054	056	054 - 2+	38	32	38	100
2025-455	147	Mission120					053	055	054	056	053 - 1+	38	3	38	100
2025-455	147	Mission120					053	055	054	056	055 - 3+	38	3	38	100
2025-455	148	Mission500					054	056	054	056	054 - 2+	139	57	136	100
2025-455	148	Mission500					054	056	054	056	051 - NEGATIVE	139	1	136	0
2025-455	148	Mission500					054	056	054	056	053 - 1+	139	2	136	0
2025-455	148	Mission500					054	056	054	056	055 - 3+	139	77	136	100
2025-455	148	Mission500					054	056	054	056	056 - 4+	139	2	136	100
2025-455	151	Clari. Uro					053	055	054	056	054 - 2+	24	19	24	100
2025-455	151	Clari. Uro					053	055	054	056	055 - 3+	24	5	24	100
066 URINAL.-UROBILINOGEN															
2025-451	011	AMES NM10S					061	061	061	061	061 - NORMAL, NEG	32	32	32	100
2025-451	013	BAYER CLI					061	061	061	061	061 - NORMAL, NEG	20	20	20	100
2025-451	067	URISCAN					061	061	061	061	061 - NORMAL, NEG	55	55	55	100
2025-451	072	URS-9-TECO					061	061	061	061	061 - NORMAL, NEG	57	57	57	100
2025-451	080	ROCHE (CHE					061	061	061	061	061 - NORMAL, NEG	36	36	36	100
2025-451	089	AIMSTRIP					061	061	061	061	061 - NORMAL, NEG	153	151	151	100
2025-451	089	AIMSTRIP					061	061	061	061	062 - 2	153	2	151	0
2025-451	094	CLINITEK					061	061	061	061	061 - NORMAL, NEG	108	108	108	100
2025-451	102	ACON LAB					061	061	061	061	061 - NORMAL, NEG	118	118	118	100
2025-451	131	iCHEM VELO					061	061	061	061	061 - NORMAL, NEG	36	36	36	100
2025-451	140	MISSION A					061	061	061	061	061 - NORMAL, NEG	37	37	37	100
2025-451	145	CLINITEK					061	061	061	061	061 - NORMAL, NEG	42	42	42	100
2025-451	147	Mission120					061	061	061	061	061 - NORMAL, NEG	38	37	37	100
2025-451	147	Mission120					061	061	061	061	062 - 2	38	1	37	0
2025-451	148	Mission500					061	061	061	061	061 - NORMAL, NEG	140	140	140	100
2025-451	151	Clari. Uro					061	061	061	061	061 - NORMAL, NEG	24	24	24	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 108 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
066 URINAL.-UROBILINOGEN													
2025-452	011	AMES NM10S			061	061	061	061	061 - NORMAL, NEG	32	32	32	100
2025-452	013	BAYER CLI			061	061	061	061	061 - NORMAL, NEG	20	20	20	100
2025-452	067	URISCAN			061	061	061	061	061 - NORMAL, NEG	55	55	55	100
2025-452	072	URS-9-TECO			061	061	061	061	061 - NORMAL, NEG	57	57	57	100
2025-452	080	ROCHE (CHE			061	061	061	061	061 - NORMAL, NEG	36	36	36	100
2025-452	089	AIMSTRIP			061	061	061	061	061 - NORMAL, NEG	153	151	151	100
2025-452	089	AIMSTRIP			061	061	061	061	062 - 2	153	2	151	0
2025-452	094	CLINITEK			061	061	061	061	061 - NORMAL, NEG	108	108	108	100
2025-452	102	ACON LAB			061	061	061	061	061 - NORMAL, NEG	118	118	118	100
2025-452	131	iCHEM VELO			061	061	061	061	061 - NORMAL, NEG	36	36	36	100
2025-452	140	MISSION A			061	061	061	061	061 - NORMAL, NEG	37	37	37	100
2025-452	145	CLINITEK			061	061	061	061	061 - NORMAL, NEG	42	42	42	100
2025-452	147	Mission120			061	061	061	061	061 - NORMAL, NEG	38	37	37	100
2025-452	147	Mission120			061	061	061	061	062 - 2	38	1	37	0
2025-452	148	Mission500			061	061	061	061	061 - NORMAL, NEG	140	140	140	100
2025-452	151	Clari. Uro			061	061	061	061	061 - NORMAL, NEG	24	24	24	100
2025-453	011	AMES NM10S			061	061	061	061	061 - NORMAL, NEG	32	32	32	100
2025-453	013	BAYER CLI			061	061	061	061	061 - NORMAL, NEG	20	20	20	100
2025-453	067	URISCAN			061	061	061	061	061 - NORMAL, NEG	55	55	55	100
2025-453	072	URS-9-TECO			061	061	061	061	061 - NORMAL, NEG	57	57	57	100
2025-453	080	ROCHE (CHE			061	061	061	061	061 - NORMAL, NEG	36	36	36	100
2025-453	089	AIMSTRIP			061	061	061	061	061 - NORMAL, NEG	153	151	151	100
2025-453	089	AIMSTRIP			061	061	061	061	062 - 2	153	2	151	0
2025-453	094	CLINITEK			061	061	061	061	061 - NORMAL, NEG	108	108	108	100
2025-453	102	ACON LAB			061	061	061	061	061 - NORMAL, NEG	118	118	118	100
2025-453	131	iCHEM VELO			061	061	061	061	061 - NORMAL, NEG	36	36	36	100
2025-453	140	MISSION A			061	061	061	061	061 - NORMAL, NEG	37	37	37	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 109 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-453	145	CLINITEK			061	061	061	061	061 - NORMAL, NEG	42	42	42	100
2025-453	147	Mission120			061	061	061	061	061 - NORMAL, NEG	38	37	37	100
2025-453	147	Mission120			061	061	061	061	062 - 2	38	1	37	0
2025-453	148	Mission500			061	061	061	061	061 - NORMAL, NEG	140	139	139	100
2025-453	148	Mission500			061	061	061	061	064 - 8	140	1	139	0
2025-453	151	Clari. Uro			061	061	061	061	061 - NORMAL, NEG	24	24	24	100
066 URINAL. -UROBILINOGEN													
2025-454	011	AMES NM10S			061	061	061	061	061 - NORMAL, NEG	32	32	32	100
2025-454	013	BAYER CLI			061	061	061	061	061 - NORMAL, NEG	20	20	20	100
2025-454	067	URISCAN			061	061	061	061	061 - NORMAL, NEG	55	55	55	100
2025-454	072	URS-9-TECO			061	061	061	061	061 - NORMAL, NEG	57	57	57	100
2025-454	080	ROCHE (CHE			061	061	061	061	061 - NORMAL, NEG	36	36	36	100
2025-454	089	AIMSTRIP			061	061	061	061	061 - NORMAL, NEG	153	151	151	100
2025-454	089	AIMSTRIP			061	061	061	061	062 - 2	153	2	151	0
2025-454	094	CLINITEK			061	061	061	061	061 - NORMAL, NEG	108	108	108	100
2025-454	102	ACON LAB			061	061	061	061	061 - NORMAL, NEG	118	118	118	100
2025-454	131	iCHEM VELO			061	061	061	061	061 - NORMAL, NEG	36	36	36	100
2025-454	140	MISSION A			061	061	061	061	061 - NORMAL, NEG	37	37	37	100
2025-454	145	CLINITEK			061	061	061	061	061 - NORMAL, NEG	42	41	41	100
2025-454	145	CLINITEK			061	061	061	061	062 - 2	42	1	41	0
2025-454	147	Mission120			061	061	061	061	061 - NORMAL, NEG	38	37	37	100
2025-454	147	Mission120			061	061	061	061	062 - 2	38	1	37	0
2025-454	148	Mission500			061	061	061	061	061 - NORMAL, NEG	140	140	140	100
2025-454	151	Clari. Uro			061	061	061	061	061 - NORMAL, NEG	24	24	24	100
2025-455	011	AMES NM10S			062	064	061	063	061 - NORMAL, NEG	32	2	32	100
2025-455	011	AMES NM10S			062	064	061	063	062 - 2	32	14	32	100
2025-455	011	AMES NM10S			062	064	061	063	063 - 4	32	16	32	100
2025-455	013	BAYER CLI			061	063	061	063	061 - NORMAL, NEG	20	5	20	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS								
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-455	013	BAYER CLI				061 063	061 063				062 - 2	20	8	20	100
2025-455	013	BAYER CLI				061 063	061 063				063 - 4	20	7	20	100
2025-455	067	URISCAN				062 064	061 063				061 - NORMAL, NEG	55	11	55	100
2025-455	067	URISCAN				062 064	061 063				062 - 2	55	3	55	100
2025-455	067	URISCAN				062 064	061 063				063 - 4	55	33	55	100
2025-455	067	URISCAN				062 064	061 063				064 - 8	55	8	55	100
2025-455	072	URS-9-TECO				061 063	061 063				061 - NORMAL, NEG	57	8	57	100
2025-455	072	URS-9-TECO				061 063	061 063				062 - 2	57	30	57	100
2025-455	072	URS-9-TECO				061 063	061 063				063 - 4	57	19	57	100
2025-455	080	ROCHE (CHE				061 061	061 063				061 - NORMAL, NEG	36	33	36	100
2025-455	080	ROCHE (CHE				061 061	061 063				062 - 2	36	3	36	100
2025-455	089	AIMSTRIP				061 061	061 063				061 - NORMAL, NEG	153	124	152	100
2025-455	089	AIMSTRIP				061 061	061 063				062 - 2	153	22	152	100
2025-455	089	AIMSTRIP				061 061	061 063				063 - 4	153	6	152	100
2025-455	089	AIMSTRIP				061 061	061 063				064 - 8	153	1	152	0
2025-455	094	CLINITEK				062 064	061 063				061 - NORMAL, NEG	108	8	108	100
2025-455	094	CLINITEK				062 064	061 063				062 - 2	108	39	108	100
2025-455	094	CLINITEK				062 064	061 063				063 - 4	108	58	108	100
2025-455	094	CLINITEK				062 064	061 063				064 - 8	108	3	108	100
2025-455	102	ACON LAB					061 063				061 - NORMAL, NEG	118	80	118	100
2025-455	102	ACON LAB					061 063				062 - 2	118	29	118	100
2025-455	102	ACON LAB					061 063				063 - 4	118	9	118	100
2025-455	131	iCHEM VELO				062 064	061 063				062 - 2	36	1	36	100
2025-455	131	iCHEM VELO				062 064	061 063				063 - 4	36	35	36	100
2025-455	140	MISSION A					061 063				061 - NORMAL, NEG	37	29	37	100
2025-455	140	MISSION A					061 063				062 - 2	37	6	37	100
2025-455	140	MISSION A					061 063				063 - 4	37	2	37	100
2025-455	145	CLINITEK				061 063	061 063				061 - NORMAL, NEG	42	1	42	100
2025-455	145	CLINITEK				061 063	061 063				062 - 2	42	41	42	100
2025-455	147	Mission120				061 061	061 063				061 - NORMAL, NEG	38	36	38	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-455	147	Mission120			061 061	061 063		062 - 2	38	2	38	100
2025-455	148	Mission500			061 061	061 063		061 - NORMAL,NEG	140	133	138	100
2025-455	148	Mission500			061 061	061 063		062 - 2	140	3	138	100
2025-455	148	Mission500			061 061	061 063		063 - 4	140	2	138	100
2025-455	148	Mission500			061 061	061 063		064 - 8	140	2	138	0
2025-455	151	Clari. Uro				061 063		061 - NORMAL,NEG	24	17	24	100
2025-455	151	Clari. Uro				061 063		062 - 2	24	4	24	100
2025-455	151	Clari. Uro				061 063		063 - 4	24	3	24	100
184 URINALYSIS LEUKOCYTE												
2025-451	011	AMES NM10S			001 001	001 001		001 - Negative	34	34	34	100
2025-451	013	BAYER CLI			001 001	001 001		001 - Negative	20	20	20	100
2025-451	067	URISCAN			001 001	001 001		001 - Negative	55	55	55	100
2025-451	072	URS-9-TECO			001 001	001 001		001 - Negative	53	53	53	100
2025-451	080	ROCHE (CHE			001 001	001 001		001 - Negative	33	33	33	100
2025-451	089	AIMSTRIP			001 001	001 001		001 - Negative	150	148	148	100
2025-451	089	AIMSTRIP			001 001	001 001		003 - Small	150	1	148	0
2025-451	089	AIMSTRIP			001 001	001 001		004 - Moderate	150	1	148	0
2025-451	094	CLINITEK			001 001	001 001		001 - Negative	107	107	107	100
2025-451	102	ACON LAB			001 001	001 001		001 - Negative	114	114	114	100
2025-451	131	iCHEM VELO			001 001	001 001		001 - Negative	36	36	36	100
2025-451	140	MISSION A			001 001	001 001		001 - Negative	41	41	41	100
2025-451	145	CLINITEK			001 001	001 001		001 - Negative	40	40	40	100
2025-451	147	Mission120			001 001	001 001		001 - Negative	37	37	37	100
2025-451	148	Mission500			001 001	001 001		001 - Negative	141	141	141	100
2025-451	151	Clari. Uro			001 001	001 001		001 - Negative	24	24	24	100
2025-452	011	AMES NM10S			001 001	001 001		001 - Negative	34	34	34	100
2025-452	013	BAYER CLI			001 001	001 001		001 - Negative	20	20	20	100
2025-452	067	URISCAN			001 001	001 001		001 - Negative	55	55	55	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 112 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-452	072	URS-9-TECO			001 001	001 001		001 - Negative	53	53	53	100
2025-452	080	ROCHE (CHE			001 001	001 001		001 - Negative	33	33	33	100
2025-452	089	AIMSTRIP			001 001	001 001		001 - Negative	150	150	150	100
2025-452	094	CLINITEK			001 001	001 001		001 - Negative	107	107	107	100
2025-452	102	ACON LAB			001 001	001 001		001 - Negative	114	114	114	100
2025-452	131	iCHEM VELO			001 001	001 001		001 - Negative	36	36	36	100
2025-452	140	MISSION A			001 001	001 001		001 - Negative	41	41	41	100
2025-452	145	CLINITEK			001 001	001 001		001 - Negative	40	40	40	100
2025-452	147	Mission120			001 001	001 001		001 - Negative	37	37	37	100
2025-452	148	Mission500			001 001	001 001		001 - Negative	141	141	141	100
2025-452	151	Clari. Uro			001 001	001 001		001 - Negative	24	24	24	100
184 URINALYSIS LEUKOCYTE												
2025-453	011	AMES NM10S			001 001	001 001		001 - Negative	34	34	34	100
2025-453	013	BAYER CLI			001 001	001 001		001 - Negative	20	20	20	100
2025-453	067	URISCAN			001 001	001 001		001 - Negative	55	55	55	100
2025-453	072	URS-9-TECO			001 001	001 001		001 - Negative	53	53	53	100
2025-453	080	ROCHE (CHE			001 001	001 001		001 - Negative	33	33	33	100
2025-453	089	AIMSTRIP			001 001	001 001		001 - Negative	150	150	150	100
2025-453	094	CLINITEK			001 001	001 001		001 - Negative	107	107	107	100
2025-453	102	ACON LAB			001 001	001 001		001 - Negative	114	114	114	100
2025-453	131	iCHEM VELO			001 001	001 001		001 - Negative	36	36	36	100
2025-453	140	MISSION A			001 001	001 001		001 - Negative	41	41	41	100
2025-453	145	CLINITEK			001 001	001 001		001 - Negative	40	40	40	100
2025-453	147	Mission120			001 001	001 001		001 - Negative	37	37	37	100
2025-453	148	Mission500			001 001	001 001		001 - Negative	141	140	140	100
2025-453	148	Mission500			001 001	001 001		005 - Large	141	1	140	0
2025-453	151	Clari. Uro			001 001	001 001		001 - Negative	24	24	24	100
2025-454	011	AMES NM10S			002 004	003 005		002 - Traces	34	1	34	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-454	011	AMES NM10S		002	004	003	005			003 - Small	34	29	34	100
2025-454	011	AMES NM10S		002	004	003	005			004 - Moderate	34	4	34	100
2025-454	013	BAYER CLI		002	004	003	005			003 - Small	20	19	20	100
2025-454	013	BAYER CLI		002	004	003	005			004 - Moderate	20	1	20	100
2025-454	067	URISCAN		004	005	003	005			001 - Negative	55	1	54	0
2025-454	067	URISCAN		004	005	003	005			003 - Small	55	5	54	100
2025-454	067	URISCAN		004	005	003	005			004 - Moderate	55	24	54	100
2025-454	067	URISCAN		004	005	003	005			005 - Large	55	25	54	100
2025-454	072	URS-9-TECO		002	004	003	005			003 - Small	53	38	53	100
2025-454	072	URS-9-TECO		002	004	003	005			004 - Moderate	53	15	53	100
2025-454	080	ROCHE (CHE		004	005	003	005			004 - Moderate	33	2	33	100
2025-454	080	ROCHE (CHE		004	005	003	005			005 - Large	33	31	33	100
2025-454	089	AIMSTRIP		002	004	003	005			002 - Traces	150	46	150	100
2025-454	089	AIMSTRIP		002	004	003	005			003 - Small	150	93	150	100
2025-454	089	AIMSTRIP		002	004	003	005			004 - Moderate	150	11	150	100
2025-454	094	CLINITEK		002	004	003	005			002 - Traces	107	4	107	100
2025-454	094	CLINITEK		002	004	003	005			003 - Small	107	98	107	100
2025-454	094	CLINITEK		002	004	003	005			004 - Moderate	107	5	107	100
2025-454	102	ACON LAB		002	004	003	005			001 - Negative	114	1	113	0
2025-454	102	ACON LAB		002	004	003	005			002 - Traces	114	9	113	100
2025-454	102	ACON LAB		002	004	003	005			003 - Small	114	65	113	100
2025-454	102	ACON LAB		002	004	003	005			004 - Moderate	114	37	113	100
2025-454	102	ACON LAB		002	004	003	005			005 - Large	114	2	113	100
2025-454	131	iCHEM VELO		004	005	003	005			004 - Moderate	36	2	36	100
2025-454	131	iCHEM VELO		004	005	003	005			005 - Large	36	34	36	100
2025-454	140	MISSION A		002	004	003	005			001 - Negative	41	1	40	0
2025-454	140	MISSION A		002	004	003	005			002 - Traces	41	5	40	100
2025-454	140	MISSION A		002	004	003	005			003 - Small	41	24	40	100
2025-454	140	MISSION A		002	004	003	005			004 - Moderate	41	11	40	100
2025-454	145	CLINITEK		003	005	003	005			004 - Moderate	40	40	40	100

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-454	147	Mission120			002 004	003 005		002 - Traces	37	11	37	100
2025-454	147	Mission120			002 004	003 005		003 - Small	37	24	37	100
2025-454	147	Mission120			002 004	003 005		004 - Moderate	37	2	37	100
2025-454	148	Mission500			002 004	003 005		002 - Traces	141	20	141	100
2025-454	148	Mission500			002 004	003 005		003 - Small	141	82	141	100
2025-454	148	Mission500			002 004	003 005		004 - Moderate	141	39	141	100
2025-454	151	Clari. Uro			002 004	003 005		002 - Traces	24	1	24	100
2025-454	151	Clari. Uro			002 004	003 005		003 - Small	24	15	24	100
2025-454	151	Clari. Uro			002 004	003 005		004 - Moderate	24	8	24	100
184 URINALYSIS LEUKOCYTE												
2025-455	011	AMES NM10S			001 001	001 001		001 - Negative	34	34	34	100
2025-455	013	BAYER CLI			001 001	001 001		001 - Negative	20	20	20	100
2025-455	067	URISCAN			001 001	001 001		001 - Negative	55	53	53	100
2025-455	067	URISCAN			001 001	001 001		002 - Traces	55	1	53	0
2025-455	067	URISCAN			001 001	001 001		005 - Large	55	1	53	0
2025-455	072	URS-9-TECO			001 001	001 001		001 - Negative	53	53	53	100
2025-455	080	ROCHE (CHE			001 001	001 001		001 - Negative	33	33	33	100
2025-455	089	AIMSTRIP			001 001	001 001		001 - Negative	150	150	150	100
2025-455	094	CLINITEK			001 001	001 001		001 - Negative	107	107	107	100
2025-455	102	ACON LAB			001 001	001 001		001 - Negative	114	114	114	100
2025-455	131	iCHEM VELO			001 001	001 001		001 - Negative	36	34	34	100
2025-455	131	iCHEM VELO			001 001	001 001		002 - Traces	36	2	34	0
2025-455	140	MISSION A			001 001	001 001		001 - Negative	41	40	40	100
2025-455	140	MISSION A			001 001	001 001		003 - Small	41	1	40	0
2025-455	145	CLINITEK			001 001	001 001		001 - Negative	40	40	40	100
2025-455	147	Mission120			001 001	001 001		001 - Negative	37	37	37	100
2025-455	148	Mission500			001 001	001 001		001 - Negative	141	140	140	100
2025-455	148	Mission500			001 001	001 001		005 - Large	141	1	140	0
2025-455	151	Clari. Uro			001 001	001 001		001 - Negative	24	24	24	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 115 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary**MONTH 5 OF YEAR 2025**

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 80 PREGNANCY TEST						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
063 URI-PREGNANCY TEST														
2025-451	091	AIM STEP				001	001	001	001	001 - NEGATIVE	34	34	34	100
2025-451	101	HCG Alere				001	001	001	001	001 - NEGATIVE	24	24	24	100
2025-452	091	AIM STEP				002	002	002	002	002 - POSITIVE	34	34	34	100
2025-452	101	HCG Alere				002	002	002	002	002 - POSITIVE	24	24	24	100
2025-453	091	AIM STEP				001	001	001	001	001 - NEGATIVE	34	34	34	100
2025-453	101	HCG Alere				001	001	001	001	001 - NEGATIVE	24	24	24	100
2025-454	091	AIM STEP				001	001	001	001	001 - NEGATIVE	34	34	34	100
2025-454	101	HCG Alere				001	001	001	001	001 - NEGATIVE	24	24	24	100
2025-455	091	AIM STEP				002	002	002	002	002 - POSITIVE	34	34	34	100
2025-455	101	HCG Alere				002	002	002	002	002 - POSITIVE	24	24	24	100

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 116 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS			GRP: 75 URINALYSIS SEDIMENT						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
150 URINAL.- SEDIMENT											
2025-461					037 037		012 - TRANSITIO.	914	1	912	0
2025-461					037 037		037 - SPERMATOZ.	914	912	912	100
2025-461					037 037		038 - YEAST/FUN.	914	1	912	0
2025-462					027 027		003 - GRANULAR C	914	1	905	0
2025-462					027 027		015 - CA. SULFAT	914	2	905	0
2025-462					027 027		022 - TYROSINE	914	4	905	0
2025-462					027 027		027 - CA. PHOSP.	914	905	905	100
2025-462					027 027		028 - TRIPLE PH.	914	2	905	0
2025-463					012 012		009 - LEUKOCYTE	914	2	874	0
2025-463					012 012		010 - RENAL TUB.	914	35	874	0
2025-463					012 012		012 - TRANSITIO.	914	874	874	100
2025-463					012 012		033 - OVAL FAT B	914	1	874	0
2025-463					012 012		037 - SPERMATOZ.	914	1	874	0
2025-463					012 012		042 - WBC in clu	914	1	874	0
2025-464					003 003		002 - FATTY CAST	914	1	887	0
2025-464					003 003		003 - GRANULAR C	914	887	887	100
2025-464					003 003		005 - RED CELL C	914	24	887	0
2025-464					003 003		027 - CA. PHOSP.	914	1	887	0
2025-464					003 003		039 - E. vermic.	914	1	887	0
2025-465					039 039		039 - E. vermic.	914	913	913	100
2025-465					039 039		040 - S. haemat.	914	1	913	0

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 117 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS				GRP: 98 OCCULT BLOOD							
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH	REFeree LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
154 FECAL OCCULT BLOOD														
2025-471	001	PEROXIDASE			001	001	001	001		001 - NEGATIVE	352	352	352	100
2025-471	002	INMMUASSAY			001	001	001	001		001 - NEGATIVE	757	757	757	100
2025-472	001	PEROXIDASE			002	002	002	002		002 - POSITIVE	352	352	352	100
2025-472	002	INMMUASSAY			002	002	002	002		001 - NEGATIVE	757	1	756	0
2025-472	002	INMMUASSAY			002	002	002	002		002 - POSITIVE	757	756	756	100
2025-473	001	PEROXIDASE			002	002	002	002		002 - POSITIVE	352	352	352	100
2025-473	002	INMMUASSAY			002	002	002	002		001 - NEGATIVE	757	3	754	0
2025-473	002	INMMUASSAY			002	002	002	002		002 - POSITIVE	757	754	754	100
2025-474	001	PEROXIDASE			001	001	001	001		001 - NEGATIVE	352	352	352	100
2025-474	002	INMMUASSAY			001	001	001	001		001 - NEGATIVE	757	756	756	100
2025-474	002	INMMUASSAY			001	001	001	001		002 - POSITIVE	757	1	756	0
2025-475	001	PEROXIDASE			002	002	002	002		002 - POSITIVE	352	352	352	100
2025-475	002	INMMUASSAY			002	002	002	002		001 - NEGATIVE	757	1	756	0
2025-475	002	INMMUASSAY			002	002	002	002		002 - POSITIVE	757	756	756	100

SPEC: 10 CHEMISTRY				SUB: 60 SPECIAL TESTS				GRP: 90 SPECIAL TEST						
ANALYTE									NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE		METHOD		SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
068 CARCINOE. ANTIG. CEA				CLIA TEST ID #: 352		EVALUATION CRITERIA: TARGET VALUE 15 % OR 1.00 {GREATER}								
2025-421		38 ROCHE E						18	14.778	0.635	4.29	12.600	17.000	

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-421	44	BECK.COUL.				20	18.515	1.085	5.86	15.700	21.300
2025-421	50	ARC				10	17.320	0.938	5.41	14.700	19.900
2025-421	58	ATELLICA				10	17.071	0.636	3.73	14.500	19.600
068 CARCINOE. ANTIG. CEA			CLIA TEST ID #: 352	EVALUATION CRITERIA: TARGET VALUE 15 % OR 1.00 {GREATER}							
2025-422	38	ROCHE E				18	27.939	1.270	4.54	23.700	32.100
2025-422	44	BECK.COUL.				20	36.525	1.596	4.37	31.000	42.000
2025-422	50	ARC				10	33.770	1.811	5.36	28.700	38.800
2025-422	58	ATELLICA				10	32.043	1.083	3.38	27.200	36.800
2025-423	38	ROCHE E				18	1.833	0.100	5.45	0.800	2.800
2025-423	44	BECK.COUL.				20	1.750	0.136	7.77	0.800	2.800
2025-423	50	ARC				10	1.950	0.092	4.73	1.000	3.000
2025-423	58	ATELLICA				10	1.086	0.422	38.90	0.100	2.100
2025-424	38	ROCHE E				18	0.867	0.075	8.60	0	1.900
2025-424	44	BECK.COUL.				20	0.710	0.044	6.14	0	1.700
2025-424	50	ARC				10	1.170	0.438	37.46	0.200	2.200
2025-424	58	ATELLICA				10	0.829	0.420	50.68	0	1.800
2025-425	38	ROCHE E				18	21.294	0.951	4.47	18.100	24.500
2025-425	44	BECK.COUL.				20	27.350	1.721	6.29	23.200	31.500
2025-425	50	ARC				10	25.040	1.754	7.00	21.300	28.800
2025-425	58	ATELLICA				10	24.629	0.848	3.44	20.900	28.300
069 PROS. SPEC-ANTIG-PSA			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}							
2025-421	29	VITROS				44	7.677	0.337	4.39	6.100	9.200
2025-421	38	ROCHE E				53	14.423	0.829	5.75	11.500	17.300
2025-421	44	BECK.COUL.				48	14.057	0.616	4.38	11.200	16.900
2025-421	50	ARC				21	13.124	1.020	7.77	10.500	15.700
2025-421	57	S. EXL 200				54	14.734	0.675	4.58	11.800	17.700
2025-421	58	ATELLICA				20	13.570	0.836	6.16	10.900	16.300

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
069	PROS. SPEC-ANTIG-PSA	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}							
2025-422	29 VITROS			44	14.455	0.670	4.64	11.600	17.300	
2025-422	38 ROCHE E			53	27.428	1.619	5.90	21.900	32.900	
2025-422	44 BECK.COUL.			48	26.264	1.312	5.00	21.000	31.500	
2025-422	50 ARC			21	25.281	1.697	6.71	20.200	30.300	
2025-422	57 S. EXL 200			54	28.294	1.594	5.63	22.600	34.000	
2025-422	58 ATELLICA			20	25.125	1.508	6.00	20.100	30.200	
2025-423	29 VITROS			44	0.100	0.000	0.00	0	0.300	
2025-423	38 ROCHE E			53	0.000	0.000	0.00	0	0.200	
2025-423	44 BECK.COUL.			48	0.000	0.000	0.00	0	0.200	
2025-423	50 ARC			21	0.000	0.000	0.00	0	0.200	
2025-423	57 S. EXL 200			54	0.076	0.043	56.31	0	0.300	
2025-423	58 ATELLICA			20	0.020	0.040	200.00	0	0.200	
2025-424	29 VITROS			44	0.300	0.000	0.00	0.100	0.500	
2025-424	38 ROCHE E			53	0.240	0.056	23.41	0.000	0.400	
2025-424	44 BECK.COUL.			48	0.300	0.000	0.00	0.100	0.500	
2025-424	50 ARC			21	0.200	0.000	0.00	0.000	0.400	
2025-424	57 S. EXL 200			54	0.242	0.053	21.93	0.000	0.400	
2025-424	58 ATELLICA			20	0.225	0.043	19.25	0.000	0.400	
2025-425	29 VITROS			44	10.930	0.352	3.22	8.700	13.100	
2025-425	38 ROCHE E			53	20.957	1.181	5.63	16.800	25.100	
2025-425	44 BECK.COUL.			48	20.081	0.969	4.83	16.100	24.100	
2025-425	50 ARC			21	19.043	1.244	6.53	15.200	22.900	
2025-425	57 S. EXL 200			54	21.546	1.115	5.18	17.200	25.900	
2025-425	58 ATELLICA			20	19.515	1.195	6.12	15.600	23.400	
071	VITAMIN B 12	CLIA TEST ID #: 600	EVALUATION CRITERIA: TARGET VALUE 25 % OR 30.00 {GREATER}							
2025-421	29 VITROS			29	639.071	29.061	4.55	479.000	799.000	

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 120 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST					
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-421	38	ROCHE E			40	660.000	38.562	5.84	495.000	825.000
2025-421	44	BECK.COUL.			27	476.667	32.422	6.80	358.000	596.000
2025-421	50	ARC			21	662.476	35.633	5.38	497.000	828.000
2025-421	57	S. EXL 200			19	627.211	28.138	4.49	470.000	784.000
2025-421	58	ATELLICA			17	582.438	32.160	5.52	437.000	728.000
071 VITAMIN B 12			CLIA TEST ID #: 600	EVALUATION CRITERIA: TARGET VALUE 25 % OR 30.00 {GREATER}						
2025-422	29	VITROS			29	778.214	53.366	6.86	584.000	973.000
2025-422	38	ROCHE E			40	1076.000	79.309	7.37	807.000	1345.000
2025-422	44	BECK.COUL.			27	701.889	48.047	6.85	526.000	877.000
2025-422	50	ARC			21	1029.095	97.481	9.47	772.000	1286.000
2025-422	57	S. EXL 200			19	962.316	43.733	4.54	722.000	1203.000
2025-422	58	ATELLICA			17	843.294	89.228	10.58	632.000	1054.000
2025-423	29	VITROS			29	0.000	0.000	0.00	0	30.000
2025-423	38	ROCHE E			40	897.487	83.587	9.31	673.000	1122.000
2025-423	44	BECK.COUL.			27	574.111	35.570	6.20	431.000	718.000
2025-423	50	ARC			21	851.667	84.553	9.93	639.000	1065.000
2025-423	57	S. EXL 200			19	756.611	19.522	2.58	567.000	946.000
2025-423	58	ATELLICA			17	706.000	106.346	15.06	530.000	883.000
2025-424	29	VITROS			29	254.893	8.723	3.42	191.000	319.000
2025-424	38	ROCHE E			40	258.256	42.518	16.46	194.000	323.000
2025-424	44	BECK.COUL.			27	192.519	14.405	7.48	144.000	241.000
2025-424	50	ARC			21	272.143	28.414	10.44	204.000	340.000
2025-424	57	S. EXL 200			19	281.474	19.618	6.97	211.000	352.000
2025-424	58	ATELLICA			17	205.765	24.472	11.89	154.000	257.000
2025-425	29	VITROS			29	763.897	44.013	5.76	573.000	955.000
2025-425	38	ROCHE E			40	868.875	55.728	6.41	652.000	1086.000
2025-425	44	BECK.COUL.			27	610.222	27.735	4.55	458.000	763.000

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 121 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary**MONTH 5 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS			LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-425	50	ARC				21	822.381	66.568	8.09	617.000	1028.000
2025-425	57	S. EXL 200				19	801.895	26.705	3.33	601.000	1002.000
2025-425	58	ATELLICA				17	755.000	68.789	9.11	566.000	944.000

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE						
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST		REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
146 GLYCOHEMOGLOBIN			CLIA TEST ID #: 420		EVALUATION CRITERIA: TARGET VALUE 8 %						
2025-431	12	COBAS/INT.				26	8.112	0.247	3.05	7.500	8.800
2025-431	12	COBAS/INT.				26	8.550	0.350	4.09	7.900	9.200
2025-431	14	IMMUNOTUR.				16	8.481	0.281	3.31	7.800	9.200
2025-431	22	VITROS				57	8.039	0.220	2.73	7.400	8.700
2025-431	31	IMMUNOTURB				52	8.241	0.218	2.65	7.600	8.900
2025-431	40	SIEMENS DI				71	8.380	0.154	1.83	7.700	9.100
2025-431	46	ARCHITECT				17	7.841	0.206	2.63	7.200	8.500
2025-431	48	ATELLICA				19	7.753	0.167	2.15	7.100	8.400
2025-431	50	CS400DIRUI				11	8.436	0.519	6.15	7.800	9.100
2025-432	12	COBAS/INT.				26	5.175	0.109	2.11	4.800	5.600
2025-432	12	COBAS/INT.				26	4.940	0.224	4.54	4.500	5.300
2025-432	14	IMMUNOTUR.				16	5.106	0.198	3.88	4.700	5.500
2025-432	22	VITROS				57	4.772	0.127	2.66	4.400	5.200
2025-432	31	IMMUNOTURB				52	4.825	0.253	5.25	4.400	5.200
2025-432	40	SIEMENS DI				71	4.956	0.132	2.66	4.600	5.400
2025-432	46	ARCHITECT				17	4.806	0.094	1.95	4.400	5.200
2025-432	48	ATELLICA				19	4.706	0.085	1.80	4.300	5.100
2025-432	50	CS400DIRUI				11	4.809	0.392	8.15	4.400	5.200
2025-433	12	COBAS/INT.				26	8.325	0.217	2.60	7.700	9.000

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 122 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE					
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-433	12	COBAS/INT.		26	8.154	0.244	2.99	7.500	8.800
2025-433	14	IMMUNOTUR.		16	8.519	0.246	2.88	7.800	9.200
2025-433	22	VITROS		57	8.065	0.201	2.50	7.400	8.700
2025-433	31	IMMUNOTURB		52	8.221	0.288	3.51	7.600	8.900
2025-433	40	SIEMENS DI		71	8.384	0.183	2.19	7.700	9.100
2025-433	46	ARCHITECT		17	7.841	0.197	2.52	7.200	8.500
2025-433	48	ATELLICA		19	7.795	0.167	2.14	7.200	8.400
2025-433	50	CS400DIRUI		11	8.400	0.538	6.40	7.700	9.100
146 GLYCOHEMOGLOBIN		CLIA TEST ID #: 420		EVALUATION CRITERIA: TARGET VALUE 8 %					
2025-434	12	COBAS/INT.		26	6.050	0.403	6.66	5.600	6.500
2025-434	12	COBAS/INT.		26	5.769	0.311	5.39	5.300	6.200
2025-434	14	IMMUNOTUR.		16	5.919	0.292	4.93	5.400	6.400
2025-434	22	VITROS		57	5.637	0.155	2.75	5.200	6.100
2025-434	31	IMMUNOTURB		52	5.553	0.284	5.12	5.100	6.000
2025-434	40	SIEMENS DI		71	5.806	0.174	3.00	5.300	6.300
2025-434	46	ARCHITECT		17	5.553	0.109	1.96	5.100	6.000
2025-434	48	ATELLICA		19	5.463	0.142	2.60	5.000	5.900
2025-434	50	CS400DIRUI		11	5.873	0.256	4.36	5.400	6.300
2025-435	12	COBAS/INT.		26	5.773	0.265	4.60	5.300	6.200
2025-435	12	COBAS/INT.		26	6.175	0.342	5.54	5.700	6.700
2025-435	14	IMMUNOTUR.		16	5.863	0.176	3.01	5.400	6.300
2025-435	22	VITROS		57	5.633	0.172	3.05	5.200	6.100
2025-435	31	IMMUNOTURB		52	5.573	0.274	4.91	5.100	6.000
2025-435	40	SIEMENS DI		71	5.794	0.171	2.95	5.300	6.300
2025-435	46	ARCHITECT		17	5.547	0.104	1.87	5.100	6.000
2025-435	48	ATELLICA		19	5.467	0.105	1.93	5.000	5.900
2025-435	50	CS400DIRUI		11	5.936	0.293	4.94	5.500	6.400
SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D					

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 123 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D					
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
178 Vitamin D			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-281	3	VITROS			46	82.044	5.665	6.90	66.000	98.000
2025-281	5	ROCHE E			37	51.000	6.500	12.75	41.000	61.000
2025-281	5	ROCHE E			37	49.139	5.381	10.95	39.000	59.000
2025-281	9	BECK.COUL.			44	57.860	4.044	6.99	46.000	69.000
2025-281	11	ARC			19	55.222	2.740	4.96	44.000	66.000
2025-281	25	S. DIME			30	51.000	3.256	6.38	41.000	61.000
2025-281	27	ATELLICA			19	91.389	4.098	4.48	73.000	110.000
2025-282	3	VITROS			46	109.957	6.718	6.11	88.000	132.000
2025-282	5	ROCHE E			37	73.649	8.927	12.12	59.000	88.000
2025-282	5	ROCHE E			37	76.875	6.753	8.79	62.000	92.000
2025-282	9	BECK.COUL.			44	78.279	5.324	6.80	63.000	94.000
2025-282	11	ARC			19	75.667	3.266	4.32	61.000	91.000
2025-282	25	S. DIME			30	66.633	3.638	5.46	53.000	80.000
2025-282	27	ATELLICA			19	112.789	5.970	5.29	90.000	135.000
2025-283	3	VITROS			46	51.217	4.185	8.17	41.000	61.000
2025-283	5	ROCHE E			37	27.875	2.713	9.73	22.000	33.000
2025-283	5	ROCHE E			37	25.667	3.930	15.31	21.000	31.000
2025-283	9	BECK.COUL.			44	37.023	2.592	7.00	30.000	44.000
2025-283	11	ARC			19	34.500	1.708	4.95	28.000	41.000
2025-283	25	S. DIME			30	34.800	2.088	6.00	28.000	42.000
2025-283	27	ATELLICA			19	56.263	6.256	11.12	45.000	68.000
2025-284	3	VITROS			46	22.478	3.119	13.88	18.000	27.000
2025-284	5	ROCHE E			37	8.000	1.871	23.39	6.000	10.000
2025-284	5	ROCHE E			37	7.167	1.624	22.67	6.000	9.000
2025-284	9	BECK.COUL.			44	15.674	1.694	10.81	13.000	19.000
2025-284	11	ARC			19	14.167	0.601	4.24	11.000	17.000

7/22/2025

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICOPAGE : 124 (124)
DATE : 7/22/2025
TIME : 12:51:17

Participant Summary

MONTH 5 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D					
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-284	25	S. DIME			30	18.900	1.599	8.46	15.000	23.000
2025-284	27	ATELLICA			19	23.000	2.616	11.37	18.000	28.000
178 Vitamin D			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-285	3	VITROS			46	125.295	1.791	1.43	100.000	150.000
2025-285	5	ROCHE E			37	102.500	6.727	6.56	82.000	123.000
2025-285	5	ROCHE E			37	98.189	12.483	12.71	79.000	118.000
2025-285	9	BECK.COUL.			44	97.093	5.273	5.43	78.000	117.000
2025-285	11	ARC			19	95.500	5.188	5.43	76.000	115.000
2025-285	25	S. DIME			30	80.433	4.551	5.66	64.000	97.000
2025-285	27	ATELLICA			19	135.842	7.618	5.61	109.000	163.000